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treatments that improve chronic skin lesions and inadequate patient education on living 
with CLE. 
Phase two was a cross-sectional survey in 57 patients to assess QoL and its 
correlates, using constructs within the Revised Wilson and Cleary Model. The 
dependent variables were operationalized as: a CLE-specific QoL measure, CLEQoL 
(CLEQoL-mental and CLEQoL physical) and the SF-36 (mental component summary 
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(MCS) and physical component summary (PCS)), yielding four separate regression 
models. From the CLEQoL models – mental and physical, the combination of fatigue 
and body image explained 71.0 and 73.0 percent of the variance in overall QoL, 
respectively; with body image being the strongest predictor [β=0.64; p <0.01 (mental) 
and β=0.49, p<0.01 (physical)]. For the SF-36 models – MCS and PCS, the model 
accounted for 54.0 and 69.0 percent of the variance in overall QoL, respectively. 
Pruritus (β=-0.41; p <0.05), fatigue (β=-0.29; p <0.05), race/ethnicity (β=-0.23; p 
<0.05), and social support (β=0.41; p <0.01) were significant predictors in the SF-36 
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in CLE patients and could be used to help health care providers interpret and assess 
QoL outcomes in CLE patients. 
These studies underscore several of the issues affecting QoL in CLE patients. 
Through the use of a theoretical framework, patient-centered and clinical outcomes 
were integrated to facilitate a fuller understanding of the several factors impacting QoL 
in CLE patients. As such, future studies aimed at understanding QoL in CLE patients 
could incorporate a multi-phase, multi-method approach using a theoretical framework. 
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1 
CHAPTER ONE: INTRODUCTION 
This chapter delineates the overview of the disease, research problem, and study 
significance. 
1.1 SYSTEMIC LUPUS ERYTHEMATOUS 
Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease and 
has changed in recent years from an often life-threatening disease with high rates of 
early mortality to a more chronic disease with increased life expectancy.
4-7
 SLE is most
commonly seen in the African-American, Asian and Hispanic ethnicities.
8
 About nine
out of 10 people with SLE are women (CDC 2012),
9
 with the disease primarily
affecting them during their reproductive years. One possible explanation for the higher 
rates of SLE seen in women could be due to hormonal differences. Although not 
validated thoroughly by research, the hormonal theory may be the only logical 
explanation as to why women are diagnosed with SLE more often than men.
10,11
 A
review of the global incidence data between 2006 and 2010 shows the estimated SLE 
incidence rates to be 1 to 25 per 100,000 in North America, South America, Europe, 
and Asia.
12,13
 Symptoms of SLE may include extreme fatigue, painful and swollen
joints, swollen glands, facial rash, unexplained fever, hair loss, cognitive and memory 




1.1.1 CUTANEOUS MANIFESTATIONS OF SLE 
Of the eleven American College of Rheumatology (ACR) diagnostic criteria for 
SLE,
14
 only four (malar rash, discoid lesions, oral ulcers, and photosensitivity) are
cutaneous in nature, with many patients with cutaneous lupus erythematosus (CLE) 
showing little or no systemic symptoms. Such cases, with isolated cutaneous 
involvement, are referred to as CLE. The prevalence of SLE ranges from 15 – 46 per 
100,000 with CLE occurring at a rate of 71 – 74 per 100,000 persons.
15-18
 CLE is
diagnosed and managed by a dermatologist unless there is systemic involvement, as in 
SLE, in which case a rheumatologist and dermatologist may work together.
19
Management of CLE centers on formulating a regimen of photoprotection, topical, and 
systemic therapies designed to reduce disease activity and cosmetic damage. 
CLE is a chronic dermatologic autoimmune disease marked by photosensitive 
lesions that can vary in appearance depending on the subtype.
20,21
 The etiology of CLE
is not fully understood, but it is speculated that genetic, hormonal, immunological 
abnormalities (e.g., cytokine, B-cells and T-cells dysfunction) and environmental 
factors (especially ultraviolet irradiation) might play a role.
22,23
 CLE is categorized into
three main subgroups, including acute cutaneous lupus (ACLE), subacute cutaneous 




The vast majority of ACLE patients will develop SLE; however, fewer SCLE or 
CCLE patients will develop SLE. These CLE subsets are defined by clinical symptoms, 
the average duration of symptoms, and histological and serological findings.
17,24
 ACLE 
most often manifests as localized malar (butterfly) rash; erythema occurs over both 
cheeks and extends over the nasal bridge and spares nasolabial folds. ACLE is also 
frequently associated with systemic disease, and its lesions are photosensitive and quite 
transient, lasting only several days or weeks.
17
 SCLE is considered to be highly 
photosensitive and may be persistent; the most frequently-affected areas are shoulders, 
forearms, neck and upper torso while the face is usually spared.
17
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has a rather fast onset and manifests as scaly annular erythematous plaques that tend to 
coalesce and produce the polycyclic array. 
The most common subtype of CCLE is discoid lupus erythematosus (DLE); 
other variants exist but are considered to be rare.
25
 DLE manifests as indurated 
erythematous plaques and papules that can result in significant scarring and alopecia.
17
 
There is little mortality impact for DLE patients unless SLE or potentially severe co-
morbidities develop (e.g., cancer).
26,27
 
DLE can also occur either in the localized or generalized form. The localized 
form, which is the most common type, involves the face, scalp, neck, and extensor 
aspect of arms; while the generalized form occurs both above and below the neck, and 
typically involves the extensor forearms and hands.
17
 DLE lesions are considered to be 
photosensitive and may be persistent, often forming larger confluent and disfiguring 
plaques. DLE is always limited to the skin. Many persons living with CLE wear 
protective clothing to shield themselves from the ultraviolet rays of the sun. These 
protective garments may include large hats and other head gear, face masks, or long 
sleeves.
11,28
 Thus photoprotective measures are a critical component of therapy, as 
ultraviolet A/B irradiation has been shown to induce lesions. Lesions are initially 
treated with topical/intralesional corticosteroids, and if persistent, systemic antimalarial 
therapies are used. However, approximately 25 percent of patients are refractory to 





1.2 IMPACT OF CLE ON QUALITY OF LIFE 
While dermatologic diseases, in general, have been shown to have a significant 
impact on quality of life,
29,30
 there is limited information as to the extent in which CLE 
affects a patient’s quality of life. Studies have reported that patients with dermatologic 
diseases are not only distressed about the disease itself but also how others perceive 
them as a result of their appearance.
31,32
 Consequently, dermatologic patients may 
experience higher rates of mental health conditions, especially anxiety and depression, 
with a prevalence ranging from approximately 20-40%, compared to 11-30% seen in 
the general population.
33-35
 CLE is perceived as being less severe and having a better 
prognosis than SLE; however in its chronic forms (e.g., DLE), it can last for several 
years and may lead to severe disability and permanent disfiguration.
16,36
 Moreover, 
CLE is a “chronic” condition that can be managed but not cured; therefore, patients are 
expected to visit their physicians regularly and are often placed on medications for a 
long period, many of which have serious side effects.
26
 Due to the potential for 
irreversible skin damage and disfiguration in CLE, there is a high unmet need for 
therapies. Currently, there are no disease-modifying therapies for CLE, and thus there 
is an important need for therapies that prevent or reduce the size of CLE lesions, 
prevent flares and permanent skin damage, and/or minimize scarring. 
Given the severity of the disease, CLE has a significant and distinct impact on the 
quality of life of such patients. A recent cross-sectional study of 117 patients with DLE 
reported that patients with DLE do experience significant quality of life impairment 
when compared to those without skin disease as well as those with a variety of other 
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skin diseases like rosacea, acne, and non-melanoma skin cancer. DLE patients were 
also found to be more highly affected by symptoms of itching and bleeding of their 
skin than patients with other forms of CLE. This study reported that some factors, such 
as female gender and smoking may be correlated with impairment of multiple domains 
of quality of life in DLE. However, the study used dermatologic measures that are not 
specific to CLE or DLE and, therefore, may not have captured all salient aspects of 




1.3 DISEASE ASSESSMENT  
Disease activity and damage in SLE patients are measured by clinicians via the 
use of disease assessment tools. It is important to measure both disease activity and 
damage so as to: evaluate outcomes, observe differences in patient groups, estimate 
responses to therapy under investigation, and assess disease trends longitudinally for 
observational and clinical trials.
38
 These tools are also called the SLE responder index 
(SRI). The Safety of Estrogens in Lupus Erythematosus – Systemic Lupus 
Erythematosus Disease Activity Index (SELENA-SLEDAI), the British Isles 
Assessment Group Instrument (BILAG), and the Physician’s Global Assessment 
(PGA) are common tools used to measure disease activity in SLE patients,
39-43
 while 
the Brief Index of Lupus Damage (BILD) and Lupus Damage Index Questionnaire 
(LDIQ) are used to quantify disease damage.
44,45
 
Although these SRIs have been used to assess some form of cutaneous 
manifestation, they do not measure skin-specific activity and damage – as seen in CLE. 
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To this end, the Cutaneous Lupus Erythematosus Disease Area and Severity Index 
(CLASI) was developed by dermatologists, using a framework of commonly-used tools 
in dermatology,
46
 and has been validated against other cutaneous tools.
47,48
 The CLASI 
has been reported to be reliable and responsive to changes in cutaneous activity and 
damage;
47,49
 hence, it is increasingly used in clinical trials.
50
 The CLASI activity score 
is based on erythema, scaling, mucous membrane involvement and alopecia with a 
range of 0–70, while the CLASI damage score is measured by dyspigmentation and 
scarring also with a possible range of 0–70. Disease severity in patients with CLE have 




While clinician-reported outcome measures, such as CLASI, provide the clinician 
perspective on disease activity and damage, they do not measure the patient 
perspective. Given the impact of CLE on the quality of life of patients and the 
increasing prominence of patients’ involvement in their care, it is important also to 
assess outcomes directly from the patients’ perspectives.  
 
1.4 PATIENT-REPORTED OUTCOME (PRO) MEASURES 
PRO measures are increasingly used in clinical trials to measure the effects of 
treatments on patients. The relatively objective clinical outcome measures were 
traditionally considered in the clinical trials to evaluate therapies. More recently, 
subjective measures, such as PRO or ‘humanistic’ measures are now considered to be 
equally important. PROs are reports that are directly elicited from patients to assess 
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their health conditions, without interpretation of the patient’s response by a clinician or 
anyone else.
51
 The Food and Drug Administration (FDA) recommends collection of 
PRO data during a clinical trial and use of PRO information in making conclusions 
about the treatment effect at the time of medical product approval.
51
 
PROs are crucial in clinical trials for several reasons. First, some treatment 
effects are known only to the patient, and physiologic measures may not reflect how a 
patient functions or feels. Second, the FDA may require that a molecule demonstrates 
improvement in symptoms. If this is the case, biomarkers may not be sufficient as they 
measure objective changes rather than patient-perceived symptom reduction. Further, 
PROs can demonstrate treatment benefit, appear in FDA labeling, and/or can be used in 
publication and dissemination. The FDA looks favorably upon PROs that demonstrate 
good content validity and psychometric qualities and that have been developed in 




1.4.1 PRO MEASURES USED IN CLE PATIENTS 
At present, there are only a few PRO instruments used in patients with CLE. 
They are the Body Image Quality of Life Inventory (BIQLI),
48,52







 and Visual Analog Scale (VAS).
55
 
With the exception of the VAS, all of the PROs were used to assess the quality of life 





1.5 PROBLEM STATEMENT  
Dermatological diseases have been long recognized for their detrimental effect on 
the quality of life and health status of patient.
34,56-61
 While their impact on the patients 
has been well recognized, it is only recently that PRO measures have been used as 
assessment tools in both the management of chronic skin disease and the evaluation of 
new treatments.
62
 Disease-specific measures have been developed to assess the impact 
of atopic eczema, urticarial, contact dermatitis, scleroderma, acne, vitiligo, and 
Hidradenitis suppurativa on QoL but none to assess the impact of CLE.
56-58,62
 While all 
of the PRO measures used in CLE patients are presumed applicable, they were not all 
developed with input from patients with CLE. Also, CLE patients were not included in 
the concept elicitation phase via the use of qualitative interviews to elicit patient burden 
or concepts relevant to CLE patients. Also, most of the studies in which these PRO 
measures were used in CLE patients did not report psychometric properties. Hence, 
such instruments may not fully capture the relevant disease burden of CLE patients. 
Therefore, more work is needed to test the validity of existing PRO measures in the 
CLE population to allow use in future drug development and outcomes evaluation. In 
the future, ground-breaking therapies are expected to be launched into the market, 
resulting in an increase in the choice of treatment for patients with CLE. In order to 
make optimal therapeutic decisions on these new therapies, a better understanding of 





1.6 STUDY RELEVANCE  
CLE has clear effects on biological/physiological indicators, symptom status, 
functional status, general health perceptions, and overall QoL.
20
 No curative therapy 
currently exists for CLE, making chronic disease management the operating clinical 
paradigm. Many CLE symptoms and related functional impairments are difficult or 
impossible to measure through laboratory or physician assessments. Due to the 
heterogeneous nature of CLE as well as the health issues experienced, the health 
perceptions of patients can differ significantly from those of clinicians. It is, therefore, 
important to use subjective measures, such as PROs to be able to capture QoL in 
patients with CLE. One of the goals of Healthy People 2020 is to help individuals of all 
ages increase life expectancy and improve their QoL; the challenge is to be aware of 
what factors affect a person’s QoL. Thus, there is a significant gap in the literature as 
current QoL measures may not capture all issues relevant to CLE, since CLE patients 





CHAPTER TWO: LITERATURE REVIEW 
  
A review of the literature relevant to this study is presented. The major topics 
addressed are overview of CLE, conceptualization and measurement of quality of life 
(QoL), concepts of QoL applied to healthcare, attributes of QoL, approaches to 
measuring QoL, patient perspectives and QoL, and PRO measures used in CLE 
patients. 
 
2.1       OVERVIEW OF CLE 
Based on clinical morphology and average lesional life span, lupus 
erythematosus-specific skin lesions are divided into three broad categories.
17
 These 
include acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus 
erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE). CCLE is 
the largest subtype of CLE and can occur as an isolated skin disease or in conjunction 
with SLE. Discoid Lupus Erythematosus (DLE) is the most common subtype of CCLE 
and can occur in a generalized form with lesions above and below the neck, or in a 
localized form, typically appearing as lesions above the neck in sun-exposed areas. 
Common symptoms include lesions that are red, patchy, crusty, scaling plaques, and 
these lesions are sometimes characterized by erythema, scarring, and dyspigmentation. 
While the lesions may appear anywhere on the body, they usually erupt like a “coin-
like” or disc appearance on the ears, face, scalp, back, neck or any part of the body 
exposed to sunlight.
63
 Patients may experience disfigurement and symptoms that can be 





2.1.1 EPIDEMIOLOGY OF CLE 
Unbiased epidemiologic data on CLE are difficult to find as most studies are 
performed either by rheumatologists or dermatologists. This is because CLE patients, 
who do not present with SLE, are underreported by rheumatologists or over-reported by 
dermatologists.
65
 The prevalence has been estimated to be between 17 and 48 per 
100,000. CLE occurs at all ages and among all ethnic groups; it occurs more frequently 
in African Americans than in whites or Asians. DLE, in particular, is responsible for 50-
85 percent of cases of CLE and occurs 2-3 times more frequently in women than in 





2.1.2 ETIOLOGY OF CLE 
Several studies have reported that smoking may lead to the development of 
CLE, and UV radiation may worsen CLE lesions.
67-69
 Another phenomenon known as 
the Koebner phenomenon that arises from non-specific injury to the skin as a result of 
trauma has also been attributed to the development of CLE.
70
 The inflammatory process 
associated with CLE is thought to result from complex autoimmune mechanisms. 
Although associations with some complex histological antigens have been reported, 










2.1.3 RISK FACTORS OF CLE 
Strong risk factors associated with CLE are UV light exposure, smoking and 





2.1.4 PATHOPHYSIOLOGY OF CLE 
The accurate pathophysiology of CLE is not yet fully understood. However, it is 
suggested that the process is an immune-mediated one due to the detection of immune 





2.1.5 SYMPTOMS OF CLE 
Fatigue, pain, skin manifestations such as rash and photosensitivity, and hair 
loss (alopecia) are symptoms commonly reported in patients with CLE.
17,55,72,73
 
Decreased energy and vitality resulting in the inability to engage in recreational or 





2.1.6 DIAGNOSIS AND PROGNOSIS OF CLE 
CLE is primarily diagnosed clinically. Referral to a specialist dermatologist is 
warranted as diagnoses by non-specialists could be a difficult process. CLE lesions 
should be recognized and treated early; scarring, alopecia, changes in skin pigmentation 
may increase if it is not clinically managed early.
23
 CLE can have a significant impact 
on quality of life of patients due to its prolonged course, and chronic refractory lesions 
14 
 
can often lead to psychological and social distress. In some cases, CLE may resolve 
spontaneously, but, if left untreated can lead to progressive lesions that spread to 
produce larger areas of scarring. Due to UV light exposure particularly in the spring and 




2.1.7 TREATMENT OF CLE 
CLE treatment is based on inflammatory activity and the extent of skin lesions. 
The primary goals of treatment are to improve physical appearance, reduce scarring and 
control existing lesions, and prevent the development of new lesions.
75
 In addition to 
strict photoprotection, treatment can either be in the form of pharmacologic agents, 
supportive measures, or surgical care.
75-77
 
Pharmacologic agents in the form of topical glucocorticoids are considered as 
first-line therapy for CLE.
78
 Other agents like topical calcineurin inhibitors have also 
been shown to be effective in CLE treatment.
79,80
 Patients with widespread skin lesions 
or high inflammatory disease or those who have not been responsive to topical therapy 
are managed systemically with antimalarial agents like hydroxychloroquine, quinacrine, 
and chloroquine.
81,82
 Patients who have failed on topical agents or antimalarial therapy 
could be treated with methotrexate, retinoids, or the antibacterial agent, dapsone.
82-84
 
Retinioids and thalidomide have limited use in patients of childbearing age due to their 
teratogenicity.
85
 Supportive measures include limiting sun exposure, wearing protective 
clothing or using high factor sunscreens. Cosmetic camouflage may also be used for 
15 
 
lesions that are in visible places. Burned-out scarred lesions may be excised surgically 





2.1.8 ECONOMIC AND HUMANISTIC BURDEN OF CLE 
While there is no data on the economic burden of CLE, a study published in 
2013 reported that patients with SLE had an average annual direct cost ranging from 
$2,214 to $16,875 and an average annual productivity loss cost ranging from $2,239 to 
$35,540.
86
 Due to the chronic nature of CLE, the comorbidities (especially psychiatric 
disorders like anxiety and depression)
26,33,35
 that occur as the disease progresses and the 
negative impact of CLE on patients’ health-related QoL (HRQoL) and productivity, the 
burden associated with the management of CLE can be significant. HRQoL parameters 
affected by CLE include mental well-being and physical and social functioning. CLE 




2.2      CONCEPTUALIZATION AND MEASUREMENT OF QUALITY OF    
           LIFE (QOL) 
The term “quality of life” has been used for decades to describe the expectations 
of satisfaction, psychological fulfillment and well-being of people.
87,88
 QoL has 
different connotations to different people, and its definition is based on the area of 
application, in that economists might define it as material goods and social workers or 
policy makers might define it as social welfare.
89
 QoL is a complex construct, and there 
are many inconsistencies in its definition.
90,91
 These inconsistencies and many 
16 
 
definitions of QoL across the literature have made it difficult to uniformly compare 
findings.  
A study published in 1981
92
 found that less than 10 percent of 250 studies citing 
quality of life in the title gave a definition. Similarly, Gill and Feinstein,
93
 assessing 75 
randomly chosen articles that had described measuring ‘quality of life,' found that 11 
(15%) had given a conceptual definition of the term ‘quality of life’ or had described 
the contents of measures used. The resultant effect of this ambiguity is that it is often 
impossible to determine what exactly is being measured, and the rationale for including 




 identified a 
broad set of definitions for QoL used in healthcare. Specifically, QoL was grouped into 
five broad categories: a normal life, achievement of personal goals, social utility, 
natural capacity, and happiness/satisfaction. Ferrans further argues that when selecting a 
QoL instrument for use in clinical research and practice, considerations should be given 
to those that reflect: the definition of QoL selected, the perception of the individual 
whose QoL is being measured, the multidimensional nature of QoL rather than focusing 
on health concerns, and the differences in individual values.
94
 In many cases, the 
definition of QoL in ascertained from how the researcher uses and measures it.
94
 
 According to the World Health Organization (WHO), QoL can be defined as 
individuals’ perceptions of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, standards, and 
concerns. Specifically, QoL was defined as a broad ranging concept affected in a 
complex way by the person's physical health, psychological state, the level of 
17 
 
independence, social relationships, personal beliefs and their relationship to salient 
features of their environment.
95
 Fitzpatrick, Davey, Buxton & Jones
96
 conducted a 
systematic review where they documented the definitions of health and QoL, and its 
evolution in decades. These findings are replicated in Figure 2.1.  
Since the 1970s, QoL has had a growing importance in the field of health care. 
Draper and Thomson
88
 conducted a literature search on “Medline” using the phrase 
“quality of life” where they reported finding only two papers published between 1966 to 
1970, 114 studies in 1971 to 1975, 938 papers in 1976 to 1980 and up to 11,000 papers 
in 1996 to 1999. This rapid increase in QoL publications has been attributed to 
advances in medical practice as well as increases in the evaluation of the quality of the 
prolonged lives in patients with chronic diseases.
97
 Given that there are many patients 
with chronic, manageable diseases, assessing their QoL has become a standard 














Illustrations of range of definitions and discussions of health and QoL by 
Fitzpatrick, Davey, Buxton & Jones 
 Health as a ‘state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity.’
99
 
 ‘Quality of life is an individual’s perception of their position in life in the 
context of the culture and value systems in which they live and in relation to 
their goals, expectations, standards, and concerns.’
100
 
 ‘Quality of life refers to patients’ appraisal of and satisfaction with their current 
level of functioning as compared to what they perceive to be ideal.’
101
 
 ‘Health-related quality of life is the value assigned to duration of life as 
modified by the impairment, functional states, perceptions and social 
opportunities that are influenced by disease, injury, treatment or policy.’
102
 
 ‘Health-related quality of life refers to the level of well-being and satisfaction 
associated with an individual’s life and how this is affected by disease, 
accidents, and treatments from the patient’s point of view.’
103
 
 ‘Quality of life is enhanced when the distance between the individual’s attained 
and desired goals is less.’
104
 
 ‘Quality of life measures the difference, or the gap, at a particular period of 







2.3      CONCEPTS OF QOL APPLIED TO HEALTHCARE 
Several concept analyses have been conducted by health scholars to capture the 
definition and attributes of QoL.
97,105-109
 Using the concept analysis framework of 
Walker and Avant,
110
 several experts reviewed the concept of QoL and its critical 
attributes.
97,105-109
 Below is a summary of their findings. 
Figure 2.1: Illustrations of range of definitions and discussions of health and QoL 
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2.4       ATTRIBUTES OF QOL 
For the most part, there is a consensus among these experts regarding the 
attributes of QoL. First, QoL is subjective and captures the perception of an 
individual,
97,109,111,112




 Second, objective 
indicators that may serve as proxies for examining QoL in those who are unable to 
communicate, only play a supplementary role in the assessment.
97,109,113,114
 However, 
results from these objective findings are not comparable with those obtained from self-
assessments. Third, QoL is dynamic in nature.
97,113
 Fourth, QoL is a multidimensional 
concept that contains social, physical, and psychological dimensions.
111-113
 Last, QoL is 
culture-specific and based on an individual’s perception.
113
 To add more validity to 
these core attributes identified, more literature reviews were done to provide a deeper 
understanding of each attribute and their relationship to QoL. Expanded illustrations of 
the five QoL attributes are provided below: 
 
2.4.1 FIRST ATTRIBUTE: QOL IS SUBJECTIVE AND CAPTURES THE 
PERCEPTION OF AN INDIVIDUAL 





 further pointed out that an individual’s QoL is based on that 
individual’s interpretation rather than observable variables or comparison with other 
persons. More specifically, QoL can also be considered to be “the degree to which a 
person enjoys the important possibilities of his or her life.”
116
 These definitions are 
based on the valuation placed on life experience by the individual without any reference 
20 
 




 based this contradiction on the notion that objective 
assessments are based on imposed observable standards while those of subjective 
measures are based on the perceptions of an individual. It should also be noted that 
because responses given to subjective measures are ‘subjective,’ they can be susceptible 
to situational influences, such as social desirability, response bias, poor recall, self-





2.4.2 SECOND ATTRIBUTE: OBJECTIVE INDICATORS AND 
SUPPLEMENTARY ASSESSMENT  
Objective indicators have been shown to be used as a proxy in examining QoL 
in individuals who are unable to provide subjective feedback, such as comatose or 
mentally incompetent patients. In such cases, objective indicators like lab values (if 
appropriate) might be used instead. However, if the individual being assessed is 
mentally competent enough to provide subjective feedback, the results from both 
objective and subjective assessments may not be comparable.
97
 Results from these 
objective findings are not comparable with those obtained from self-assessments. For 
example, when assessing the impact of vomiting on the QoL of a person, an objective 
assessment of this would only count the number of times of vomiting, whereas a 
subjective assessment, which is based on individual perceptions, would consider the 
cause and meaning behind the vomiting, such as the triggers behind the vomiting. In 
this case, it is thus apparent that the subjective and objective assessments would be 
different. The context of personal situations is not included in the objective assessments.  
21 
 
Additionally, findings from the literature report discrepancies in proxy QoL 
assessment when completed by significant others of patients and health care 
givers.
120,121
 Sneeuw et al.
120
 compared QoL ratings of patients by 100 patients with 93 
significant others and their health care providers, including 97 doctors and 99 nurses. 
Patients, significant others, doctors and nurses were asked to complete the Dartmouth 
Coop Functional Health Assessment/World Organization of National Colleges, 
Academies and Academic Association of General Practitioners (COOP/WONCA) 
charts independently of each other. The COOP/WONCA assesses QoL by using a core 
set of domains, including physical fitness, feelings, daily and social activities, overall 
health and pain. Scores range from 1 to 5, with 1 representing the best and 5 indicating 
the worst level of functioning or well-being. While no statistically significant 
differences were observed between patients’ and nurses’ ratings, the physicians’ ratings 
indicated less pain than those reported by the patients but indicated more impaired 
feelings. Further, significant others rated patients as having more pain, more impaired 
levels of feelings and daily activities, and poorer overall health and QoL than the 
patients themselves did. In addition to the discrepancies observed in ratings, the authors 
also reported differences in the perceived importance of various QoL domains.  
Rothwell, McDowell, Wong, and Dorman
122
 compared the judgments of 
clinicians on which domains of health in the Short Form 36 (SF-36) would be most 
important to patients themselves. A statistically significant difference was observed in 
the choices selected between the 42 patients with multiple sclerosis and their 25 
physicians. The physicians were significantly more likely to give higher ratings to 
22 
 
physical role limitations and physical functioning than they were with mental health and 
emotional role limitations. The results suggest that while patients were more concerned 
about their mental health, doctors focused on the domains related to physical abilities.   
 
2.4.3 THIRD ATTRIBUTE: QOL IS DYNAMIC IN NATURE 
QoL has been described by several researchers as being dynamic in nature.123-126 
Due to ever-changing life events, the progression of illness, and personal developments, 
individuals may rate their QoL differently over time,
125
 which may change their 
perception of which domains of QoL are important.
126
 When people face a life-
threatening or chronic illness, they tend to adjust their internal standards and values to 
accommodate the adverse circumstances.
124,127
 As a result, it is important for the content 




2.4.4 FOURTH ATTRIBUTE: QOL IS A MULTIDIMENSIONAL CONCEPT  
Skevington
128
 stated that “QoL is about the meaning people derive from the 
important aspects of their life,” therefore, it is unlikely that a single parameter of human 
experience will capture the QoL of an individual.
129
 QoL has been widely described as 
multidimensional with dimensions ranging from physical, psychological to social.
113,130
 
These three broad dimensions align with the components of health delineated by the 
World Health Organization (WHO):
99
 “health is a state of complete physical, mental, 
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and social well-being and not merely the absence of disease…” A model was developed 
by Spilker
2














 the pyramid has three levels. The topmost level is the 
overall assessment of well-being and the perception of overall QoL while the middle 
level contains the essential multidimensional domains of health, that is, physical, 
psychological, and social dimensions. The lowest level consists of the micro-
components constituting each QoL dimension. These smaller components are 
observable and measurable and are important factors in persons whose QoL are being 
measured. To ensure that the measures of QoL are practicable enough, domains 





Figure 2.2: Three levels of quality of life
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2.4.5 FIFTH ATTRIBUTE: QOL IS CULTURE-SPECIFIC AND BASED ON 
AN INDIVIDUAL’S PERCEPTION  
Individuals often evaluate their life circumstances in the context of their culture 
and values, especially when making appraisals regarding their QoL.
97
 Thus, 
assessments of QoL in patients from different cultures will produce different results.
131
 
Chen, Miaskowski, Dodd, and Pantilat
132
 provided a deeper context to the sociocultural 
dimension of the cancer pain experienced by Chinese patients. The authors reported that 
Chinese cancer patients view pain as a complex experience that can only be understood 
through an understanding of several Eastern philosophies and religions of Taoism, 
Buddhism, and Confucianism. Also, Chinese patients view the body as a whole energy 
field that ought to be in harmonious balance with its environment. These cultural 
influences and beliefs may lead to differences in pain management and perception, 
which may impact a patient’s QoL.  
 
2.5        APPROACHES TO MEASURING QOL 
There are two main philosophical approaches to measuring QoL: the health 
status approach, and the well-being approach. These two approaches have different 
implications in assessment, with one approach involving objective and observable 
outcomes, and the other entailing the perception and valuation by the individual. 
The health status approach focuses mostly on observable or behavioral 
outcomes. Kaplan and Anderson
133
 state that quality of life is “the impact of health 
conditions on function.” Indeed, the impact of illness on daily functioning and capacity 
25 
 
has been captured by several QoL instruments. A classic example is the Sickness 
Impact Profile, which measures the behavioral impact of illness and diseases. The 
emotional subscale questions that measure emotions, feelings and sensations ask about 
laughing, crying or acting irritably, rather than internal states.
134
 Moreover, QoL 
measures are often validated by examining their associations with “objective” measures 
of diseases, such as disease severity indicators or physician ratings.
135
 Objective QoL 
measures are therefore used to reflect more closely clinical indicators than subjective 
assessments given that they are readily measured and observable. Further, the use of an 
objective approach ensures clear definitions of concepts that are easily measured and 
thus result in high interrater reliability. Also, objective measures allow for comparison 
across individuals, and to know where an individual stands relative to other groups or 
individuals. Nonetheless, objective measures have been reported to be poor predictors 
of well-being and satisfaction of patients, since they often do not take into consideration 
the perceptions of the patients.
136,137
 
The well-being approach focuses on an individual’s perception of their QoL 
rather than observable measures or comparisons with groups or other persons. The 
proponents of this approach purport that QoL is a “state of mind, not a state of 
health.”
115
 Above and beyond simple physical processes or variables, subjective 
assessment considers the experience and valuations of the patients. For example, 
Brown, Renwick and Nagler
117
 stated that QoL is whatever people think comprise 
quality in their life. QoL has also been considered to be “the degree to which a person 
enjoys the important possibilities of his or her life.”
138
 These two definitions reflect the 
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emphasis being placed on the individual’s valuation of their life experience. Hunt
91
 
even suggested that an individual’s QoL is made up of several complex interactions and 
idiosyncratic personal values that the notion of a traditional measurement of it is 
inappropriate. Also, since subjective measures represent the culmination of complex, 
internal processes that may differ across respondents unlike objective measures, 
findings from subjective measures are not readily comparable across individuals. 
Despite these arguments, subjective experiences have continued to be captured through 
measurement by researchers. Indeed, there are many merits to using the subjective 
approach to capture QoL. For example, subjective measures operationalize the internal 
judgement of the participants rather than what the researcher deems important; in many 
cases, the individual’s perception is indeed the outcome of interest.
108
 Subjective 
measures have also been reported to be more strongly associated to the outcomes of 
interest and are better suited for the study of broadly-defined concepts than their 
“objective” counterparts.
139
 Also, subjective measures of QoL have been reported to 
have good reliability, be fairly sensitive to changes, to have adequate validity, and 
converge well with other measures of well-being.
140
 
The subjective approach to assessing QoL has the potential to provide detailed 
and useful information about the experiences of people with chronic clinical 
conditions.
141
 Researchers utilizing this approach focus more on understanding the 
everyday experience as it is lived by the respondents; such researchers do not seek to 




2.6       PATIENT PERSPECTIVES AND QOL 
 The term “quality” could imply subjective assessment, and as such, QoL 
measures should incorporate the patients’ perspectives. Moreover, if the goal of QoL 
assessments is to assess an individual’s perception of how good or poor their life 
experience is, then simple health ratings will not suffice to capture appropriately these 
measures. For example, clinicians and standardized instruments used in chronic diseases 
focus mostly on physical symptoms rather than capturing the full range of psychosocial 
issues.
142
 The use of patient-centered outcome instruments will give respondents the 
opportunity to report on their area of lives that matter.
143,144
 Given the increasing 
interest in individualized care in patients with chronic diseases, exploring the patients’ 
perspectives by asking meaningful questions is the first step to developing valid QoL 
measures. These measures that are used to gain insight from patients’ perspectives into 
which aspects of their health matter and on how diseases and treatment impact their 
QoL are called Patient-Reported Outcome (PRO) measures.
51
 Data generated from PRO 
measures are used as adjuncts in clinical-making decisions when monitoring outcomes 
from clinical interventions. Further, the use of PROs is important in improving 
communication between physicians and patients.
51
 
Common concepts measured by PROs include health status, quality of life 
(QoL), health-related quality of life (HRQoL), symptoms and functioning, well-being 
and treatment satisfaction.
51
 Other important considerations for use of any PRO 
measure include: (1) whether the measure is disease-specific or generic; (2) which life 
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domains (e.g., psychological well-being, social functioning) are being studied and 




2.6.1 GENERIC OR DISEASE-SPECIFIC PRO MEASURES 
PRO measures can either be generic or disease-specific. Generic instruments 
are designed to assess life domains across a broad range of populations. They can also 
be used in different settings, health interventions, and medical treatments.
145
 Generic 
instruments may be in the form of health profiles, single indices, or utility measures.  
Health profiles are single instruments that attempt to measure the relevant 
dimensions from a patient’s perspective.
145,146
 The Short Form - 36 (SF-36) Health 
Survey
54
 is an example of a health profile designed to assess general health and 
evaluates the following domains over the past four weeks: physical functioning (PF), 
role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social 
functioning (SF), role-emotional (RE) and mental health (MH). Health profile 
instruments differ in length, in the time needed to complete the surveys, and on 
domains measured.
147
 In addition, scales from health profile measures may either yield 
one score, called an index, or they may have questions for each category, yielding 
separate scores.
148
 Health profile instruments were not developed for specific diseases 
but rather with input from participants in the general population. As a result, they allow 
for broad comparisons of the relative impact of various health care programs, 
treatments and interventions.
145,146
 They also may provide insights to constructing 





 However, health profile instruments are too general for certain 
interventions and may not be responsive to clinical changes over time.
62,63
 
Single indices reduce several concepts to a unidimensional scale. For example, 
the Karnofsky Performance Status score,
150
 commonly used in cancer trials, allows 
patients to be classified as to their functional impairment. Single indices are brief and 
easy to administer but are less reliable and valid and yield limited information 
compared to multi-domain scales.
151
 
Utility measures are derived from economic principles based on decision 
analysis and prioritization of choice.
152
 The term utility refers to the prefential value 
placed on a certain particular health state. Domain scores range from 0 to 1, with a 
score of 0 indicating death and a score of 1 indicating a perfect state.
153
 One of the most 
well-studied examples and a generic measure of health outcomes is the EQ-5D. It 
consists of 6 items that cover five main domains (mobility, self-care, usual activities, 
pain/comfort, anxiety/depression) and a general visual-analog scale (VAS) for health 
status. A preference-based set of weights (or algorithm) is used to calculate a single 
index-based utility score of QoL from each profile score.
154,155
 Utility measures are 
amenable to economic analyses, particularly to cost-utility analyses.
149
 For example, 
findings from a cost-utility analysis may be used as justification to allocate resources to 
treatment. However, utility measures do not provide details as to the aspects of 
patients’ lives that are affected.
149
 Similar to health profiles, utility measures may not 





Specific instruments measure the specific areas of primary interest (i.e., 
population, problem, domain or function).
145,146
 This approach improves 
responsiveness since only specific aspects are measured.
145
 For example, disease-
specific measures are used to capture domains of QoL of relevance to a specific patient 
disease group. Disease-specific measures are also more likely to be of clinical 




An example is the Myotonic Dystrophy Health Index (MDHI),
156
 which 
measures overall disease burden and impact of key symptomatic themes in patients 
with myotonic dystrophy type-1 (DM1). The MDHI scale consists of 114 items, with 
17 subscales that measure the most important symptomatic DM1 themes. The weighted 
sum of responses is transformed to a 0–100 scale by expressing it as a percentage of the 
maximum possible value, with a score of 100 representing the most severe disease 
burden and a score of zero representing no disease impact.
145
 The drawback to using 
specific instruments such as the MDHI is that they are not comprehensive enough and 
cannot be used to compare across diseases states or even populations.
149
 Another 
example is the Vitligo-specific health-related quality of life (VitiQoL), which was 
recently developed and validated in use for patients with vitiligo.
157,158 
Since there is no one group of instruments that will achieve all the potential 
attributes of an ideal PRO measure, multiple instruments may be used. For example, 
health profiles and disease-specific measures may be used together so as to increase the 





Finally, regardless of whether a PRO measure is generic or disease-specific, it 
must demonstrate satisfactory psychometric properties including item response theory 





2.7     PRO MEASURES USED IN CLE PATIENTS1 
At present, there are a small number of PRO instruments used in patients with 
CLE. This section will focus specifically on the PRO instruments used to capture 
disease burden in CLE patients that were identified through a systematic review. 
Findings from the systematic review identified the PROs used in CLE patients 
were: Body Image Quality of Life Inventory (BIQLI),
48,52







 and Visual Analog Scale (VAS).
55
 With the 
exception of the VAS, all of the PROs were specifically used to assess QoL in CLE 





                                                          
1 Ogunsanya ME, Kalb SJ, Kabaria A, Chen S. A systematic review of patient-reported 
outcomes in patients with cutaneous lupus erythematosus. Br J Dermatol. 
2017;176(1):52-61.    
Ogunsanya ME conducted the literature review and drafted the manuscript. 
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251 Yes, CLASI 
damage 
median 
scores =  
7.33, 
range (4 – 
10) 
To evaluate the impact 
of lupus-related skin 
damage on skin-specific 
QoL and to analyze 
differences stratified by 
ethnic background. 
Skindex-29 There was no significant 
correlation between CLASI 
damage scores and Skindex 
domains overall. African 
American patients exhibited a 
high rate of DLE and 
experienced damage early in 
their disease course, frequently in 

















To assess whether the 
skin symptoms in CLE 
are associated with the 
QOL using the Japanese 
versions of the Skindex-
29 and CLASI 
Skindex-29 Female gender in ‘‘Functioning’’ 
and “emotions” and older age in 
“symptoms” before treatment 
were significant risk factors for 
poor QoL. Also, the presence of 
inflammatory alopecia and 
photosensitivity were also 


















= 17, range 
(8-48) 
To evaluate the 
association of pain and 
pruritus with 
Dermatologic Quality of 
Life (QoL) and 
cutaneous disease 
activity in patients with 
1) specific cutaneous 
lupus erythematosus 
(CLE) lesions, 2) non-
specific CLE lesions and 






and pruritus  
VAS 
Pain was identified pain as a 
factor that correlated with 


























(18 – 93 
years). 
Median age 
was 67 years 
39 No 
To assess whether 
patients who 
demonstrated response 
to treatment also 
experienced change to 
their quality of life. 
Skindex-29 
Response in disease activity 
was accompanied by an 
improvement in skin-specific 
quality of life measures. 
Correlation analysis suggests 
that disease activity is not the 















To compare quality of 
life indicators between 
patients with CLE at 
the University of Texas 
Southwestern (UTSW) 
Medical Center and 





Most quality of life indicators 
were similar between the two 
CLE populations. Differences in 
psychosocial behavior, and a 
larger proportion of patients 
with SLE and females in the 
UTSW group likely attributed 
to differences in a minority of 











To compare the QoL 
of patients with DLE 






Patients with DLE have a worse 
quality of life than patients with 
SLE. It is believed that this fact 
is generated by the difference in 















To determine the 
prevalence of 
photosensitivity among 
CLE population and to 




Self-reported photosensitivity is 
very common among cutaneous 
lupus patients and is associated 
with significant impairments 
related to symptoms, emotions, 




























To determine how CLE 
affects QoL and which 
independent variables are 






CLE patients have very impaired 
quality of life, particularly from 
















To determine how to use 
the CLASI to classify 
patients according to 
disease severity (mild, 
moderate, and severe) and 
to identify which patients 
respond to therapy. 
Skindex-29 
 
The CLASI can be used to 
categorize patients into severity 
groups and to identify clinically 













To assess the relationship 
between the change in 
CLE disease severity and 
quality of life. 
Skindex-29 
 
Skindex-29 (QoL) scores did not 
easily correlate with improvement 
or deterioration of the disease. 
QoL does not uniformly improve 
as the activity of the disease 
wanes. This may mean that 
attention to cosmetic outcomes 
may need to become a routine part 














To translate the DLQI into 
Brazilian–Portuguese, to 
culturally adapt it, and to 
evaluate its reliability and 
validity in the assessment 






The results suggest that the 
Brazilian–Portuguese version of 
the DLQI is a reliable and valid 
outcome measure to be used in 
CLE clinical studies. 
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Table 2.1 reports some key data on study design and findings. Overall, 1,272 CLE patients were enrolled in the 
articles reviewed. Out of eleven studies, four were conducted outside of the US,
55,73,74,161
 while seven studies were conducted 
in and recruited patients from the US.
20-22,26,30,49,160
 Symptoms and HRQoL were evaluated using generic HRQoL instruments 
or instruments developed for skin diseases (either alone or in conjunction with other instruments). The most frequently used 
was the Skindex, applied in eight (66.7%) studies,
20-22,26,30,49,73,160
 followed by the DLQI in three (25%) studies.
53,74,161
 
However, neither of these PRO measures was devised ad hoc to measure HRQoL in CLE patients specifically. This means 
that while all of the PRO measures used in CLE patients are applicable, they were not all developed with input from patients 
with CLE. Also, CLE patients were not included in the concept elicitation phase via the use of qualitative interviews to elicit 







2.7.1 BODY IMAGE QUALITY OF LIFE INVENTORY (BIQLI) 
The Body Image Quality of Life Inventory (BIQLI) was designed to explore 
and quantify how a person’s body image experiences affect several life domains such 
as social functioning, sexuality, sense of self and emotional well-being. The BIQLI 
does not measure body image per se; rather, it assesses the impact of one’s body image 
experiences on various psychosocial domains of life.
162
 Body image is based on 
Erickson’s theory of psychosocial development during the adolescent years because it 
is a period of self-searching. Erikson
163
 postulates that the bid to gain confidence and 
search for themselves further drives adolescents away from their parents. The BIQLI is 
a 19-item scale with acceptable reliability and validity, and it is commonly used in 
studies assessing body image.
52,162,164,165
 It has a recall/observation period of four 
weeks and is scored on a 7-point scale ranging from very negative (-3) to very positive 
(+3). A composite score is calculated, with a higher score indicating better body image 
and a higher quality of life (QoL).
52
 With regards to assessing QoL in patients with 
CLE, the BIQLI has been used only in one study.
48
 Jolly, Kazmi, Mikolaitis, Sequeira, 
& Block
48
 sought to validate the CLASI against patient-reported assessment of quality 
of life and body image (using the BIQLI) Findings from this study report that the 
presence of CLASI activity on visible body areas was significantly associated with 
worsened body image and QoL concerns. The mean (SD) BIQLI score was 0.46 (1.5), 
indicating that participants had negative body image. No reliability or validity statistics 
was reported for the BIQLI scale in this study, although other studies have shown that 





2.7.2 DERMATOLOGY LIFE QUALITY INDEX (DLQI) 
The Dermatology Life Quality Index (DLQI) was designed to measure the QoL 
of dermatology patients and as an outcome measure in health services research.
53
 It was 
designed specifically for skin and connective tissue diseases. It is self-administered and 
measures health-related quality of life, including health status. The recall/observation 
period is the last week and it contains 10 questions. Questions from the DLQI can be 
further divided into six different domains: daily activities, leisure, work and school, 
symptoms and feelings regarding the disease, and interpersonal relationship and 
treatment. Each domain has a score ranging from 0 (no interference) to 3 (a lot of 
interference). Three studies have used the DLQI to assess QoL in CLE patients.
55,74,161
 
A total of 139 CLE patients were recruited in these studies, with an age range of 20 – 76 
years and with women making up to 90 percent (N=73) of the population sampled. Only 





 Overall, respondents reported high DLQI score, 
indicating that having CLE interfered a lot with their QoL. One study reported that 
DLQI was able to capture the worsening impact on the quality of life in patients with 
alopecia (also a clinically important difference), thus demonstrating discriminant 
validity.
74
 This same study reported an inter-observer reliability coefficient of 0.96 
(p<0.001).
74






2.7.3 SKINDEX  
The Skindex
29
 is a disease-specific instrument developed to measure the effects 
of skin and connective diseases on quality of life in patients. The instrument is available 
in three different forms, depending on the number of items. The Skindex 16, 29 and 61 
have 16, 29, and 61 items, respectively. The recall/observation period for each form of 
the Skindex scale differs from one another. The Skindex-16 has a recall/observation 
period of one week, and the Skindex 29 and 61 have a recall/observation period of four 
weeks. The Skindex-29 is the most commonly used form in CLE studies, and it focuses 
on three domains: symptoms (seven items), emotions (10 items), and functioning (12 
items). The symptoms scale measures the physical burden of the disease, such as pain, 
itch, burning, or sensitivity. The emotions scale measures the psychological effects of 
the disease, such as depression, anxiety, embarrassment, or anger. The functioning 
subscale focuses on the changes to daily life, such as work, sleep, and relationships with 
others.
166
 The Skindex-29 is measured on a five-point Likert-type scale, and the overall 
score, as well as the individualized scores for each dimension, are converted to a scale 
of zero (no impact on QoL) to 100 (maximum impact on QoL).   
A total of seven studies used the Skindex-29 scale to measure QoL in CLE 
patients.
20-22,26,30,49,73
 Two of these seven studies added three questions to the Skindex-
29 scale to assess lupus-specific concerns (such as photosensitivity and alopecia).
21,26
 A 
total of 962 patients were recruited in these studies, with an age range of 10–82 years 
and with women making up to 84 percent (N=770) of the population sampled. Overall, 
participants reported high scores on ‘‘Emotions,’’ Symptoms,’’ and ‘‘Functioning,” 
39 
 
suggesting that patients’ QoL were somewhat severely impacted by CLE. None of the 
studies reported any psychometric properties for the scale. 
 
2.7.4 THE SHORT FORM-36 (SF-36) 
The Short Form-36 (SF-36) is a 36-item measure designed to assess general 
health and evaluates the following domains over the past four weeks: physical 
functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality 
(VT), social functioning (SF), role-emotional (RE) and mental health (MH).
54,167
 
Domain scores range from 0 to 100, with higher scores reflecting better health. In 
addition, two overall summary scores can also be obtained – Physical Component 
Summary (PCS) and Mental Component Summary (MCS) scores. Summary scores are 
transformed to have a mean of 50 and standard deviation of 10, with greater scores 
indicating better health.  
The SF-36 was not developed specifically with input from patients with CLE, 
but with participants from the general population. The SF-36 was used in two studies 
concurrently with the Skindex-29 to assess QoL in CLE patients.
21,26
 Findings from one 
of the studies reported that CLE patients scored significantly lower on both the physical 
[mean (SD) scores = 41 (13)], and the mental component scores [mean (SD) scores = 39 
(12)] than patients with other skin diseases.
26
 Further, the second study reported that 
CLE patients scored lower on the physical functioning, role-physical and general health 




The psychometric properties of the SF-36 were not evaluated in these CLE 
patients, even though the instrument has demonstrated evidence of acceptable reliability 
(internal consistency), construct validity (convergent and known-groups) and ability to 
detect change (responsiveness and sensitivity to change) in other dermatological 




2.7.5 VISUAL ANALOGUE SCALE (VAS) 
A VAS is an instrument used to measure a characteristic or attitude that is 
believed to range across a continuum of values and cannot easily be directly 
measured.
178
 The VAS was devised to capture this idea of an underlying continuum. 
Operationally, a VAS is usually a horizontal line, 100 mm in length, anchored by word 
descriptors at each end, as illustrated in Figure 2.3. The patient marks a point on the line 
that represents the perception of his/her current state. The VAS score is determined by 
measuring in millimeters from the left-hand end of the line to the point that the patient 
marks. 
 
E.g., how severe is your itching today? Place a vertical mark on the line below to 
indicate how bad you feel your itching is today. 
No itching |___________________________________________________| A lot of 
itching 




The VAS has been used in CLE patients to measure pain and pruritus, two 
important domains in CLE. Mendez-Florez, Topete, Bermejo, and Molina
55
 evaluated 
the association of pain and pruritus (as measured by VAS) with DLQI and cutaneous 
disease activity of patients with CLE. Their study findings reported that while pain and 
pruritus were important symptoms reported by CLE patients, only pain was positively 
and significantly correlated with DLQI and cutaneous disease activity.  
 
2.8        SUMMARY 
This chapter provided a comprehensive review of the literature that lends 
support to this study. CLE is a chronic, debilitating disease that significantly impacts 
the quality of life of patients. Also, while all of the PRO measures used in CLE patients 
are applicable, they were not all developed with input from CLE patients. CLE patients 
were not included in the concept elicitation phase via the use of qualitative interviews to 
elicit patient burden or concepts relevant to them. To this end, use of a CLE-specific 
PRO instrument will significantly improve the understanding of the health status of 
individuals from the patient’s perspective and provide valuable information on future 
interventions for CLE patients.  
Research on the QoL of CLE patients, including an understanding of which 
factors affect their QoL, may help inform clinicians and health policy makers regarding 




CHAPTER THREE: THEORY 
 
This chapter outlines the theoretical framework guiding this study. Further, this 
chapter delineates the relationships between demographic/personal characteristics and 
QoL in CLE patients. The ultimate goal of modeling QoL and its domains in CLE 
patients using a theoretical framework is to identify empirical factors that impact these 
patients. Further, such findings can be used to tailor interventions specifically to CLE 
patients to improve their overall QoL. 
Quality of life has become an increasingly important endpoint for clinically 
assessing patient outcomes, especially in those with ‘chronic’ diseases such as CLE. 
CLE has been reported to impair the QoL of patients.
74,179
 Therefore, to accurately 
estimate QoL in these patients, appropriate measures need to be selected to enhance the 
success of the application of the PRO measures. Finally, use of a theoretical framework 
will allow for the development, validation and eventual use of PRO measures have 
undergone a sound process.  
 
3.1   THEORETICAL MODELS USED IN QOL 
There are three different types of theoretical models used in describing QoL: 
conceptual models, conceptual framework, and theoretical frameworks. Of the three 
theoretical models, conceptual models are considered to be the least sophisticated. 
Conceptual models delineate domains and subdomains of the concept of QoL, such as 
physical, social, psychological, and functional.
180
 However, these models lack the 





frameworks, on the other hand, are organized in such a way that the nature and direction 
of the associations in the model are specified. A weakness of conceptual frameworks is 
that they are not based on time-tested theories that represent the findings of several 
investigations on how phenomena occur. Conversely, theoretical frameworks offer not 
only the nature and direction of associations but they also provide a structure of 
concepts represented in the hypothesized model.
182
 Also, theoretical frameworks 
include the added specifications of potential causality. The causal variables included in 
theoretical frameworks delineate the process that leads to the outcome variable.
183 
Assessing QoL without a theoretical framework poses a lot of issues, such as: 1) 
failure to assess if or how domains are related to one another; 2) lack of interpretation of 
the meaning of patterns observed in relationships; and 3) inability to identify whether 
the variables are moderated or mediated by the disease, the person, or treatment-related 
factors.
184
 The use of a theoretical framework also allows for placement of concepts in a 
context that will guide the development of new theories.
180
 Further, the use of a 
theoretical framework will allow for the assessments of the reliability and the validity of 
the concepts to be measured.
185
 Valid and reliable models are useful in the following 
ways: to aid researchers in understanding the complex relationships among the 
concepts, to educate health care providers on which domains of QoL have the greatest 
impact on patients’ lives, to examine the relative importance of several approaches to 
patient care, and to help translate the clinical importance of QoL.
186
  
Despite the burden of disease and mortality in CLE patients, there have been 
few attempts to examine their QoL using any health behavioral theories. To this end, the 
 
44 
next sections will focus on the QoL models commonly used in chronic diseases with the 
intent of selecting a theoretical model that can be used to capture the burden of disease 
in CLE patients.  
Examples of theoretical frameworks that have been used include those by 
Cella,
187
 the World Health Organization International Classification of Functioning, 
Disability, and Health (WHO ICF),
188
 Wilson and Cleary,
186





3.1.1 CELLA’S MULTIDIMENSIONAL QUALITY OF LIFE MODEL 
Cella’s model defines QoL in terms of domains of well-being, and it contains 
four domains: physical well-being, functional well-being, emotional well-being, and 
social well-being. Physical well-being was defined to represent a combination of 
disease symptoms, treatment side-effects, and general physical well-being as defined by 
the patient.
187
 Functional well-being, although correlated with physical well-being, is 
conceptually different from physical dimensions. Further, functional well-being was 
defined as a person’s ability to perform activities related to their personal needs, 
ambitions, or social role.
187
 Some of these activities may include walking, bathing, 
feeding, or dressing oneself. Functional well-being incorporates one’s ability to carry 
out responsibilities in and outside of the home, with families, friends and other social 
circles. 
Emotional well-being reflects both positive well-being as well as negative well-
being. A comprehensive QoL measure should assess both sides of this spectrum. 
 
45 
Finally, social well-being was described as a diverse construct that may include 
perceived social support, family relationships, intimacy, sexuality and inclusion of 
leisure activities. These four domains contribute to overall QoL and are subjective or 
self-perceived in nature. The overall scope of Cella’s model is that these domains are 
the necessary building blocks that contribute to the dynamic concept of QoL, thereby 
giving researchers the opportunity to measure the contribution of each construct to the 
QoL concept. Also, all the domains within Cella’s model make up the perceived QoL 
status of an individual; thereby the domains have the potential to impact directly the 
individual’s overall QoL. A conceptualization of this model can be seen in Figure 3.1. 
Cella
189
 describes three main purposes for assessing QoL in patients as: “a) to assess 
rehabilitation needs, b) as an endpoint in the evaluation of treatment outcome, and c) as 
a predictor of response to future treatment.”
189
 Cella’s model has been used in 
HIV/AIDS patients with liver diseases,
190






 Henderson et al.
190
 examined the relationship between Cella’s four domains 
(physical, social, emotional, and functional well-being) and overall QoL in HIV patients 
with liver diseases. Their study was a cross-sectional, retrospective study that included a 
total of 80 patients recruited from a medical center. Overall QoL was measured using 
the Ferrans and Power Quality of Life Index (QLI).
193
 The QLI is a 66-item instrument 
that measures both importance and satisfaction with life. All four domains in Cella’s 
model were significantly correlated with overall QoL (functional, r=0.329, p <.01; 
social, r = .636, p<.01; emotional, r = -.549, p<.01; and physical, r=.480, p< .01). In 
 
46 
addition, all four domains accounted for approximately 53 percent of the variance in 
overall QoL (R
2
 = .532).  
 Cella’s model is not without its limitations: one drawback of its use is the way 
QoL is defined as overall “well-being.” For example, physical well-being is a precursor 
to physical status, and physical status is dependent on certain health and physical 
symptoms that are associated with chronic and comorbid conditions.
194
 Other 
limitations are that the model has no causal process, and there are no noted indications 
of the level of significance contributed by each of the domains that comprise overall 
QoL. Finally, the linkages between the domains are not specified, and other important 




Figure 3.1: Cella's (1994) conceptualization of QOL 
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3.1.2 WORLD HEALTH ORGANIZATION INTERNATIONAL 
CLASSIFICATION OF FUNCTIONING, DISABILITY, AND HEALTH 
(WHO ICF) 
The WHO ICF model defines components of health and some health-related 
components of well-being,
195
 while providing a common and standard language that 
cuts across several disciplines and cultures.
99,195,196
 Since its inception in 1980, the 
model has evolved from focusing solely on “consequences of diseases” to “components 
of health.”
195,196
 The WHO ICF model has been used as follows: as a statistical tool (to 
collect and record data on population studies and surveys), as a clinical tool (in needs 
assessment and outcome evaluation), and as a research tool (to measure outcomes, 
environmental factors, and QoL).
195
 As a research tool, the model has been used in QoL 
studies in diseases ranging from multiple sclerosis,
197
 and oral health,
198




The WHO ICF model contains two parts. Part 1 includes Functioning and 
Disability while Part 2 deals with Contextual Factors. Functioning and Disability 
focuses on body functioning and structures, activities and participation while contextual 
factors deal with environmental and personal factors. The main concepts represented in 









Figure 3.2: Diagrammatic representation of the WHO’s ICF
195
 showing interactions 
between the consequences of disease and contextual factors 
 
The WHO ICF has the unique advantage of its wide range of applications above 
and beyond capturing QoL. This versatility has been captured in the literature.
200,201
 For 
example, the model was used in a study by Miller and colleagues
201
 as a framework to 
organize an overview of nursing and interdisciplinary care of patients with stroke. 
Therein, the model was used more for its mapping and classification abilities, as 
opposed to it being used to generate hypotheses in QoL research. Nonetheless, the 
framework is not without its limitations. First, some overlap has been observed between 
activities and participation, and, as a result, making it difficult to separate these two 
concepts.
202
 Second, it is not entirely unique to QoL research thus, it may not be used to 
capture QoL-related issues in certain disease conditions or states.
202
 Finally, the ICF 
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puts more emphasis on functioning and disability, which may not be applicable in 
certain health conditions. 
 
3.1.3 WILSON AND CLEARY QUALITY OF LIFE MODEL 
The Wilson and Cleary model is an example of a disease-based, physiological 
framework that emphasizes the impact of disease and health on QoL. The conceptual 
model was developed to help explain the relationships among patient outcomes on a 
continuum from those that are proximal (e.g., clinical variables) to those that are distal 
to the disease (e.g., quality of life), within the context of individual and environmental 
characteristics [See Figure 3.3]. The model links biological and physiological factors, 
symptoms status, functioning, general health perceptions, and overall QoL. The model 
also links individual and environmental characteristics. Individual characteristics 
represent those variables that are intrinsic to the patient such as a patient’s motivation or 
value preferences, while environmental characteristics, such as the amount of social, 
psychological or economic support, are extrinsic to the patient.  
The Wilson and Cleary model organizes concepts in a context and enhances the 
understanding of new relationships among them,
203
 which have aided health care 




While the model depicts that a linear relationship exists across the five concepts, 
Wilson and Cleary state that the unidirectional arrows between the concepts do not 
necessarily imply that reciprocal relationships cannot exist. Also, unidirectional arrows 
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between nonadjacent levels do not mean that there are no reciprocal relationships.
186
 























The model is the most widely-cited QoL model and can provide clinicians with 
a broader view of QoL than just biological factors and symptoms.
202
 However, while 
the main concepts are well-defined, the individual and environmental factors do not 
have clear definitions.
202
 Also, the model may not apply to individuals who have no 
orientation to the meaning of QoL and general health (e.g., children, comatose patients), 










Due to the complex relationships depicted in the Wilson and Cleary Model, 
updated empirical evidence, and the need for further clarity, Ferrans and colleagues 




3.1.4 FERRANS AND COLLEAGUES’ REVISED WILSON AND CLEARY 
MODEL 
Ferrans et al. used the Wilson and Cleary model as a guide to develop a revised 
QoL model.
215
 Their modifications to the original model include: 1) explicitly stating 
that biological and physiological functions are influenced by characteristics of the 
environment and the individual; 2) removing the direct effect of nonmedical factors on 
QoL because all nonmedical factors can be assumed to be under characteristics of either 
the individual or environment; and 3) deleting the labels, such as value preferences, that 
connected the characteristic and environment to the major categories of symptoms, 
functional status, general health perceptions and overall QoL because these labels 
tended to restrict characterization of the relationships.
215
 
Just like in the original model, the revised model posits four main determinants 
of overall quality of life:
216
 1) biological and physiological factors (e.g., disease activity 
and disease damage, as measured by Cutaneous Lupus Activity and Severity Index 
[CLASI)]scores); 2) symptom status, including physical and psychological symptoms 
(e.g., pain, itching, and hair loss); 3) functional status, which is a person’s ability to 
perform tasks or functions (e.g., physical functioning, and role emotional); and 4) 
general health perceptions, which is a person’s global perception of his/her own health. 
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Overall QoL is defined as the patient’s overall satisfaction with life, beyond health-
related quality of life (HRQoL). Further, characteristics of the individual (e.g., age, 
gender, and race/ethnicity) and characteristics of the environment (e.g., marital status, 
health insurance status, and residence area) influence the main QoL determinants, 
except biological/physiological factors, as well as overall QoL. The following sections 
describe each construct of the model in greater details. 
 
3.1.4.1 BIOLOGICAL AND PHYSIOLOGICAL FACTORS 
Wilson and Cleary
186
 conceptualized biological/physiological factors as any 
measurable function of cells, organs, and organ systems of an individual. Also, these 
factors are assumed to have the greatest impact on health status and exert a limiting 
relative effect on more distal variables along the causal pathway. 
Biological/physiological factors include physiological processes that support life, and 
can be quantified through lab tests, physical assessments, and medical diagnosis. 
Changes made to the biological/physiological factors can subsequently impact all other 
determinants of QoL. Therefore, medical interventions often focus on this domain to 
improve health outcomes.  
In most studies using the Revised Wilson and Cleary model, a small-to-
moderate proportion of the total variance in overall QoL was accounted for by 
biological or physiological factors. For example, in a QoL study conducted in women 
with heart disease, biological factors accounted for 13 percent of the variance in QoL,
211
 
while physiological factors accounted for 29 percent of QoL variance in another study 
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conducted in patients with AIDS.
217
 In both studies, the R
2 
contributed by either the 
biological or physiological factors was relatively smaller than that contributed by the 
other predictor variables. 
Across studies, biological and physiological factors have been operationalized 







 and comorbid conditions,
205,210,211,222
 In the case of CLE, 
disease activity and damage (as measured by the CLASI), and disease duration are 
examples of biological/physiological factors that may impact QoL in persons with 
CLE.
26,50
   
 
3.1.4.2 SYMPTOM STATUS 
Symptoms have been described by Wilson and Cleary as a “patient’s 
perception of an abnormal physical, emotional, or cognitive state,” and classified into 1) 
physical symptoms, 2) psychological symptoms, and 3) psychophysical.
223
 The model 
further suggests that biological and physiological factors, as well as characteristics of 
the individual and environment, have an impact on symptom status, although the effect 
of biological and physiological factors is unclear.
223
 Also, the influence of symptom 





 reported that symptoms such as dyspnea and fatigue were key 
predictors of QoL and accounted for the largest proportion of variance in QoL in 
patients with heart failure. In a study by Sousa & Williamson
224
 conducted in adults 
with GI bleeding, symptoms related to GI bleeding accounted for a moderate proportion 
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of variance in QoL at baseline (R
2
=20.2%, P<.01) and one-month follow-up (R
2
=23.2%, 
P<.01). In persons with HIV/AIDS, the HIV-Problem Checklist, which was used to 
measure symptoms, accounted for 24 percent of the variance of QoL, a higher 
proportion of the variance compared to the other predictor variables.
220
 
Contrary to the above studies, symptom status accounted for less than five 





 In both studies, an HIV symptom checklist (HIV/AIDS-TARGETED 
QoL (HAT-QoL) questionnaire) measured the frequency and intensity of HIV-related 
signs and symptoms.  
In the study by Phaladze et al., stepwise multiple regressions were used to 
identify significant predictors when each measure was entered according to the order of 
precedence established by Wilson and Cleary. The overall model accounted for 53 
percent of the variance in the overall QoL. An important finding from the study was that 
even though the average number of symptoms reported by participants was more than 
17, the number of symptoms ceased being significant (B=-.028, r
2
=.186) when 
functional status was entered into the regression model (B=-.432, r
2
=.492). The limited 
explanatory power of symptom status may have been due to a potential measurement 
error in that the two measures (symptom status and functioning) may have been 
measuring the same phenomenon. 
In another study, Portillo et al.
225
 suggested that difficulties with the overall 
measurement model may have been due to the floor-effects of their overall QoL 
measure – HAT-QoL or because of conceptual issues. Specifically, the authors 
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purported that even though the HAT-QoL measure is a disease-specific instrument 
developed to measure overall QoL (domains like overall functioning, life satisfaction, 
health worries, financial worries, and disclosure), it may not have adequately reflected 
the impact of the disease on a multiethnic study. The total variance explained by the 
model was 23 percent.  
Sousa and Kwok
204
 further tested the Revised Wilson and Cleary model of 
QoL in patients living with AIDS (N=917). The study data was generated from an 
ongoing longitudinal, observational database of patients with an HIV-associated illness 
who were under the care of community-based providers. In this study, structural 
equation modeling was used to test the five concepts (biological/physiological factors, 
symptom status, functioning, general health perceptions, and overall QoL) in the model. 
Biological/physiological factors were operationalized as CD4 count; symptom status 
was measured using a revised version of the Sign and Symptom Checklist for Persons 
with HIV disease.
227
 The Health Assessment Questionnaire-Disability Index (HAQ-
DI)
228
 was used to measure functioning. The HAQ-DI is a self-reported questionnaire 
that measures functional health over the previous week by asking a total of 20 questions 
in eight different categories: activities, reach, grip, eating, dressing, hygiene, walking 
and arising. General health perceptions were measured using a 100 mm visual analog 
scale that focuses on perceived health status. Overall QoL was measured by combining 
two-specific second-order factors including mental health and health worry.
229
 Using 
structural equation modeling (SEM), the authors simultaneously tested all of the causal 
relationships among the factors that comprised overall QoL. The results from the study 
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showed that the Revised Wilson and Cleary model fit the data, with each of the 
relationships between the higher order general factors being significant (p<0.05). Based 
on modification indices, the authors were able to propose an alternative model linking 
symptom status directly with general health perceptions and overall QoL. Alternative 
models are generated to identify better fitting models that are more parsimonious.
194
 
Finally, symptom status is usually measured using disease-specific or symptom-specific 





3.1.4.3 FUNCTIONAL STATUS 
Functional status is the next level in the Wilson and Cleary model. Functional 
status has been characterized as a person’s ability to perform tasks or functions and 
adjust to his/her environment. Functional status can be assessed subjectively or 
objectively over a given period.
186
 While symptom status is an immediate determinant 
of functioning, other aspects of an individual’s personal and social environment (e.g., 
social support, medical treatment, access to care) may also have an impact on 
functioning.  
Physical, social, role and psychological functioning are the four domains that 
are mainly used to assess functional status. While it is known that these four domains 
are not the only domains of interest to patients, health care providers, and researchers, 





A cross-sectional, retrospective study by Phaladze et al.
226
 examined the 
meaning of QoL in people living with HIV/AIDS in four countries in Sub-Saharan 
Africa: Botswana, Lesotho, South Africa, and Swaziland. Using a convenience sample 
of 743 people, the authors implemented the Revised Wilson and Cleary model for 
categorizing variables, such as demographic characteristics and measures of severity of 
illness and examining their relationship to QoL, which was defined as life satisfaction in 
this study. Data was analyzed using hierarchical multiple regression, and results showed 
that subjects with higher life satisfaction scores were less educated, did not have an 
AIDS diagnosis or other comorbid conditions and had higher functioning scores. The 
combinations of variables in the model explained 53.2 percent of the variance in life 
satisfaction (QoL). Further, participants’ self-reported overall functioning explained the 
greatest variance in life satisfaction (QoL), with a unique R
2






 tested the Revised Wilson and Cleary model in a sample of 79 
Dutch patients with Pompe disease at a medical center in Rotterdam, Germany. In this 
cross-sectional study, five factors in the model were operationalized as follows: 
biological/physiological factors by enzyme activity, muscle strength, and respiratory 
function; symptom status by fatigue; functional health by the Rotterdam Handicap Scale 
[RHS]
233
 (The RHS score ranges from 9 to 36, with higher scores indicating lower 
levels of handicap); general health perceptions by the EQ-5D Visual Analog Scale (EQ-
5D VAS);
234
 and overall QoL by the SF-36.
167
 The characteristics of the individual and 
the environment included age, gender, and disease duration. The data was analyzed 
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using multiple regression which showed that functional health was affected by fatigue, 
muscle strength and respiratory function. The overall model was significant and 
accounted for 35 percent of the variance in overall QoL (R
2
 = 0.352; p <.01). 
Orfila et al.
235
 assessed the relationships between 1) gender, 2) performance-
based functional ability, 3) chronic diseases, and 4) sociodemographic variables and 
QoL (measured by the Nottingham Health Profile (NHP) questionnaire) among an 
elderly general population. The authors utilized sequential multiple linear regression 
analysis to test the Revised Wilson and Cleary model to examine the magnitude of the 
relationships among the variables in the model.  The authors reported that functional 
capacity and depression were significantly related to overall QoL. 
Psychological functions – including emotions and feelings (such as 
depression) and body image – and comorbidities are examples of concepts that have 
been reported to affect the functional status of patients with CLE.
21,73,74,236
 The impact 
of facial lesions and other CLE-related symptoms may result in social withdrawal and 




3.1.4.4 GENERAL HEALTH PERCEPTIONS 
Wilson and Cleary defined general health perception as an overall subjective 
rating of health and represents an integration or synthesis of biological factors, 
symptom status, and functional status.
223
 The inclusion of a general health perceptions 
measure in a conceptual QoL model allows for additional subjective input that sums not 
only the biological/physiological function, symptoms status and functional status, but 
 
59 
also incorporates characteristics of the individual and his/her environment. Further, the 
addition of measures of general health perceptions may help explain a portion of QoL 
that is not captured by the other determinants in the model because of the complex 
nature of the QoL construct. 
General health perceptions are purported to be among the best predictors of 
the use of general medical and mental health services.
238,239
 General health perceptions 
are exemplified as personal beliefs and evaluations of general health status.
240
 Measures 
of general health perceptions utilize available information from participants about their 
health, by taking into consideration the differences in preferences, values, needs, and 
attitude.
240
 Respondents are usually asked for an assessment of their health in general; 
this makes it possible to assess both the subjective information people have about their 
health and their evaluation of that information. For example, single-item measures ask 
the respondents to rate their perception of their current health status: “In general, how 
would you rate your present health” or “How do you feel about your own health?” 
Responses are scored on an ordinal scale from excellent to poor.
241
 In line with the 
Revised Wilson and Cleary model of QoL, general health perceptions should be 
included in studies of QoL; overlooking such a measure could lead to an inability to 
capture a subjective, individualized but yet important component of QoL. 
 Janz et al.
211
 described the impact of clinical and psychosocial factors on the 
QoL of older women (n=570) with heart diseases, guided by the original Wilson and 
Cleary model. Overall QoL was measured by a single item asking participants “How 
has the overall quality of your life been during the past four weeks—that is, how have 
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things been going for you lately?” (1 = “not well at all” … 5 = “very well”). The results 
indicated that all study model variables explained 46.8 percent of the variation in QoL, 




Some concepts of general health perceptions that are relevant to CLE patients 
include impact and satisfaction with treatment and concerns for the future. Medications 
used in CLE patients have dose-limiting toxicities, and patients have reported being 
concerned about the efficacy of their medications and the duration of effect as well as 
the negative side-effects of their medications.
242,243
 Also, increased pill burden is a 
concern for CLE patients due to the treatment of CLE sequelae such as pruritus or 
concomitant treatment of SLE.
243,244
 Finally, perception of overall skin health was 
assessed as a measure of general health perception. 
 
3.1.4.5 CHARACTERISTICS OF THE INDIVIDUAL AND ENVIRONMENT 
Characteristics of the individual (e.g., values and patient preferences) as well 
as the environment (e.g., social, economic, and psychological support) are recognized as 
factors affecting symptom status, functional status, general health perceptions and 
overall QoL.
3,223
 Ferrans and colleagues
215
 revised the Wilson and Cleary model by 
adding pathways between characteristics of the individual and the environment as well 
as biological and physiological factors.  
According to Wilson and Cleary, characteristics of the individual are specific 





 Characteristics of the environment are a conglomerate of external conditions 
that include all tangible and intangible resources available in the individual’s 
surroundings.
223
 For example, income and social support are examples of tangible and 
intangible resources, respectively, that are often associated with health outcomes. 
 In most regression models, characteristics of the individual and environment 
which are both conceptualized as demographic variables account for a minor proportion 
(< 10 %) of the outcome variable (QoL).
210,222,245,246
 For example, increasing age was a 
significant predictor of worse QoL in patients with heart failure but it only accounted 





education levels and poorer financial status – which were operationalized as 
characteristics of the individual and the environment – were linked to poor QoL in 
persons with advanced HIV in a study conducted in Sub-Saharan Africa,
205
 and in 
another multisite international study.
225
 In these two studies, the R
2
 values accounted for 
by the demographic variables were also less than 10 percent. 
 Female gender,
21,49,73
 low SES (income),
21
 and being African American
30,48
 are 
examples of individual and economic factors that were associated with poor quality of 
life in CLE patients.  
 
3.1.4.6 OVERALL QUALITY OF LIFE 
Overall quality of life is the final component of the Wilson and Cleary Model. 
Given that the model itself assesses QoL, this particular measure could be regarded as 
the quintessential aspect of the model.
247
 The overall QoL measure differs from the 
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other measures because it provides the summation of all the components that come 
before it in the model. Overall QoL can be measured using a single global QoL item or 
through multiple-item scales assessing life satisfaction or happiness.
247
 The Spritzer 
Uniscale
248
 which is one of the most commonly used QoL measures, is an example of a 
measure using a single global question. The scale consists of a single item asking 
participants to: “Please rate your overall quality of life.” The Functional Assessment of 
Cancer Therapy/Functional Assessment in Chronic Illness Therapy (FACT/FACIT)
249
 
and the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC QLQ-C30)
250
 are other examples of global QoL questions. The 
item for FACT/FACIT is “I am content with the quality of my life right now,” and the 
EORTC QLQ-C30 states, “How would you rate your overall quality of life during the 
past week?”  
Studies have reported that the overall QoL measure from the Wilson and Cleary 
model differs significantly from the other measures in the model, providing more robust 
information than symptoms, functioning, and general health perception.
251,252
 In a cross-
sectional study conducted in 493 cognitively intact patients 80 years of age and older, 
Covinsky et al.
252
 reported a lack of agreement between patient rating of their health 
and overall QoL. The authors reported that 43 percent of patients with the worst 
physical functioning reported their overall QoL to be good or better. Conversely, 15 
percent of patients who reported their physical functioning as ‘best’ reported their QoL 
as only fair or poor. Additionally, 21 percent of patients with the least psychological 
distress rated their QoL to be fair or poor. 
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From a meta-analysis of 12 studies in chronic disease, Smith et al.
251
 developed 
path models to demonstrate how patients make determinations of QOL and whether 
QOL is different from health status. The results from their study indicated that patients’ 
perspectives, their overall QoL, and health status are different constructs. The authors 
further noted that when it comes to rating their QoL, patients place more importance on 
mental health rather than on physical functioning. The reverse was reported to be true 
for health status where patients give more emphasis to physical functioning than to 
mental health. A plausible explanation for these findings is that conclusions may differ 
significantly depending on whether the outcome of interest being measured is health 
status or overall QoL.
251
 These findings provide a good argument for including overall 
QoL, in addition to other measures assessing symptoms status, functioning, and health 
status.   
Vidrine, Amick, Gritz, and Arduino
206
 used a modified version of the Wilson 
and Cleary model in HIV patients from an outpatient clinic in Texas (N=348). In their 
study, four out of the five factors from the model were operationalized to reflect the 
population of interest. For example, biological/physiological factors were measured as 
self-reported nadir CD4 cell count; symptom status by the New England Medical Center 
(NEMC) pain scale;
253
 functional status by The Household and Leisure Time Activities 
Questionnaire (HLTA);
254
 and overall QoL by the Medical Outcomes Study (MOS) SF-
12 health survey.
255
 The characteristics of the individual were measured by 
socioeconomic status, which was operationalized using two educational variables (years 
of education and educational attainment) and one occupational variable (a 6-item 
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ordinal hierarchy of functional attributes as defined by the 1970 US Census Bureau). 
The authors modified their model by the addition of a variable that assessed individual 
risk behaviors. These individual risk behaviors included smoking status, alcohol 
consumption, and illicit drug use. Structural equation modeling (SEM) was used to test 
simultaneously all of the causal relationships in the model. LISREL, an SEM software, 
was used to analyze the data and the authors reported that the Revised Wilson and 
Cleary model was well supported and fit the data, χ2 (44) = 57.62, p=0.08 and RMSEA 
(root mean square of approximation) = 0.03. (RMSEA <0.06 with an upper 90% 





 used SEM to test the Revised Wilson and Cleary model in 
patients with coronary heart disease (N=465), who were recruited from a cardiology 
multicenter hospital in Austria. Overall QoL was measured using the MacNew Heart 
Disease Quality of Life Questionnaire.
259
 Data to measure all the determinants of QoL 
and overall QoL were collected from these patients at three different points of time 
(baseline evaluation, at 1-month and 3-month follow-up). The study’s main goal was to 
find out whether the Revised Wilson and Cleary model applied to patients with 
coronary heart disease and is stable over time in this particular group of patients. At 
both baseline and over the other data collection points, the authors reported satisfactory 
fits of the model. The final model linked clinical variables, such as the number of 
diseased vessels and the number of risk factors, to global QoL through the mediating 
effects of the experience of actual symptoms (i.e., symptom status), physical 
functioning, and general health perceptions. Depression and anxiety symptoms exerted 
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the most significant influence on QoL. Their study findings provided empirical 
evidence for the Revised Wilson and Cleary theoretically-derived QoL model. The 
overall model explained at least 49 percent of the variance in subjective global QoL. 
Finally, the study findings support the use of SEM models in the investigation of the 
perception of QoL in patients with heart failure.
258
 
Importantly, the Revised Wilson and Cleary model has been demonstrated to 
enhance knowledge about QoL in a range of diverse populations coping with long-term 
health issues.
204,247,260,261
 For example, Wyrwich and colleagues
260
 applied the Wilson 
and Cleary model to patients with generalized anxiety disorder, and the authors 
concluded that this model improved understanding and usefulness of health status for 
this population. Also, Ferrans,
247
 who employed this model to assess symptom 
management of patients in cancer trials, concluded that the use of an all-encompassing, 
multidimensional approach as the Revised Wilson and Cleary model yielded valuable 
information about patients’ treatment experience and outcomes.
261
 The revised model is 
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3.2 STRENGTHS AND LIMITATIONS OF QoL IN CLE 
The literature review captured the effects that CLE has on the QoL of patients, 
specifically the impact of the disease on the physical, psychological, functioning, and 
general health perception domains. Further, the literature review emphasized that the 
use of a theoretical framework is crucial in understanding the complex QoL construct. 
Several studies have examined QoL in patients with CLE.
20,21,26,55,73,74,160,262 However, 
none of these studies have used a theoretical framework that clearly delineates the 
antecedents of QoL.
215
 Further, no studies were identified using the Revised Wilson and 
Cleary model,
215
 which was expanded to include a simplified conceptualization of and 
pathway to QoL. Also, no known studies have assessed biological/physiological 
functions, symptom status, functioning, general health perceptions, and various 
characteristics of the individual and the environment in CLE patients. Studies that used 
a more holistic measure of QoL in CLE patients, in the form of patient-reported 
outcomes, did not delineate a holistic theoretical framework to guide the inclusion or 
precedence of their study variables, thus further limiting the predictor variables used to 
explain QoL. Thus, future studies are needed to fill these knowledge 
gaps.
20,21,26,55,73,74,160,262   
QoL research in CLE patients is scant and has mainly focused on operationalizing 
health-related QoL; this narrow conceptualization leaves a gap in our understanding of 
QoL in CLE patients and its influencing factors. Also, studies, which use QoL 
theoretical frameworks that incorporate relevant health-related factors as well as 
characteristics of the individual and the environment, are needed. Understanding QoL 
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through this holistic view with the use of theoretical framework will add to our 
understanding of QoL in patients with CLE. 
 
3.3 SUMMARY 
Research in rare diseases is limited by several methodological challenges, mainly 
due to insufficient statistical power as a result of small patient sample sizes.
263
 Despite 
these challenges, policy makers require information on the therapeutic value of 
therapies for rare diseases to support their reimbursement decisions.
264
 In the event of a 
lack of long-term follow-up data from sufficiently large sample sizes, as is likely in a 
rare disease like CLE, conceptual models can be used to describe the disease burden 
and factors important to QoL in patients. Such conceptual models aid the extrapolation 
of outcomes based on limited sample sizes, by combining data with known-disease 
specific correlations.
232
 The theoretical framework chosen for this study to investigate 
the concept of QoL within the context of patients with CLE is the Revised Wilson and 
Cleary model by Ferrans et al.
215
 While the model has been used in other disease 
populations,
204,210,214,265
 there is currently no known research on its use in patients with 
CLE. To this end, this dissertation addresses that gap in the literature.  
The ultimate goal of methodically modeling QoL and its domains among patients 
with CLE is to identify empirically the domains of QoL that are adversely affected so as 
to tailor interventions specifically to this patient population. This is important to help 
these patients toward an improved overall QoL, knowing the significant negative effects 
of CLE on QoL.
20,21,26,55,73,74,160,262 Further, the use of the Revised Wilson and Cleary 
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model will enable the linking of traditional clinical variables and concepts found in the 
literature to the pathways of the most relevant QoL concepts in CLE patients.
223
 
  All the studies reviewed in this chapter used either multiple regression to 
examine the explanatory power of the model or SEM to test the overall model in QoL 
studies. Analysis of variance was also an example of a statistical method frequently 
used in these QoL studies. There are no gold standard criteria for the critical appraisal 
of models using either regression analyses or SEM. For this study, multiple regression 
and analysis of variance models will be used to examine the relationship between 
overall QoL and its correlates. Figure 3.5 contains the theoretical path model listing the 
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3.4 STUDY OBJECTIVES AND HYPOTHESES 
The objectives and hypotheses for the study are detailed below and will be tested 
using two specified models based on the following two measurements of QoL. The 
dependent measure of QoL for Model 1 is the newly-developed CLEQoL and for Model 
2 is the SF-36. 
 
Objectives and Hypotheses 
The specific objectives and hypotheses of this study are: 
 
Objective 1: To describe participants’ biological and physiological factors (CLE 
subtype, disease activity, disease damage, and disease duration), symptom status, (pain, 
pruritus, and fatigue), functioning (body image, depression, and comorbidity), general 
health perceptions (side-effects from CLE medications, skin health perception, and pill 
burden), characteristics of the individual (age, gender, education, race/ethnicity, and 
smoking status), characteristics of the environment (marital status, income, and social 
support), and overall QoL (CLEQoL and SF-36). 
 
Objective 2: To determine the predictive ability of biological and physiological factors 
(CLE subtype, disease activity, disease damage, and disease duration), symptom status 
(pain, pruritus, and fatigue), functioning (body image, depression and comorbidity), and 
general health perceptions (side-effects from CLE medications, skin health perception, 
and pill burden) in explaining overall QoL in patients with CLE while controlling for 
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characteristics of the individual (age, gender, education, race/ethnicity, and smoking 
status) and characteristics of the environment (marital status, income, and social 
support). 
 
H2A: Biological and physiological factors (CLE subtype, disease activity, 
disease damage, and disease duration), symptom status (pain, pruritus, and 
fatigue), functioning (body image, depression, and comorbidity), and general 
health perceptions (side-effects from CLE medications, skin health perception, 
and pill burden) will explain a significant amount of variance in overall QoL 
(CLEQoL and SF-36) while controlling for characteristics of the individual (age, 
gender, education, race/ethnicity, and smoking status) and characteristics of the 
environment (marital status, income, and social support). 
H2B1: Biological and physiological factors (CLE subtype, disease activity, 
disease damage, and disease duration) will be positive and significant predictors 
of overall QoL (CLEQoL) while controlling for symptom status (pain, pruritus, 
and fatigue), functioning (body image, depression, and comorbidity), general 
health perceptions (side-effects from CLE medications, skin health perception, 
and pill burden), characteristics of the individual (age, gender, education, 
race/ethnicity, and smoking status) and characteristics of the environment 
(marital status, income, and social support). 
H2B2: Biological and physiological factors (CLE subtype, disease activity, 
disease damage, and disease duration) will be negative and significant predictors 
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of overall QoL (SF-36) while controlling for symptom status (pain, pruritus, and 
fatigue), functioning (body image, depression, and comorbidity), general health 
perceptions (side-effects from CLE medications, skin health perception, and pill 
burden), characteristics of the individual (age, gender, education, race/ethnicity, 
and smoking status) and characteristics of the environment (marital status, 
income, and social support). 
H2C1: Symptom status (pain, pruritus, and fatigue), will be positive and 
significant predictors of overall QoL (CLEQoL) while controlling for biological 
and physiological factors (CLE subtype, disease activity, disease damage, and 
disease duration), functioning (body image, depression, and comorbidity) 
general health perceptions (side-effects from CLE medications, skin health 
perception, and pill burden), characteristics of the individual (age, gender, 
education, race/ethnicity, and smoking status) and characteristics of the 
environment (marital status, income, and social support). 
H2C2: Symptom status (pain, pruritus, and fatigue), will be negative and 
significant predictors of overall QoL (SF-36) while controlling for biological 
and physiological factors (CLE subtype, disease activity, disease damage, and 
disease duration), functioning (body image, depression, and comorbidity) 
general health perceptions (side-effects from CLE medications, skin health 
perception, and pill burden), characteristics of the individual (age, gender, 
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education, race/ethnicity, and smoking status) and characteristics of the 
environment (marital status, income, and social support). 
H2D1: Functioning (body image, depression, and comorbidity) will be positive 
and significant predictors of overall QoL (CLEQoL) while controlling for 
biological and physiological factors (CLE subtype, disease activity, disease 
damage, and disease duration), symptom status (pain, pruritus, and fatigue), 
general health perceptions (side-effects from CLE medications, skin health 
perception, and pill burden), characteristics of the individual (age, gender, 
education, race/ethnicity, and smoking status) and characteristics of the 
environment (marital status, income, and social support). 
H2D2: Functioning (body image, depression, and comorbidity) will be negative 
and significant predictors of overall QoL (SF-36) while controlling for 
biological and physiological factors (CLE subtype, disease activity, disease 
damage, and disease duration), symptom status (pain, pruritus, and fatigue), 
general health perceptions (side-effects from CLE medications, skin health 
perception, and pill burden), characteristics of the individual (age, gender, 
education, race/ethnicity, and smoking status) and characteristics of the 
environment (marital status, income, and social support). 
H2E1: General health perceptions (side-effects from CLE medications, skin 
health perception, and pill burden) will be negative and significant predictors of 
overall QoL (CLEQoL) while controlling for biological and physiological 
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factors (CLE subtype, disease activity, disease damage, and disease duration), 
symptom status (pain, pruritus, and fatigue), functioning (body image, 
depression, and comorbidity), characteristics of the individual (age, gender, 
education, race/ethnicity, and smoking status) and characteristics of the 
environment (marital status, income, and social support).   
H2E2: General health perceptions (side-effects from CLE medications, skin 
health perception, and pill burden) will be positive and significant predictors of 
overall QoL (SF-36) while controlling for biological and physiological factors 
(CLE subtype, disease activity, disease damage, and disease duration), symptom 
status (pain, pruritus, and fatigue), functioning (body image, depression, and 
comorbidity), characteristics of the individual (age, gender, education, 
race/ethnicity, and smoking status) and characteristics of the environment 
(marital status, income, and social support).  
Objective 3: To determine if symptom status (pain, pruritus, and fatigue) is related to 
biological and physiological factors (CLE subtype, disease activity, disease damage, 
and disease duration), characteristics of the individual (age, gender, education, 
race/ethnicity, and smoking status) and characteristics of the environment (marital 
status, income, and social support). 
H3A: There is no association between biological and physiological factors (CLE 
subtype, disease activity, disease damage, and disease duration) and symptom 
status (pain, pruritus, and fatigue). 
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H3B: There is no association between characteristics of the individual (age, 
gender, education, race/ethnicity, and smoking status) and symptom status (pain, 
pruritus, and fatigue). 
H3C: There is no association between characteristics of the environment (marital 
status, income, and social support) and symptom status (pain, pruritus, and 
fatigue). 
 
Objective 4: To determine if functioning (body image, depression, and comorbidity) is 
related to symptom status (pain, pruritus, and fatigue), characteristics of the individual 
(age, gender, education, race/ethnicity, and smoking status) and characteristics of the 
environment (marital status, income, and social support). 
H4A: There is no association between symptom status (pain, pruritus, and 
fatigue) and functioning (body image, depression, and comorbidity). 
H4B: There is no association between characteristics of the individual (age, 
gender, education, race/ethnicity, and smoking status) and functioning (body 
image, depression, and comorbidity). 
H4C: There is no association between characteristics of the environment (marital 





Objective 5: To determine if general health perceptions (side-effects from CLE 
medications, skin health perception, and pill burden) is related to functioning (body 
image, depression, and comorbidity), characteristics of the individual (age, gender, 
education, race/ethnicity, and smoking status) and characteristics of the environment 
(marital status, income, and social support). 
H5A: There is no association between functioning (body image, depression, and 
comorbidity) and general health perceptions (side-effects from CLE 
medications, skin health perception, and pill burden). 
H5B: There is no association between characteristics of the individual (age, 
gender, education, race/ethnicity, and smoking status) and general health 
perceptions (side-effects from CLE medications, skin health perception, and pill 
burden). 
H5C: There is no association between characteristics of the environment (marital 
status, income, and social support) and general health perceptions (side-effects 
from CLE medications, skin health perception, and pill burden). 
Objective 6: To compare the predictive ability of each of the two models (Model 1 – 
CLEQoL and Model 2 – SF-36), in patients with CLE according to the proposed 
theoretical framework of the Revised Wilson and Cleary Model.  
 
H6A: The model with CLEQoL (Model 1) as the dependent variable will have a 
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CHAPTER FOUR: METHODOLOGY 
The purpose of this study was two-fold: a) to describe the quality of life (QoL) in 
patients with Cutaneous Lupus Erythematosus (CLE) and b) to identify the factors 
associated with quality of life QoL in these patients using the Revised Wilson and 
Cleary Model. This chapter is divided into nine major sections: Study Design, Sample 
Selection, Instrument Development, Study Variables, Survey Pretest, Instrument 
Distribution, Data Analyses, Hypotheses Statistical Tests, Limitations, and Summary. 
 
4.1     STUDY DESIGN 
This study employed a multi-method, multi-phase approach via: 1) use of focus 
groups (FGs) to determine the impact of CLE on patients’ lives, and 2) a cross-
sectional, non-experimental design to determine factors related to QoL in patients with 
CLE. The FGs were used to explore, describe and clarify the patients’ perspective of 
how CLE has impacted their lives, and examine patients’ perceptions of unmet needs 
regarding CLE treatment and care. 
 Self-report paper-pencil surveys were used to measure the relationships between 
previously described factors and QoL in patients with CLE. A cross-sectional design is 
best used to examine data at one point in time and to describe the status of phenomena 
and/or the relationships among these phenomena.
266
 Data were collected at one point 





4.2       PATIENT RECRUITMENT 
Due to CLE being a rare disease, patients were recruited via the registry 
maintained by the University of Texas (UT) Southwestern Medical Center.  The sites 
for data collection were the University of Texas (UT) Southwestern Medical Center and 
Parkland Health and Hospital System, both in Dallas, with over 200 patients with CLE. 
CLE patients were validated according to the four (malar rash, discoid lesions, oral 




For the focus groups, patients, from this registry, who have indicated that they 
are interested in being contacted for future research projects, who met the inclusion 
criteria (see below), and were local residents (within an hour of the data collection site) 
were invited to participate in the study. Out of considerations for transportation 
concerns to the data collection site, only patients who lived in the Dallas area were 
contacted to participate in the study. Non-registry patients were also recruited during 
their clinical visits to the hospital. 
For the final survey data collection, patients who met the inclusion criteria (see 
below) were recruited during their clinical visits to the hospital as well as from the 
patient registry of CLE patients. Clinical staff from both hospitals in Dallas also assisted 
in recruiting non-registry patients during their clinic visits. These patients were asked if 





4.2.1 INCLUSION AND EXCLUSION CRITERIA 
   The inclusion criteria in this study were as follows: 
 Patients, who have a diagnosis of CLE; 
 Must have had a clinic visit within the past two years;  
 Aged 18 years and above; and 
 Ability to give informed consent. 
 
The exclusion criteria in this study were as follows: 
 Patients with no CLE diagnosis; 
 Not had a clinic visit within the last two years; and 
 Under 18 years of age; and 
 Not capable of giving informed consent. 
 
4.2.2 IRB PROCEDURES 
This study was conducted within accordance of the guidelines set forth by the 
institutional review boards (IRBs) at both UT at Austin (2015-09-0041) and UT 
Southwestern (STU 102015-056 and STU 082010-241). Because this study involved 
human subjects, two applications – one for the FGs and a separate submission for the 
paper-pencil surveys – were submitted for approval by the IRBs at both universities.  
To protect the confidentiality of the participants, informed consent statements 
were provided at the beginning of data collection. These consent forms were reviewed 





4.3       INSTRUMENT DEVELOPMENT 
The instrument employed in this study was guided by the Revised Wilson and 
Cleary model. The constructs from the model used in this study were biological and 
physiological factors, symptom status, functioning, general health perceptions, 
characterstics of the individual and environment, and overall QoL. The revised measure 
of overall QoL was elicited from focus group interviews and select questions from the 
instruments – VitiQoL
157
 and Skindex 29+3.
21,22,26
 All study participants were 
compensated with $10 gift cards for their participation.  
 
4.3.1 FOCUS GROUPS 
Three FGs were conducted to capture the disease burden and QoL in patients 
with CLE. Six to ten CLE patients were recruited [See Appendix A] for each group and 
patients were compensated with $50 VISA gift cards for their participation in a 1 to 1.5 
hour FG session. The FGs were divided into three portions. The first portion was 
devoted to introductions, filling out consent forms, and administration of brief survey 
questions. The pre-focus group demographic survey [See Appendix B] gathered 
information on gender, age, education level, race/ethnicity, marital status, smoking 
status, insurance status, and residency area.  
The second part entailed the main discussion of the FG topics beginning with a 
description of the study purpose. Using the moderator guide [See Appendix C], FG 
participants were asked open-ended questions about how CLE affects their overall QoL. 
For example, questions were used to assess how CLE affects patients by first asking 
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participants to write down all the ways that CLE affects them.
53
 When necessary, 
probes were used to ascertain how CLE affects their work life, daily activities, social 
life, personal relationships, or leisure activities, as well as to determine the impact of 
photosensitivity, alopecia, and mental health.
53
  
In the third part of the FG, participants were handed copies of the Skindex-
29+3
29
 [See Appendix D] and VitiQoL
157
 [See Appendix E] instruments and were asked 
to review the items on the questionnaire. Feedback was received on their relevance to 
CLE and suggestions were solicited regarding items that can be added to the 
instruments to make them more relevant to CLE. The Skindex-29+3
21,22,26
 contains 32 
items but item 18 about side-effects from treatment is not scored. Symptoms, emotions, 
functioning, and lupus-specific concerns (such as alopecia and photosensitivity) are the 
four domains measured in the Skindex-29+3. VitiQoL has 15 items and focuses on three 
domains – participation limitation, stigma, and behavior. These two instruments were 
chosen due to their clinical and content relevance to CLE, such as emphasis on skin-
specific domains like emotions, symptoms, and functioning.  
FGs have been shown to be a beneficial tool to use when obtaining information 
about some phenomenon from a target population, as well as to create an environment 
that allows participants to express themselves freely.
268
 According to Rabiee,
269
 FGs are 
used to explore complex decisions and behaviors within the context of day-to-day 
living. They are also used to generate a larger amount of data compared to one-on-one 
interviews.
269
 FGs were audiotaped, and the content was analyzed by three coders 
independently. The use of FGs increased the likelihood of identifying all health issues 
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relevant to CLE patients and also highlighted emergent overall QoL issues that may not 
have been captured during the literature review. Finally, findings from the FGs were 
used to create the overall QoL measure relevant to CLE patients. The focus group 
sessions were all conducted in February 2016. 
 
4.3.2 DATA ANALYSIS 
Thematic analysis was chosen as the methodology to analyze the FG data 
because its interpretive process helps to identify common themes and to achieve 
understanding.
270
 Specifically, the thematic analysis guidelines by Braun and Clarke 
were used to analyze the FG transcripts.
271
 The guidelines are divided into six phases: a) 
familiarizing with the data, b) extracting initial codes, c) generating themes, d) 
reviewing the themes, e) defining and naming themes, and f) producing the report. Data 
analysis was conducted using Dedoose software.
272
 Validity checks were conducted 
throughout the data analysis by checking and re-checking the concepts. Using topic 
coding, recurring concepts and phrases were grouped into codes, and then sub-themes, 
which were placed under overarching themes/categories. Three coders, trained in 
qualitative research methods, independently pre-tested the definitions of the 
themes/categories by thoroughly reviewing the transcripts. Results were compared 
among the three coders and discrepancies were resolved through discussion.  
Finally, the demographic survey responses were analyzed using descriptive 




4.4       STUDY VARIABLES 
The assessment of QoL and its components in this study included the use of 
standardized and disease-specific questionnaires. This study operationalized the five 
main components of the Revised Wilson and Cleary model
215
 as follows:  
- Biological/physiological factors: CLE subtype (ACLE, SCLE, DLE, Tumid lupus, 
Lupus panniculitis), disease activity and damage (as measured by Cutaneous Lupus 
Disease Area and Severity Index (CLASI)), and disease duration. 
- Symptoms status: Pain, pruritus and fatigue numerical rating scales (NRS). 
-  Functional status: Body image, depression, and comorbidity. 
- General health perceptions: Side-effects from CLE medications, skin health 
perception, and pill burden. 
- Characteristics of the individual: Age of participants (in years), gender (male or 
female), education (current classification), race/ethnicity (African American/Black, 
Asian, Caucasian, Hispanic, and Other), and smoking status (current smoker, former 
smoker, and never smoker). 
- Characteristics of the environment: Marital status (single, divorced, 
married/domestic partner, widowed, or separated), income (using ZIP codes and 
median household income) and social support]. 
 Finally, measures for biological/physiological factors were collected by the 
physician and through retrospective medical chart reviews with the clinical staff. Once 
collected, these measures were linked, using unique patient IDs, with the measures for 
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the remaining factors – symptom status, functioning, general health perception, and 
overall QoL, which were all patient self-report measures. 
 
4.4.1 DEPENDENT VARIABLES 
Overall QoL was measured using two separate scales. Based on the WHO 
recommendations for the development of QoL measures, a disease-specific instrument 
(CLEQoL, created from focus group findings and other instruments) [See Appendix F] 
and a generic instrument (SF-36) [See Appendix G] served as the measures for overall 
QoL in the current study. CLEQoL was adapted from the Skindex 29+3, VitiQoL, and 
from content analyses of FG findings in CLE patients. Finally, use of the CLEQoL in 
addition to SF-36 in measuring QoL in CLE patients will provide complementary and 
comprehensive information. 
 
4.4.1.1 CUTANEOUS LUPUS ERYTHEMATOSUS QUALITY OF LIFE 
(CLEQoL) 
The CLEQoL is a 36-item quality of life measure for CLE; it includes 32 items 
from the Skindex-29+3 (but item 18 about side-effects of treatment is not scored),
21,22,26
 





 scale consists of three domains: symptoms, emotions, and 
functioning,
29
 and three additional questions to assess lupus-specific concerns (such as 
photosensitivity and alopecia).
26,273
 The additional questions from VitiQoL assess 
photoprotection practices and body image. Similar to the Skindex-29+3, the CLEQoL 
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assessed how often (Never, Rarely, Sometimes, Often, All the time) during the previous 
four weeks the patient experienced the effect described in each item. Scores of 0 
(never), 25 (rarely), 50 (sometimes), 75 (often), and 100 (all the time) are assigned to 
each question and averaged to determine each domain score from 0-100, with higher 
scores indicating poorer QoL. 
 
4.4.1.2 SHORT-FORM (SF)-36 
The SF-36 measures responses to eight subscales (36 items) relating to general 
health including physical functioning, role-physical, bodily pain, general health, vitality, 
social functioning, role-emotional and mental health. Each subscale is transformed onto 
a 0–100 scale and converted into a norm-based score (using a mean of 50 and a SD of 
10 for the U.S. general population), allowing for comparison of scores to other medical 
conditions.
21,54
 Two overall summary scores were obtained – Physical Component 
Summary (PCS) and Mental Component Summary score (MCS) scores. Summary 
scores were transformed to have a mean of 50 and standard deviation of 10, with higher 
scores indicating a higher QoL.  
 The SF-36 has evidence of acceptable reliability (internal consistency), construct 
validity (convergent and known-groups) and the ability to detect change 








4.4.2 INDEPENDENT VARIABLES 
4.4.2.1 BIOLOGICAL/PHYSIOLOGICAL FACTORS 
The measures for biological/physiological factors were assessed by the 
physician and collected at the time of each patient visit to the clinic or in retrospective 
chart reviews with the clinical staff.  
Specifically, biological and physiological factors were examined using: 1) the 
clinician-reported outcome measure, the Cutaneous Lupus Erythematosus Disease Area 
and Severity Index (CLASI)
50
 to assess both disease activity and damage, 2) CLE 
subtype, and 3) disease duration. The CLASI [See Figure 4.1] is designed as a table 
where the rows represent anatomical areas, and the columns score major clinical 




Total CLASI activity and damage scores were derived from the arithmetic sum 
of each of the individual scores on items in a given cutaneous activity field. Activity 
was scored on the basis of erythema (13 items; scored on scale of 0-3 with a possible 
score ranging from 0-39), scale/hypertrophy (13 items; scored on scale of 0-2 with a 
possible score ranging from 0-26), mucus membrane involvement (coded as ‘0’ for 
absent and ‘1’ for presence of lesion or ulceration), acute hair loss (coded as ‘0’ for no 
and ‘1’ for yes), and non-scarring alopecia (coded as ‘0’ for absent, ‘1’ for diffuse; non-
inflammatory, ‘2’ for focal or patchy in one quadrant, and ‘3’ for focal or patchy in 
more than one quadrant). The total CLASI activity scores can range from 0 to 70, with 
higher scores denoting greater disease activity.
46
 Severity groups are indicated by the 
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following CLASI activity score ranges: mild (0-9), moderate (10-20), and severe (21-
70).
236
 Similarly, the total CLASI damage score was the arithmetic sum of the items 
rated by per body region for damage caused by dyspigmentation, 
scarring/atrophy/panniculitis, and scarring of the scalp. Scores can range from 0 to 70, 
with higher scores indicating greater disease damage.
46
 The CLASI has been reported to 
have an intraclass correlation coefficient for inter-rater reliability of 0.86 – 0.90 for the 
activity score and of 0.90 – 0.92 for the damage score.
46,50
  
CLE subtype was assessed by acute (ACLE), subacute (SCLE), chronic (DLE, 
Tumid lupus, Lupus panniculitis), and Other; CLE subtype was then recoded into two 
categories: DLE vs non-DLE. Disease duration was assessed through reviews of 
patients’ medical records to determine how long they have been diagnosed with CLE by 














4.4.2.2 SYMPTOM STATUS 
Symptom status was assessed using unidimensional scales
274,275
 to measure 
symptom-related issues of pain, fatigue and pruritus. Examples of unidimensional scales 
are the Verbal Rating Scale (VRS), the Visual Analog Scale (VAS), and the Numerical 
Rating Scale (NRS). These three examples are the most widely used methods for 






 In this study, 
the NRS format was used to measure symptom status as this format has been shown to 
be well accepted in patient populations and it also provides a better assessment than the 
VAS or the VRS.
278
   
 
4.4.2.2.1 NUMERICAL RATING SCALE (NRS) FOR PAIN 
The NRS for pain is a unidimensional measure of pain intensity in 
adults.
279,280
 Although various versions exist, the most commonly used is the variant 
developed by Farrer and colleagues
281
 – the pain intensity numeric rating scale (PI-
NRS). The PI-NRS is a segmented numeric version in which respondents choose a 
whole number (0-10 integers) that best describes the intensity of their pain.
280
 Similar to 
the pain VAS, the PI-NRS is anchored at both ends with extreme measures describing 
pain intensity.
279,280
 The PI-NRS is a single 11-point numeric scale with 0 representing 
one pain extreme (e.g., “no pain”) and 10 representing the other pain extreme (e.g., 
“pain as bad as you can imagine”). Higher scores indicate greater pain intensity. The 
scale has a recall period of the last 24 hours. High test–retest reliability (r = 0.95 – 0.96) 
has been reported in other patient populations and the scale has demonstrated good 
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construct validity as it was highly correlated to the VAS in patients with chronic pain 
(correlations range from 0.86 to 0.95). Using the PI-NRS, in this study, pain was 
measured as: 
Directions: Please circle the one number on the scale that best answers the question. 
 
On average, how much PAIN have you experienced in the last 24 hrs? 
  
 0 1 2 3 4 5 6 7 8 9 10 
No pain         Pain as bad 
  as you can imagine    
    
 
  
4.4.2.2.2 NUMERICAL RATING SCALE (NRS) FOR PRURITUS/ITCH 
The Worst Itch Numeric Rating Scale (WI-NRS) was used to assess 
pruritus/itch. It was originally developed to measure the severity of itching in patients 
with psoriatic skin conditions.
282
 The WI-NRS is a single 11-point numeric scale with 0 
representing “no itching” and 10 representing “itch as bad as you can imagine.” Higher 
scores indicate higher itch severity. The scale has a recall period of the last 24 hours. No 
psychometric properties have been reported for the scale. Similar to the WI-NRS, 
itching was measured in this study as shown below: 
 
 
Directions: Please circle the one number on the scale that best answers the question. 
 
On average, how much ITCH have you experienced in the last 24 hrs? 
 0 1 2 3 4 5 6 7 8 9 10 
No itch                              Itch as bad  







4.4.2.2.3 NUMERICAL RATING SCALE (NRS) FOR FATIGUE 











 For this study, the 
Worst Fatigue – Numeric Rating Scale (WF-NRS)
286
 was used to assess the severity of 
fatigue during the previous 1-week period. The WF-NRS has been validated for 
assessing fatigue severity in patients with ankylosing spondylitis,
286
 and rheumatoid 
arthritis.
288 Responses were on an 11-point numeric rating scale with anchors at 0 (No 
fatigue) and 10 (Fatigue as bad as you can imagine). Higher scores on the WF-NRS 
indicate higher fatigue severity. Fatigue severity was measured in this study as shown 
below: 
 
Directions: Please circle the one number on the scale that best answers the question. 
On average, how much FATIGUE have you experienced in the past week? 
 0 1 2 3 4 5 6 7 8 9 10 
No fatigue                    Fatigue as bad  





Functioning was conceptualized as three different measures: body image, 
depression, and comorbidity. Body image was measured by the Body Image Scale 
(BIS)
289
 which was developed in collaboration with the European Organization for 
Research and Treatment of Cancer (EORTC) Quality of Life Study Group. The BIS is a 
10-item scale developed to measure changes in body image in patients with cancer. 
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Responses range from 0 (not at all) to 3 (very much). BIS scores were calculated by 
adding the score obtained on each item, yielding a range of possible scores from 0–30. 
Higher scores indicate a greater degree of body image dissatisfaction. Cronbach’s alpha 




Depression was measured by two items: “Have you been diagnosed (by a 
professional) with depression?” (“0” for no, and “1” for yes),” and if yes, whether they 
were currently receiving treatment for depression (“0” for no, and “1” for yes). 
Comorbidity was assessed by using the Self-Administered Comorbidity Questionnaire 
(SCQ).
290
 The SCQ addresses 13 major body systems with three binary question 
regarding the occurrence of health-related problems (problem score), treatments 
received or medication (treatment score), and limitations experienced in daily life 
(limitation score). The sum of all the affirmed items from the three sub-scores make up 
the total score of the SCQ, ranging from 0 to 39, with higher scores indicating higher 
comorbidity scores and limitations.
291
 Further, three CLE-relevant additional conditions 
were added to the SCQ,
290
 which were rheumatoid arthritis, hepatitis, and HIV. 
However, depression was taken out of the list of comorbidities as this was already being 
measured as a separate variable. As a result, the scores for the final SCQ measure 






4.4.2.4 GENERAL HEALTH PERCEPTIONS 
General health perceptions were assessed by using measures from the 
LupusPRO, which focus on impact and satisfaction with treatment. The LupusPRO
292
 is 
a 43-item measure that quantifies the effects of systemic lupus erythematosus (SLE) or 
its treatment on QoL in adults with SLE over the previous four weeks. It is composed of 
eight HRQoL domains [lupus symptoms (3 items), cognition (2 items), lupus 
medications (2 items), procreation (2 items), physical health (5 items), pain vitality (5 
items), emotional health (6 items), and body image (5 items)] and four non-HRQoL 
domains [(desires-goals (4 items), social support (2 items), coping (3 items), and 
satisfaction with care (4 items)]. Items are rated on a 5-point Likert scale from 0 (none 
of the time) to 4 (all of the time), and a “not applicable” response is included for some 
questions. Item scores are totaled for each domain item, and the mean domain score is 
obtained by dividing the total score by the number of items in that domain. The mean 
raw domain score is transformed to scores ranging from 0 (worst QoL) to 100 (best 
QoL) by dividing by 4 [the number of Likert responses (5 responses) minus 1] and then 
multiplying by 100, as below: 
(Mean raw domain score/4) x 100= Transformed score for the domain. 
Total HRQoL and non-HRQoL scores were obtained by averaging the domain scores 
within each construct.  
The LupusPRO was developed based on input from SLE patients in both 
concept elicitation and cognitive interview phases of research. Evaluation of the 
psychometric properties of the LupusPRO in SLE patients demonstrates evidence of 
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acceptable reliability (internal consistency and reproducibility) and construct validity 
(concurrent and known groups).
48,292
 The ability to detect change (responsiveness and 
sensitivity to change) was not reported for the LupusPRO.
48,292
 While the measures in 
the LupusPRO were developed for and in SLE patients, some of the domains are 
relevant and similar to CLE patients; these are lupus medications, desires-goals, and 
social support, and these were the only measures from the LupusPRO used in this 
current study. 
Side-effects and medication burden were measured with two items from the 
LupusPRO, respectively: “In the past 4 weeks, how often did you experience the 
following due to your CLE: serious side-effects associated with CLE medications, and 
concerns about the number of medications you currently take for your CLE?” Items 
were rated on a 5-point Likert scale from 0 (none of the time) to 4 (all of the time) and 
“not applicable (recoded as ‘0’ for scoring);” each item was then reverse-coded. 
Domain scores ranged from 0 to 8, with higher scores reflecting lower medication 
burden, and subsequently lower treatment impact. Finally, skin health perception was 
measured on an 11-point numeric rating scale with anchors at 0 (Worst skin imaginable, 
i.e., total body burn) and 10 (Perfect health), with higher scores indicating better 
perceptions of skin health. 
 
4.4.2.5 CHARACTERISTICS OF THE INDIVIDUAL 





Age was measured by asking respondents in what year were they born. The year 




Participants were asked to indicate whether they are male (‘1’) or female (‘2’). 
 
Education  
Participants were asked to indicate their highest educational attainment from the 




This was measured by asking participants to indicate which of the listed 
categories best describes their race/ethnicity: African American/Black, Asian, 
Caucasian, Hispanic, or Other. Race/ethnicity was then recoded as African 
American/Black vs. Others (Asian, Caucasian, Hispanic, or Other). 
 
Smoking Status  
Participants were asked if they smoked cigarettes using three categories: Former 
Smoker, Never smoker, and Current Smoker, which was then recoded into two 
categories as “1” for current/former smoker and “2” for never smoker). 
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4.4.2.6 CHARACTERISTICS OF THE ENVIRONMENT 
Characteristics of the environment were measured as follows: 
  
Marital status 
Marital status was measured as Single, Divorced, Married/Domestic Partner, 
Widowed, or Separated. This variable was then recoded into two categories as “1 




Socioeconomic (SES) indices at the ZIP code level were calculated from 
publicly-available data on annual median household income.
293
 The annual median 
household income served as a proxy for individual-level annual income. 
 
Social Support 
Social support was measured by a single item from the LupusPRO: “Generally, I 
receive support from friends and/or family?” Response scales ranged from 0 (none of 
the time) to 4 (all of the time); and “not applicable (recoded as ‘0’ for scoring),” with 
higher scores reflecting higher social support. Table 4.1 below summarizes the sources 





Table 4.1: Sources of Construct Measurement 





This assessed participants’ overall quality of life. The CLEQoL contains 36 items (Item 18 about 
side-effects of treatment is not scored) and asked participants how often (Never, Rarely, 
Sometimes, Often, All the time) during the previous four weeks they experienced the effect 
described in each item. Scores of 0 (never), 25 (rarely), 50 (sometimes), 75 (often), and 100 (all 
the time) w assigned to each question and averaged to determine each domain score from 0-100. 



















Thirty-six items assessed general health and evaluated the following domains over the past four 
weeks: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), 
vitality (VT), social functioning (SF), role-emotional (RE) and mental health (MH).
54
 Each score 
was transformed onto a 0–100 scale and converted into a norm-based score (using a mean of 50 






















Disease activity and damage: CLASI disease activity and damage scores ranged from 0 to 70 with 




Disease duration was measured by reviewing patients’ medical records to see how long they have 












Pain was measured using the pain intensity numeric rating scale (PI-NRS).
281
 The PI-NRS is a 
single 11-point numeric scale with 0 representing one pain extreme (e.g., “no pain”) and 10 
representing the other pain extreme (e.g., “pain as bad as you can imaging”). Higher scores 









The Worst Itch Numeric Rating Scale (WI-NRS)
282
 was used to asses pruritus/itching. It is a 
single 11-point numeric scale with 0 representing “no itching” and 10 representing “itch as bad as 
you can imagine.” Higher scores indicated higher itch severity. The scale has a recall period of the 






The Worst Fatigue – Numeric Rating Scale (WF-NRS)
286
 was used to assess the severity of 
fatigue during the previous 24-hour period. Responses are on an 11-point numeric rating scale 
with anchors at 0 (No fatigue) and 10 (fatigue as bad as you can imagine). Higher scores on the 







Depression: A two-item question asked participants if they have ever been professionally 
diagnosed with depression (“0” for no and “1” for yes) and if yes, whether they were currently 








*Item was reverse-coded 
 
Table 4.1: Sources of Construct Measurement (Cont’d) 







Body Image: A 10-item scale that measured changes in body image. Responses ranged from 0 (not 
at all) to 3 (very much); yielding a possible score ranging from 0 to 30 with higher scores indicating 








Self-Administered Comorbidity Questionnaire (SCQ): A 14-item scale that measured health-related 
problems, medications or treatments received, and limitations experienced. The SCQ yielded a 
possible score ranging from 0 to 42 with higher scores indicating higher scores indicating higher 
comorbidity.  
 











Side-effects from CLE medications: This was measured by using one item from the LupusPRO 
measured on a 5-point Likert response scale ranging from 0 (none of the time) to 4 (all of the time), 
and “not applicable (recoded as ‘0’ for scoring).” Scores ranged from 0 to 4 and were reverse coded 









Pill Burden: This was assessed by a single measure from the Lupus PRO. Responses were rated on 
a 5-point Likert scale from 0 (none of the time) to 4 (all of the time); and “not applicable.” Scores 







Skin health perception: This was measured using a single item numeric scale to assess patients’ 
current perception of their skin health. Responses were on an 11-point numeric rating scale with 
anchors at 0 (worst skin imaginable, i.e., total burden) to 10 (perfect health). Higher scores on this 











These are baseline measures that may or may not directly/indirectly influence the QoL of CLE 
patients: 
- Age of participants (in years) 
- Gender (male, female) 
- Education (lower than high school, high school, college, or graduate degree) 
- Race/ethnicity (African American/Black, Asian, Caucasian, Hispanic, or Other) 














These are factors that are assumed to include tangible and intangible resources available in the 
individual’s surroundings:
223








- Marital status (single, divorced, married/domestic partner, widowed, or separated) EMR 
- Income  EMR 








4.5     SURVEY PRETEST 
After the FG transcripts were content-analyzed and the instrument was created, 
the questionnaires were pretested by patients and physicians to ensure content validity 
and readability of all questions and responses. Participants were asked to give feedback 
on potential issues with format/layout, length, unclear or confusing questions, unclear or 
confusing answer choices, instructions, relevance, and face validity.
295
 Once the 
feedback was received, necessary changes were made to improve the questionnaire 
before being administered to the final, target population.  
 
4.6     INSTRUMENT DISTRIBUTION 
CLE is a chronic, rare disease with a prevalence rate of 30 - 41 cases per 100,000 
persons. To this end, registries are the best sources of identifying patients as they serve 
as a large repository of patient information such as diagnosis, age, gender, and 
medications. The University of Texas (UT) Southwestern Medical Center and Parkland 
Health and Hospital System maintain a large registry database for CLE patients and 
served as the sites for patient recruitment. In addition, patients who were not in the 
registry were recruited during their clinical visit to the hospital. 
Each survey packet contained a cover letter [See Appendix H], detailing the 
purpose of the study and the importance of respondents’ participation. Patient 






Using the paper-pencil surveys [See Appendix I], participants were recruited 
during their clinical visits to the hospital. Clinical staff from both hospitals in Dallas 
assisted in recruiting patients during their clinic visits. These patients were asked if they 
would be interested in participating in a study about CLE and how it affects them. If the 
patient agreed and met our eligibility criteria, he/she was handed a copy of the 
questionnaire. Completed surveys were handed to the clinic personnel and kept in 
folders provided to them.  
 
4.7    DATA ANALYSES 
Data from the final survey were coded and analyzed using SPSS version 23. The 
significance level for this study was set a priori as 0.05. 
Descriptive Statistics 
 Each continuous/interval variable was examined for its distribution, range, 
mode, median, mean, and standard deviation. Normality tests, skewness, and kurtosis 
were carried out on continuous and interval-level variables. All interval-level data 
(dependent variables only) were screened to ensure that the normality assumptions were 
met before applying statistical tests.  
For dichotomous and nominal-level variables, frequencies were assessed to 
determine if the requirements for cell sizes are met. Finally, data were screened for 




 Independent samples t-tests (for explanatory variables with two levels) and 
ANOVA (for explanatory variables with more than two levels) were conducted on study 
variables. 
 
Multiple Regression Analyses 
 The statistical objectives of this current study were to develop two regression 
models to predict overall QoL (assessed using CLEQoL and SF-36) in patients with 
CLE using biological and physiological factors (CLE subtype, disease activity, disease 
damage, disease duration), symptom status, (pain, pruritus, fatigue), functioning (body 
image, depression, comorbidity), and general health perceptions (side-effects from CLE 
medications, skin health perception, pill burden), as main predictor variables. 
Characteristics of the individual (age, gender, education, race/ethncity, and smoking 
status) and the environment (marital status, income, and social support) served as the 
covariates of the study. 
Due to the small sample size, the study objectives (from Chapter 3) were revised 
to include only the predictor variables that were empirically important and strongly 
related to the dependent variables. To achieve this, parsimonious models were built by 
first running bivariate analyses to determine which independent variables and covariates 
were significant and should be included in the final multivariate regression model. As a 
result, the predictor variables in the hypothesis/objectives and multiple regression 
models were reduced from 21 to nine. The reduced model is below in Figure 4.2. 
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Multiple linear regressions were used to assess: 1) the relationships between the 
four main determinants (biological and physiological factors, symptom status, 
functioning, and general health perceptions), and intrinsic (characteristics of the 
individual) and extrinsic (characteristics of the environment) factors as predictor 
variables with overall QoL serving as the dependent variable. Each construct was 
entered into the model simultaneously: 
 
Y1 = B0 + B1X1 + B2X2 + B3X3 + B4X4 + B5X5 + B6X6 + B7X7 + B8X8 + B9X9ei 
Y2 = B0 + B1X1 + B2X2 + B3X3 + B4X4 + B5X5 + B6X6 + B7X7 + B8X8 + B9X9ei 
Y1= overall quality of life as measured by the CLEQoL 
Y2= overall quality of life as measured by the SF-36 
B0= intercept 




X5= body image 
X6= side-effects from CLE medications  
X7= race/ethnicity 
X8= smoking status 
X9= social support 
ei = error term 
 
The Bs are the regression coefficients for the respective predictor variables. The 
dependent variables in the regression equations are Y1 and Y2. 
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Tests for multivariate normality, linearity, and homoscedasticity were carried 
out on relevant variables by examining standardized residual scatterplots.
296
 Normality 
is met when all variables and possible linear combinations of variable are distributed 
normally. If met, the differences between the observed and predicted values (residual) 
are distributed proportionately across the center of the scatterplot. Normality was 
examined via statistical or graphical analyses; by using skewness and kurtosis. 
Skewness implies that the shape of a unimodal distribution is asymmetrical about its 
mean.
297
 Kurtosis is a measure of the ‘peakedness’ of the distribution.
298
 In this study, 
normality was assessed with histograms, residual scatterplots, and probability plots. 




Pearson’s correlation assumes that variables are linearly related to one another. 
Thus, linearity and homoscedasticity (uniform distributions) assumptions were assessed 
by visually inspecting the coordinate pairs of data points of two continuous variables 
via data plotted in a scatterplot.
297,300
 Violating any of these assumptions may not 
necessarily compromise data analysis but rather weakens it. In the event of violation, 
data can be transformed.
296
 
Multicollinearity is another potential problem that could be seen in multivariate 
modeling. This occurs when two predictor variable are highly correlated with one 
another. The presence of multicollinearity can inflate the standard deviation of 
regression weights and decrease statistical power. Multicollinearity can be detected 





multicollinearity exists between predictor variables, only one variable will be included 
in the final regression model. 
 
Reliability and Validity 
Reliability was assessed using an index of internal consistency (e.g., Cronbach’s 
alpha).
301,302
 The reliability of multi-item scales (CLEQoL, SF-36, and Body Image) 
was assessed via Cronbach’s alpha, where an acceptable value of internal consistency 
was α ≥ 0.60.
303
 Construct validity was assessed using exploratory factor analysis to 
determine the number of factors (or subscales) within the construct. The Kaiser–Meyer–
Olkin (KMO) test (where a value of ≥0.80 indicates adequate data fit) and the Bartlett’s 
test of sphericity were used to check the appropriateness of the study sample and the 
factor analysis model.
304,305
 The number of factors was determined based on 
eigenvalues and scree plot. Items with absolute loading values of 0.3 or greater were 
















 Pain  
 Pruritus  
















Overall Quality of 
Life 
 
Characteristics of the Environment: 
 Social support 
Characteristics of the Individual: 
 
 Race/ethnicity 





4.7.1 SAMPLE SIZE DETERMINATION 
To ensure adequate power to decrease the probability of accepting an incorrect 
null hypothesis, sample size estimations should be performed a priori.
307
 This is also 
important in ensuring that the statistical analyses to be conducted will be capable of 
supporting the stated hypotheses under investigation.
308
 In estimating appropriate 
sample sizes, estimates of effect size from past studies using the Wilson and Cleary 
Model (multiple R ranging from 0.39 to 0.53; i.e., R
2
 of 39.2% - 53%),
205,235,309,310
 a 
significance level of 0.05, 80 percent power, and nine predictor variables were used. 
The power analysis was conducted using GPower software, and the estimated sample 
was calculated as a range from 39 - 50 subjects.
311
 Accordingly, the current sample of 
size of 57 patients is adequate to power the study. 
 
4.8       HYPOTHESES STATISTICAL TESTS 
The theoretical framework of the Revised Wilson and Cleary Model of Patient 
Outcomes
3,223
 served as the framework for this study. Use of this framework guided the 
research in terms of: 1) identifying the relevant measurement variables for CLE, and 2) 
identifying potential links among the variables within the complex construct of quality 
of life.
223 Tables 4.2 – 4.3 provide an outline of the revised objectives, hypotheses, and 






Table 4.2: Description of Measurement Level and Statistical Test of Study 
Variables 
Variables Measurement Level Statistical Procedure 
Dependent Variable 
















 Frequencies for 
ordinal and nominal 
variables 
 *Coefficient alpha 
(multi-item scales) 







CLE subtype Nominal 
Disease activity Interval 
Disease damage Interval 




Pruritus  Interval 











General Health Perceptions 
Side-effects from CLE 
medications 
Interval 
Skin health perception  Interval 
Pill burden  Interval 
  
Characteristics of the Individual 
Age  Interval 
Gender Nominal 
Education  Ordinal 
Race/ethnicity  Nominal 
Smoking status  Nominal 
  
Characteristics of the Environment 
Marital status  Nominal 
Income Interval 





















Table 4.3: Study Objectives, Hypotheses and Corresponding Statistical Tests  
Objectives/Hypotheses Dependent 
Variable 
Independent Variable Statistical 
Test 
Objective 1: To describe participants’ biological and physiological factors (CLE subtype, disease activity, disease damage, 
and disease duration), symptom status, (pain, pruritus, and fatigue), functioning (body image, depression, and comorbidity), 
general health perceptions (side-effects from CLE medications, skin health perception, and pill burden), characteristics of the 
individual (age, gender, education, race/ethnicity, and smoking status), characteristics of the environment (marital status, 
income, and social support), and overall quality of life (CLEQoL and SF-36). 
Objective 2: To determine the predictive ability of biological and physiological factors (disease activity), symptom status 
(pain, pruritus, or fatigue), functioning (body image), general health perception (skin health perception) in explaining overall 
quality of life (QoL) in patients with CLE while controlling for characteristics of the individual (race/ethnicity, smoking 
status) and characteristics of the environment (social support). 
H2A: Biological and physiological factors (disease activity), 
symptom status (pain, pruritus, or fatigue), functioning (body 
image), general health perception (skin health perception) will 
explain a significant amount of variance in overall QoL 
(CLEQoL and SF-36) while controlling for characteristics of the 
individual (race/ethnicity, smoking status) and characteristics of 







 Biological and 
physiological factors 
(disease activity) 
 Symptom status (pain, 
pruritus, fatigue) 
 Functioning (body 
image) 
 General health 
























H2B1: Biological and physiological factor (disease activity) will 
be a positive and significant predictor of overall QoL (CLEQoL) 
while controlling for symptom status (pain, pruritus, or fatigue), 
functioning (body image), general health perception (skin health 
perception), characteristics of the individual (race/ethnicity, 
smoking status) and characteristics of the environment (social 
support). 
H2B2: Biological and physiological factor (disease activity) will 
be a negative and significant predictor of overall QoL (SF-36) 
while controlling for symptom status (pain, pruritus, or fatigue), 
functioning (body image), general health perception (skin health 
perception), characteristics of the individual (race/ethnicity, 







Table 4.3: Study Objectives, Hypotheses and Corresponding Statistical Tests (Cont’d) 
Objectives/Hypotheses Dependent 
Variable 
Independent Variable Statistical 
Test 
H2C1: Symptom status (pain, pruritus, or fatigue), will be a 
positive and significant predictor of overall QoL (CLEQoL) 
while controlling for biological and physiological factors (disease 
activity), functioning (body image) general health perception 
(skin health perception), characteristics of the individual 
(race/ethnicity, smoking status) and characteristics of the 





 Biological and 
physiological factors 
(disease activity) 
 Symptom status (pain, 
pruritus, fatigue) 
 Functioning (body 
image) 
 General health 




























H2C2: Symptom status (pain, pruritus, or fatigue), will be a 
negative and significant predictors of overall QoL (SF-36) while 
controlling for biological and physiological factors (disease 
activity), functioning (body image), general health perception 
(skin health perception), characteristics of the individual 
(race/ethnicity, smoking status) and characteristics of the 
environment (social support). 
H2D1: Functioning (body image) will be a positive and significant 
predictor of overall QoL (CLEQoL) while controlling for 
biological and physiological factors (disease activity), symptom 
status (pain, pruritus, or fatigue), general health perception (skin 
health perception), characteristics of the individual 
(race/ethnicity, smoking status) and characteristics of the 
environment (social support). 
H2D2: Functioning (body image) will be a negative and significant 
predictor of overall QoL (SF-36) while controlling for biological 
and physiological factors (disease activity), symptom status (pain, 
pruritus, or fatigue), general health perception (skin health 
perception), characteristics of the individual (race/ethnicity, 






Table 4.3: Study Objectives, Hypotheses and Corresponding Statistical Tests (Cont’d) 
Objectives/Hypotheses Dependent 
Variable 
Independent Variable Statistical 
Test 
H2E1: General health perception (skin health perception) will 
be a positive and significant predictors of overall QoL 
(CLEQoL) while controlling for biological and 
physiological factors (disease damage), symptom status 
(pain, pruritus, or fatigue), functioning (body image), 
characteristics of the individual (race/ethnicity, smoking 











 Biological and physiological 
factors (disease activity) 
 Symptom status (pain, 
pruritus, fatigue) 
 Functioning (body image) 
 General health perception 
(skin health perception) 
 
Covariates 
 Characteristics of the 
individual (race/ethnicity, 
smoking status) 
 Characteristics of the 













H2E2: General health perception (skin health perception) will 
be a negative and significant predictors of overall QoL (SF-
36) while controlling for biological and physiological factors 
(disease damage), symptom status (pain, pruritus, or 
fatigue), functioning (body image), characteristics of the 
individual (race/ethnicity, smoking status) and 
characteristics of the environment (social support). 
Objective 3: To determine if symptom status (pain, pruritus, or fatigue) is related to biological and physiological factors (disease 
activity), characteristics of the individual (race/ethnicity, smoking status) and characteristics of the environment (social support). 
H3A1: There is no association between biological and 
physiological factors (disease activity) and symptom status 
(pain). 
Symptom status   
(pain) 




H3A2: There is no association between biological and 
physiological factors (disease activity) and symptom status 
(pruritus). 
Symptom status   
(pruritus) 
H3A3: There is no association between biological and 
physiological factors (disease activity) and symptom status 
(fatigue). 











H3B1: There is no association between characteristics of the individual 
(race/ethnicity, smoking status) and symptom status (pain). 









H3B2: There is no association between characteristics of the individual 
(race/ethnicity, smoking status) and symptom status (pruritus). 
Symptom status   
(pruritus) 
H3B3: There is no association between characteristics of the individual 
(race/ethnicity, smoking status) and symptom status (fatigue). 
Symptom status   
(fatigue) 
H3C1: There is no association between characteristics of the environment (social 
support) and symptom status (pain). 







H3C2: There is no association between characteristics of the environment (social 
support) and symptom status (pruritus). 
Symptom status   
(pruritus) 
H3C3: There is no association between characteristics of the environment (social 
support) and symptom status (fatigue). 
Symptom status   
(fatigue) 
Objective 4: To determine if functioning (body image) is related to symptom status (pain, pruritus, or fatigue), characteristics of the 
individual (race/ethnicity, smoking status) and characteristics of the environment (social support). 
Objectives/Hypotheses Dependent 
Variable 
Independent Variable Statistical 
Test 
H4A1: There is no association between symptom status (pain) 
















H4A2: There is no association between symptom status 
(pruritus) and functioning (body image). 
Symptom status   
(pruritus) 
H4A3: There is no association between symptom status (fatigue) 
and functioning (body image). 
Symptom status   
(fatigue) 
H4B1: There is no association between characteristics of the 
individual (race/ethnicity) and functioning (body image). 
Characteristics of the individual 
(race/ethnicity) 
H4B2: There is no association between characteristics of the 
individual (smoking status) and functioning (body image). 
Characteristics of the individual 
(smoking status) 
H4C:  There is no association between characteristics of the 
environment (social support) and functioning (body image). 






Table 4.3: Study Objectives, Hypotheses and Corresponding Statistical Tests (Cont’d) 
Objectives/Hypotheses Dependent Variable Independent Variable Statistical 
Test 
Objective 5: To determine if general health perception (skin health perception) is related to functioning (body image), characteristics 
of the individual (race/ethnicity, smoking status) and characteristics of the environment (social support). 
H5A: There is no association between functioning 
(body image) and general health perception (skin 
health perception). 
General health perception 










H5B1: There is no association between 
characteristics of the individual (race/ethnicity) and 
general health perception (skin health perception). 
Characteristics of the individual 
(race/ethnicity) 
H5B2: There is no association between 
characteristics of the individual (smoking status) 
and general health perception (skin health 
perception). 
Characteristics of the individual 
(smoking status) 
H5C: There is no association between 
characteristics of the environment (social support) 
and general health perception (skin health 
perception). 
Characteristics of the environment  
(social support) 
Objective 6: To compare the predictive ability of each of the two models (Model 1 – CLEQoL and Model 2 – SF-36), in patients 
with CLE according to the proposed theoretical framework of the Revised Wilson and Cleary Model.  
Hypothesis Statistical Test 
H6A: The model with CLEQoL (Model 1) as the dependent variable will have a 
higher predictive ability than the model with SF-36 (Model 2), using the 
Williams’s t-tests. 
Williams’s
312 test of comparing two 




4.9       LIMITATIONS 
Several limitations are to be noted in this study. The limitations are categorized 
as 1) methodological and 2) statistical.  
 
4.9.1 METHODOLOGICAL LIMITATIONS 
The data analyses were based on cross-sectional data. This limitation would be 
of paramount concern if the purpose of the research were to explicitly assert causality in 
the sense that a change in, for example, symptom status in a particular CLE patient 
would lead to a corresponding change in functioning in that same patient. However, this 
was not the purpose of the study. Rather, the study purpose was to examine the 
relationships among the explanatory variables and overall QoL. Another limitation is 
that the sampling frame includes CLE patients located at specific clinics in North Texas. 
Thus, the results may not be generalizable to other CLE patients beyond the selected 
population. Further, the measures employed in the final questionnaire to identify factors 
that affect QoL in CLE patients may not account for all the relevant factors important 
and related to their QoL. Also, disease activity and damage have been reported to 
fluctuate over time, and this limitation may be more pronounced in instances where 









4.9.2 STATISTICAL LIMITATIONS 
One of the limitations was the small sample size which was accounted for by 
building parsimonious models. This study examined unidirectional relationships in the 
Revised Wilson and Cleary model;
3
 Ferrans et al., suggests assessing the relationships 
among the variables in a bi-directional fashion. Finally, the use of multiple regression 
only allows for examining direct effects among variables and as such indirect effects, 
which may be relevant in this conceptual model, could not be assessed.  
Even though our multiple regression generates a directional model, it is unable 
to test causal relationships between the variables when used in cross-sectional studies. It 
is also not feasible to verify whether the variables of interest in the model follow one 





This chapter outlined the methodological plans for this study. It also described 
the procedures that were used to develop the measures in the survey. The study 
variables, objectives, and hypotheses tested, as well as the statistical tests used in 





CHAPTER FIVE: RESULTS 
 This chapter presents the main findings of the study. The Revised Wilson and 
Cleary Model served as the theoretical framework for the study. The findings from the 
focus group sessions are first explained. Next, the results from the exploratory factor 
analysis and internal consistency of multi-item scales are presented. Then, the paper-
pencil surveys administered to patients with CLE are described. Descriptive statistics 
are presented for all study variables along with bivariate statistics for all theoretical 
constructs. Inferential statistics such as ANOVAs, t-tests, and multivariate regression 
analyses were used to examine the relationships among the variables with the study 
model. 
 
5.1        FOCUS GROUP RESULTS 
Table 5.1 provides an overview of participants’ demographic and disease 
characteristics. A total of 19 patients participated in three FGs, with an average age of 
49±14 years (range: 25-74 years) and an average age at diagnosis of 31±10 years 
(range: 10 – 51 years). Most participants were female (94.7%), African-American 
(68.4%), not Hispanic/Latino (89.5%), and had chronic CLE (73.7%). Most participants 
resided in urban areas (52.6%) and were mostly single, not in a relationship (31.6%) or 
married (31.6%). Participants mostly had a college degree (47.4%), perceived their 
health to be fair or good (47.4%), and had private insurance (47.4%). Finally, more than 




  Table 5.1 Patient Demographic and Disease Characteristics (N=19) 
Characteristics  Frequency (%) Mean±SD 
     Age (yrs.)  49±14 
     Age at diagnosis (yrs.)  31±10 
     Gender   
           Female 18 (94.7)  
           Male 1 (5.3)  
     Race   
           African-American 13 (68.4)  
           Caucasian 6 (31.6)  
     Ethnicity   
           Not Hispanic/Latino 17 (89.5)  
           Puerto Rican 1 (5.3)  
           Mexican-American 1 (5.3)  
     Geographic Residence   
           Urban 10 (52.6)  
           Suburban 6 (31.6)  
           Rural 3 (15.8)  
     Marital Status   
           Married 6 (31.6)  
           Single, not in a relationship 6 (31.6)  
           Single, in a relationship 4 (21.1)  
           Divorced/separated 2 (10.5)  
           Partner/living together 1 (5.3)  
     Education   
           Less than High School/GED 7 (36.8)  
           College Degree 9 (47.4)  
           Postgraduate 3 (15.8)  
     Health Insurance   
Private Insurance (e.g., BlueCross/Blue Shield) 9 (47.4)  
           Public Insurance (e.g., Medicaid, Medicare) 7 (36.8)  
           None/Self-pay 3 (15.8)  
     Smoking Status   
           Never Smoker 12 (63.2)  
           Current Smoker 4 (21.1)  
     Predominant CLE Subtype   
            Chronic  14 (73.7)  
            Subacute  3 (15.8)  
            Acute  2 (10.5)  
     Perception of Health   
            Fair 9 (47.4)  
            Good 9 (47.4)  




 Saturation was reached after the third FG. Four themes emerged from the FGs 
and captured the perceptions of patients regarding CLE and how it impacts their lives. 
Themes, sub-themes, and sample quotes are contained in Table 5.2 and summarized 
below. 
 
5.1.1 Theme 1: Disease Sequelae of Cutaneous Lupus Erythematosus (CLE) 
Three subthemes derived from this theme were physical, mental, and medication 
effects. 
 
5.1.1.1 Physical effects 
Signs and symptoms ranged from pruritus, photosensitivity, and scarring which 
affected patients with CLE on a variety of levels. Itching was problematic when not 
controlled by medication, and was especially frustrating when they are instructed not to 
scratch. One patient noted, “Everything itches on me, I take all of my clothes off and 
take a shower.” Increased sensitivity to sunlight, touch, heat, and cold were commonly 
reported by participants. Photosensitivity often limited outdoor participations, especially 
in the summer. Most female patients reported summertime as the most difficult season 
of the year since they could no longer wear bathing suits or engage in outdoor activities 
due to their photosensitivity, discoloration, and scars. Also, several patients experience 
permanent and visible skin lesions such as scarring and dyspigmentation which often 
led to embarrassment. Overall, patients were often more distressed by what others 
thought of their physical appearance than from the physical manifestations of the 
120 
 
disease. Thus, many patients resorted to the use of cover-ups like wigs, hats, or 
sunglasses. Moreover, younger patients in our study expressed poorer self-image and 
compared their appearance to those of their peers. As patients grew older, they cared 
less about what others thought about their visible lesions. This sentiment was exhibited 
through this comment:  
“I used to care more when I was younger and about what they thought. Now, I 
am more like, this is me if you care or not.” 
 
5.1.1.2  Mental Effects 
Self-reported depression, insomnia, and anxiety were core concerns of patients 
that bordered on mental health. Patients who reported being depressed talked about 
having suicidal attempts (or thoughts), mood swings, and not wanting to be around 
people anymore. For example, one patient said, “My confidence was so worn down that 
I stopped going out with friends because I might be somewhere and all of the sudden I 
don’t feel well. I have learned to navigate that through the years, but it has definitely 
affected me socially.”  
Many patients complained of severe sleep disturbance, ranging from problems 
initiating sleep, to maintaining, and having restful sleep. It is uncertain whether these 
issues were related to medical side effects or anxiety as sequelae from their CLE. Also, 
patients with female progenies worried regularly about the possibility of passing CLE 
down. In the words of one patient: “My baby is 25, and I worry about that every day. 
My son, he doesn’t have it yet, but my brother does.” 
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5.1.1.3  Medication Effects 
Patients raised several concerns regarding the toxicities and number of 
medications they were using. One female patient expressed regret as to giving up her 
plans to have more kids because of the teratogenic effects of thalidomide. Most patients 
reported taking an excessive number of pills to manage their disease. In addition, some 
patients feared that more pills could be added to their current regimen as the disease 
progresses. Also, not having many treatment options was another issue echoed by 
participants. Thus, patients expressed the need for more drugs to be developed for CLE. 
One patient displayed her frustration by saying, “It’s like since I was diagnosed 30 
years ago, and there has been no difference in the treatment. I am still using the same 
medications as I did many years ago. I wished there were different treatment options.” 
 
5.1.2 Theme 2: Effects on Social Interaction from CLE 
5.1.2.1 Social Anxiety 
Patients not only found it hard to interact with others but were often worried that they 
would be a burden to others. As a result, this affected their relationships with other 
people, especially romantically. One patient noted, “I was married one time and it kind 
of messed up my relationship with my husband because he felt like I was always tired or 
I will always complain about my face or something.” Other patients also reported how 
their friendship circle was thinning out. This was described as: “I had to separate myself 
from my friends; at first, they kinda judge you. They are like ‘Oh, you are sick again’. 
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What do you mean sick again? I have been sick. They don’t really understand what you 
are going through.” 
 
5.1.2.2 Public Misconceptions and Education 
Patients also indicated how they have been either labeled as illicit drug users 
(due to excessive use of cover-up clothing), victims of domestic violence (due to visible 
skin discoloration), or contagious (due to active lesions). One patient explained,  
“I used to be a manager and I have rashes on my hand. People will look at me 
funny like they were disgusted to take money for me.”  
Patients expressed the need for a proper way to educate the public about CLE. 
Particularly, patients yearned for more compassion and understanding from the public 
and hoped that CLE would receive the same recognition other diseases like HIV/AIDS 
and cancer. 
 
5.1.2.3 Seriousness and Unpredictable Nature of CLE 
Because of CLE’s unpredictable nature, most patients, especially younger ones 
frequently reported being unable to make long-term career goals due to their uncertainty 
over timing and frequency of disease flares. As a result, they had to give up their jobs 
which in turn, led to increased worrying and anxiety. Even on a daily basis, patients 
reported how sudden flares can render them unable to perform menial tasks. This, in 
turn, increases the patient’s dependence on others for assistance. 
“I think it is very difficult for people to understand because of the ups and 
downs. A lot of times you are feeling good, and they don’t understand the quick 
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changes. Again, I am a mother. With my kids, a lot of times I don’t feel like 
doing anything with them because of my lack of energy. It is very hard for me.” 
  
5.1.3 Theme 3: Coping Mechanisms on Living with CLE 
5.1.3.1 Positive Strategies 
Most patients with CLE reported strategies used to cope with the disease. 
Positive coping strategies include relying on family members, friends, and loved ones 
for support, as well as the reliance on faith to help them through tough times. One 
patient explained, “My faith helps me cope; praying, and just reading the Bible.” 
 
 
5.1.3.2 Distracting/Negative Strategies 
On the other hand, patients also engaged in avoidance techniques to distract 
themselves from the harsh realities of having CLE, either by burying themselves with 
work or using recreational drugs.  
“I stay high (on recreational drugs). I am not going to lie. I do.” 
Several patients had developed resilience to the disease and found their ‘new 
normal.’ Also, older patients appeared to have a better understanding of the disease 
course due to their greater experience at handling different challenges. 
 
 
5.1.4 Theme 4: Unmet Needs 
Several subthemes, which were either symptom, treatment-related or social, 
were generated when patients were asked about their perceptions of unmet needs 
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regarding their treatment and care. For the symptoms and treatment-related needs, 
patients strongly expressed desires for disease-modifying therapies that can either 
reduce the signs and symptoms (e.g. scarring, discoloration, alopecia) associated with 
CLE or reduce the number of pills they currently take. Alternatively, for social needs, 
patients recommended a starter kit to navigate coping with CLE especially when newly 
diagnosed. Many patients talked about how it was often difficult to figure out the 
practical steps to take to deal with CLE, such as grooming tips to conceal visible skin 
lesions. One patient referred to breast cancer as an example: 
“They have that for cancer patients. My Godmother is a breast cancer 
survivor, and I went to a seminar. They gave them this little bag that had 




Table 5.2: Major Themes and Subthemes by Participants 









- “It itches, but you’re told not to scratch it - it’s best just to try and rub it, you know?” 
- “For me, I am not totally vain but I think that’s just the main thing for me. When I was younger, I had 
pretty really thick hair which I used to wear short and got a lot of compliments for. I also had a great 
hair stylist. When I started losing it to the point when it was scarring and it didn’t come back it got to a 
point, it’s different. I get tired of the weaves and the wigs. There’s no way I can just go natural even 
because I have so much scarring.” 
Mental effects 
-  “I spent a month at a mental hospital* for suicide attempt and that was my 8th attempt. I don’t 
remember...I don’t remember if I’d struggled with depression before I was diagnosed with lupus. 
- “I know that I don’t know where the mood swings come from but it could be there. I don’t know 
where the depression comes from but it could be there. It may not have anything to do with any of this 
be it systemically or the outer. It’s just what it is.” 
Medication 
effects 
- “I take methotrexate for my skin, I mean I don’t like it because it is a chemotherapy drug and it is hard 
on your liver, but I want quality of life. If my life is shortened because of all these stuff I have been 
taking since I was 19. I still take prednisone. I have had to accept it. I need to find a way to enjoy life.” 
- “That is why I don’t take my meds a lot. I feel like it be messing me up more than it is helping me. 










- “CLE makes me not wanting to get around people. I feel like being alone.” 
- “And so I’ve been told sometimes that I use lupus as a crutch or an excuse to behave a certain way. 
There are days when you just don’t want to interact. I know that I don’t know where the mood swings 




- “I went to 7-Eleven and someone said ‘what man did you like that?’ I jumped up and left home right 
quick. I didn’t think about putting my makeup on. I look at it like this; it’s some ignorant people in the 
world. And instead of staring at me like a child, ask me what’s wrong, ‘cause I have a bad mouth.”  
- “I just don’t know how to explain it to people. You know, I have a really good friend, she knows I 
have lupus and that is all she knows. She doesn’t know what it is. How do you explain it to people? 




nature of the 
disease 
- “I think it is very difficult for people to understand because of the ups and downs. A lot of times you 
are feeling good, and they don’t understand the quick changes. Again, I am a mother. With my kids, a 
lot of times I don’t feel like doing anything with them because of my lack of energy. It is very hard for 
me.” “Like she said, it is very depressing. One week you may have a good week and think you are cute 












- “My faith helps me cope; praying, and just reading the bible.” 




- “I stay high (on recreational drugs). I am not going to lie. I do.” 




- “Something to reduce scarring, the damage caused by the disease. I have it a lot on my back and 
stomach. I have scars everywhere on my body and back. I know there’s stuff out there but it is 
expensive.” 
- The discoloration, can we all just clear them all together so no one has to go through this, okay?” 
-  “It (hair) should come back. A success for me will be measured by my hair growing back.” 
Treatment-
related 
- “I would have to see a reduced number of flares and an improvement in my lab work. This is 
important to me because I spend way too much time in the hospital. A 60% reduction in 
hospitalization would be a success for me.” 
- “I take over 23 medications a day, uh uh, too many!” 
- “I think something for mental and emotional balance is very important because I know that that has 
helped me.” 
Support system 
- “There are no group of people that can help you with how you can blend and cover scars, or what to 
use to cover my hair. There’s no one, you have to go out there to figure out to so much by yourself. 
There’s no support.” 
- “They have that for cancer patients. My godmother is a breast cancer survivor and I went to a 
seminar. They gave them this little bag that had all these makeup and kit.” 
  
  *




5.2    QUESTIONNAIRE PRETEST 
Based on the FG data, the final questionnaire was constructed. Ten patients and 
four physicians/clinical staff pre-tested the survey instrument before dissemination so as 
to ensure content relevance and readability. Pretesters were given instructions to 
provide feedback on the following: format/layout, length, instructions, unclear or 
confusing questions, unclear or confusing answer choices, relevance, and face 
validity.
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 Based on the feedback provided by the pretesters, changes were made to the 
questionnaires before being administered to the final, target population. Most of the 
changes made were to the wording of the questions added to the original Skindex-29+3 
to make them more consistent. 
 
5.3  SURVEY DISTRIBUTION 
  Data collection using paper-pencil surveys began in April 2016 and ended in 
October 2016. The survey packed contained a consent form detailing the purpose of the 
study as well as the potential risks and benefits.  
A total of 64 surveys were received. Seven surveys were deleted and excluded 
from analysis due to the following reasons: four were from patients with psoriasis, and 
three were deleted due to incompletion (i.e., did not answer a sufficient amount of 
questions on the survey items). Thus, the number of useable surveys was 57. Table 5.3 






Table 5.3: Primary Constructs and Representative Survey Questions 




Overall QoL – SF-36  36 1-11 
Overall QoL – CLEQoL
*
 36 12a-12kk  
Pain 1 13 
Pruritus/Itch 1 14 
Fatigue 1 15 
Body image 10 16a-16j 
Depression 1 17-18  
Comorbidity 15 19a-19o 
Side-effects from CLE medications 1 20a 
Pill burden 1 20b 
Skin health perception 1 21 
Age  1 22 
Gender 1 23 
Education  1 24 
Race/ethnicity  1 25 
Smoking status  1 26 
Marital status  1 27 
Income 1 28 
Social support 1 29 
*
Represents items developed from focus group findings and feedback from two skin questionnaires 
 (VitiQoL and Skindex-29+3) 
 
5.4    DATA PREPARATION AND CLEANING  
Data were entered into SPSS version 23 for data preparation, screening, and 
analysis. Data were assessed for normality (evaluating the symmetry and peakedness of 
the distributions) as well as the existence of outliers and the extent of missing data. 
 
5.4.1 NON-NORMALITY, MISSING DATA, AND OUTLIERS 
Normality was assessed by using skewness and kurtosis; non-normality was 
defined as having a skew >|2| and kurtosis >|7|.
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 From Table 5.4, the distributions of 
all the interval level variables did not exceed the skewness and kurtosis thresholds of 
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>|2| and >|7|, respectively. Potential outliers were screened for by inspecting z-scores of 
continuous, interval variables. No outliers were identified in the data. Using SPSS’s 
Missing Value Analysis feature, assessments were made regarding the amount and 
pattern of missing data. According to Tabachnick,
296
 the patterns of missing data is 
more important than the amount of missing data.  
Non-random missing data is more problematic than random missing data and 
can seriously impact the generalizability of the study findings. Further, “If only a few 
data points, say 5% or less, are missing in a random pattern from a large data set, the 
problems are less serious.”
296
 A total of 56 instances of missing data were observed 
across 116 survey items (N=57 respondents). Further examination of the survey data 
found that 21.1 percent (N=12) of respondents had at least one missing data value. The 
rate of missing data exceeded more than 5% for two variables – education, at a rate of 
49.1% (n=28) and the sub-question for depression, at a rate of 55.6% (n=10). As a 











Table 5.4: Skewness and Kurtosis Values of Interval-Level Variables 
 
Variable  Skewness Kurtosis 
CLEQoL 0.52 -0.82 
SF-36   
Physical Component Summary (PCS) -0.09 -1.12 
Physical Functioning (PF) -0.23 -1.16 
Role-Physical (RP) 0.32 -1.75 
Bodily Pain (BP) -0.09 -1.27 
General Health (GH) 0.25 -0.87 
Mental Component Summary (MCS) -0.51 -0.34 
Vitality (VT) 0.22 -0.79 
Social Functioning (SF) -0.13 -1.38 
Role-Emotional (RE) -0.67 -1.10 
Mental Health (MH) -0.77 0.26 
Disease activity 1.81 5.95 
Disease damage 0.65 -0.51 
Disease duration 1.43 5.75 
Pain 0.72 -0.89 
Pruritus/Itch 0.44 -1.07 
Fatigue -0.67 -1.44 
Body image 1.16 0.31 
Comorbidity 0.61 -0.96 
Side-effects from CLE medications 1.10 -0.60 
Pill burden 0.89 -0.91 
Skin health perception -0.29 -1.09 
Age -0.06 -0.74 
Income 1.56 4.14 
Social support -1.04 -0.30 
 
5.5       CONSTRUCT VALIDITY AND INTERNAL CONSISTENCY 
To assess construct validity, the factor structure of the CLEQoL scale was 
examined by conducting an exploratory factor analysis (EFA) on the 36 items via a 
maximum likelihood followed by a Varimax rotation with SPSS 23. The value of 
Kaiser–Meyer–Olkin (KMO) was 0.83, indicating that the data and sample were 
adequate for factor analysis. In addition, the approximate Chi-square value of the 
131 
 
Bartlett test of sphericity (χ
2
 = 2126.96, df = 630, p<0.001) confirmed that the factor 
model is appropriate. These two tests showed the suitability of the respondent data for 
exploratory factor analysis. 
Five factors/subscales were identified; three conformed to the initial subscales 
from the literature, corresponding to symptoms, emotions, and functioning. Two 
additional contributions to these existing factors/subscales were body image/cosmetic 
effects and photosensitivity [See Table 5.5]. As shown in Table 5.5, based on the scree 
plot (Fig. 5.1), the five factors that reported eigenvalues greater than 1, accounting for 
72.68% of the variance, were extracted. Overall, the five subscales assessed overall 
QoL specific to CLE patients. 
 
Figure 5.1: Scree plot analysis of factors in the CLEQoL scale
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Table 5.5: Exploratory factor loadings of items in the CLEQoL with five factors 
Item 
No. 
Factors of CLEQoL subscales 
Factor Loadings 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Factor 1: Emotions (% of variance = 52.77, Eigenvalue = 19.00) 
l. I am ashamed of my skin condition 0.84 0.27 0.21 0.07 0.07 
f. My skin condition makes me feel depressed 0.77 0.24 0.11 0.12 0.21 
u. I am embarrassed by my skin condition. 0.67 0.42 0.27 0.19 0.18 
bb. I am annoyed by my skin condition 0.65 0.27 0.25 0.31 0.24 
w. I am frustrated by my skin condition 0.62 0.19 0.21 0.19 0.08 
z. I am humiliated by my skin condition 0.59 0.14 0.265 -0.01 0.19 
i. I worry about getting scars from my skin condition 0.58 0.14 0.23 0.42 -0.12 
o. I am angry about my skin condition. 0.41 0.28 0.55 0.29 0.11 
c. I worry that my skin condition may be serious 0.70 0.16 0.13 0.10 0.10 
m. I worry that my skin condition may get worse 0.59 0.09 0.13 0.07 0.08 
Factor 2: Functioning (% of variance = 5.77, Eigenvalue = 2.01) 
e. My skin condition affects my social life 0.25 0.65 0.27 0.18 0.13 
h. I tend to stay at home because of my skin condition 0.27 0.58 0.18 0.14 0.23 
q. My skin condition makes showing affection difficult 0.21 0.81 0.24 0.27 0.14 
y. My skin condition affects my desire to be with people 0.18 0.79 0.17 0.17 0.21 
t. My skin condition affects my interactions with others 0.26 0.76 0.19 0.23 0.10 
cc. My skin condition interferes with my sex life 0.24 0.76 0.28 0.10 0.01 
v. My skin condition is a problem for the people I love 0.12 0.75 0.21 0.26 0.10 
k. My skin condition affects how close I can be with those I love 0.10 0.73 0.20 0.19 0.01 
n. I tend to do things by myself because of my skin condition 0.24 0.54 0.53 0.04 0.18 
d. My skin condition makes it hard to work or do hobbies 0.19 0.44 0.22 0.27 0.21 
b. My skin condition affects how well I sleep 0.17 0.73 0.25 0.18 -0.01 
dd. My skin condition makes me tired 0.22 0.58 0.24 -0.12 0.14 
Factor 3: Symptoms (% of variance = 5.03, Eigenvalue = 1.81) 
g. My skin condition burns or stings 0.28 0.22 0.56 0.14 0.09 
j. My skin itches 0.21 0.10 0.50 0.24 -0.06 
x. My skin is sensitive 0.25 0.24 0.40 0.26 0.14 
a. My skin hurts 0.26 0.06 0.87 0.13 0.17 
p. Water bothers my skin condition (bathing, washing hands) 0.06 0.18 0.69 0.03 0.04 
aa. My skin condition bleeds 0.26 0.19 0.52 0.17 0.05 













Summary of Factors/Subscales and Item Clusters of CLEQoL 
 
 
Table 5.5: Exploratory factor loadings of items in the CLEQoL with five factors (Cont’d) 
Item 
No. 
Factors of CLEQoL subscales 
Factor Loadings 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Factor 4: Body Image/Cosmetic Effects (% of variance = 4.76, Eigenvalue = 1.71) 
hh. When talking to someone, I sometimes worry about they may be 
thinking of me 
0.18 0.09 0.27 0.62 0.21 
ff. I am worried about my hair loss 0.21 0.02 -0.11 0.61 0.02 
ii. My skin condition has influenced the clothes I wear. 0.17 0.12 0.14 0.79 0.03 
jj. My skin condition has affected my grooming practices (i.e., 
haircut, use of cosmetics) 
0.16 0.18 0.08 0.49 0.24 
Factor 5: Photosensitivity (% of variance = 4.37, Eigenvalue = 1.57) 
ee. I worry about going outside because the sun might flare my disease 0.09 0.24 0.13 0.27 0.78 
gg. My skin condition prevents me from doing outdoor activities. 0.19 0.28 0.22 0.24 0.47 
kk. My skin condition has affected my sun protection efforts during 
recreation  
0.15 0.01 -0.06 0.20 0.83 
Boldface factor loadings correspond to the questions that are aligned within a particular factor 
Factors/Subscales Number of items Cluster of items Skewness Kurtosis 
Functioning 12 b; d; e; h; k; n; q; t; v; y; cc; dd 0.89 -0.35 
Emotions 10 c; f; i; l; m; o; u; w; z; bb 0.36 -1.11 
Symptoms 7 a; g; j; p; s; x; aa  0.17 -1.05 
Body image/cosmetic effects 4 ff; hh; ii; jj 0.33 -0.95 
Photosensitivity 3 ee; gg; kk -0.35 -0.80 
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Reliability estimates for all of the multi-item scales were assessed via 
Cronbach’s alpha, where an acceptable value of internal consistency is α ≥ 0.60 [See 
Table 5.6 below].
303
 All multi-item scales exhibited acceptable reliability. 
 
Table 5.6: Reliability Analyses of Study Scales 
Scale Number of Items Cronbach’s Alpha 
CLEQoL
a
 36 0.97 
Functioning 12 0.96 
Emotions 10 0.94 
Symptoms 7 0.89 
Body image/cosmetic effects 4 0.71 
Photosensitivity 3 0.74 
SF-36 36  
  Physical Component Summary (PCS)  0.87 
Physical Functioning (PF) 10 0.95 
Role-Physical (RP) 4 0.92 
Bodily Pain (BP)
*
 2 0.75 
General Health (GH) 5 0.78 
Mental Component Summary (MCS)  0.81 
Vitality (VT) 4 0.69 
Social Functioning (SF)
*
 2 -0.74* 
Role-Emotional (RE) 3 0.76 
Mental Health (MH) 5 0.81 
Body Image 10 0.95 
Comorbidity 14 0.61   
a
 Item 18 on side-effects of treatment is not scored nor included in the final CLEQoL scale 













5.6       DESCRIPTION OF STUDY VARIABLES 
Descriptive statistics of study variables are described below [See Tables 5.7 – 
5.26]. 
 




As shown in Table 5.7, patients with chronic CLE – DLE (N=39) represented 
the majority of survey respondents (68.4%).  
 
Table 5.7: Frequency Distribution of CLE Subtype 
 





Ethnicity  N Percent (%) 
Chronic CLE 46 80.7 
Discoid Lupus Erythematosus (DLE) 39 68.4 
Tumid Lupus 6 10.5 
Lupus Panniculitis 1 1.8 
Subacute Lupus Erythematosus (SCLE) 9 15.8 
Acute Lupus Erythematosus (ACLE) 2 3.5 
Total 57 100.0 
Ethnicity  N Percent (%) 
Discoid Lupus Erythematosus (DLE) 39 68.4 
Non-Discoid Lupus Erythematosus (Non-DLE) 18 31.6 
Total 57 100.0 
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Cutaneous Lupus Disease Area and Severity Index (CLASI) Scores 
CLASI activity score ranged from 0-29 and had a mean±SD score of 5.51±5.41 
indicating mild activity. Similarly, the mean±SD damage score was 8.05±7.11 [See 
Table 5.8]. 
 
Table 5.8: Means and Ranges of CLASI Scores 
 N Mean SD Min Max Median IQR 
a
Disease Activity 57 5.51 5.41 0 29.00 4.00 5.00 
b
Disease Damage 57 8.05 7.11 0 26.00 6.00 12.00 
a,b





From Table 5.9, the average year since diagnosis was 7.12±8.45 years, with a 
range of 0.10 years (1.5 months) to 39.96 years. 
Table 5.9: Mean and Range of Disease Duration 
 N Mean SD Min Max Median IQR 
Disease Duration 57 7.12 8.45 0.10 39.96 4.43 7.96 
 
 
5.6.2 SYMPTOM STATUS 
Pain 
 
Patients most commonly (42.1%) experienced no pain in the last 24 hours. The 
average pain score was 3.16±3.46 (median of 2.00). Based on the average pain score, 












From Table 5.10, plurality of patients (28.1%) reported experiencing no itching. 
The pruritus/itch scale had a mean of 3.78±3.39 (median of 3.00); this indicates that 




As shown in Table 5.10, most patients either equally experienced no fatigue 
(14.5%) and severe levels of fatigue (14.5%) within the 24-hour period. On average, the 
fatigue scale was 5.18±3.57 (median of 5.00), suggesting that patients experienced 
moderate levels of fatigue.  
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1.  On average, 
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Body image was operationalized through 10 items from the Body Image 
Scale,
289
 which was developed in collaboration with the European Organization for 
Research and Treatment of Cancer (EORTC) Quality of Life Study Group. The 10-item 
scale was scored from 0 (not at all) to 3 (very much), with a possible score range of 0-
30. Total body image scale had a mean of 8.78±8.92 and a median score of 6.00 [See 
Table 5.11]. The total average score indicates that participants had a lesser degree of 
body image dissatisfaction.  
The highest means±SD per individual items (scored 0–3) were noted for items 
referring to dissatisfaction with the appearance of scar (1.25±1.16), perceived change in 
physical attractiveness (1.16±1.20), self-consciousness (1.09±1.09), dissatisfaction with 
body (0.91±1.06), and dissatisfaction when dressed (0.91±1.02). Internal consistency of 
the items on the Body Image Scale was acceptable at a Cronbach’s α = 0.95 [See Table 
5.12]. 
 











 6.00 8.92 0.00 30.00 
a





    Table 5.12: Frequency Distribution of the Body Image Scale 







































b)  Have you felt less 
physically attractive as 




















c)  Have you been 
dissatisfied with your 
appearance when 
dressed? 













d)  Have you been feeling 
less 
feminine/masculine as 
a result of your disease 
or treatment? 













e)  Did you find it 
difficult to look at 
yourself naked? 









f)  Have you been feeling 
less sexually attractive 
as a result of your 
disease or treatment? 













g)  Did you avoid people 
because of the way 
you felt about your 
appearance? 













h)  Have you been feeling 
the treatment has left 



















i)  Have you felt 
dissatisfied with your 
body? 









j)  Have you been 
dissatisfied with the 
appearance of your 
scar? 













Score Total 55 8.78
b





      
 aTotals do not equal 57 due to missing responses   
 bThe composite score for the overall scale calculation based on 57 responses, possible scale range 0 to +30 





When asked if they have ever been diagnosed with depression, the majority of 
respondents (68.4%) indicated having no prior diagnosis of depression [See Table 5.13]. 
,x 
  Table 5.13: Mean and Frequency Distribution of Depression 
 
  If yes, are you currently being treated for depression? 
aTotals do not equal 18 due to missing responses  
 
Comorbidity 
Comorbidity was measured with 14 items from the Self-Administered 
Comorbidity Questionnaire (SCQ).
290
 As shown in Table 5.14, the SCQ scale had a 
mean of 3.32±3.23 (median=2.00), indicating lower comorbidity level and limitations. 
Since there are 14 questions with three binary questions, the possible range for the total 
scores is 0 to 42 [See Table 5.14]. Most of the participants indicated having high blood 
pressure (45.1%) and back pain (43.1%). Out of those who indicated having high blood 
pressure, a majority of them were receiving medication/treatment for it (95.5%) and 
about 85 percent of these patients thought that having high blood pressure did not limit 
Depression N Percent 
“0”(No) 39 68.4 
“1”(Yes) 18 31.6 




“0”(No) - - 
“1”(Yes) 8 100 
Score Total 8 100 
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them. Similarly, out of the patients who positively responded to having back pain, 
seventy-five percent (75%) did not receive medication/treatment for it and most 
(72.2%) indicated limitations. Internal consistency of the items on the SCQ scale was 
acceptable (Cronbach’s α = 0.61). Findings are summarized in Table 5.15. 
 
  Table 5.14: Mean Total Comorbidity Scores   
Variable N Mean Median SD Minimum Maximum 
Comorbidity 57 3.32
a
 2.00 3.23 0.00 10.00 
a
The composite score for the overall scale calculation based on 57 responses, possible scale 





Table 5.15: Mean and Frequency Distribution of Total Comorbidity Scores 
                                                                Frequency Distribution of Response Choices N (%) 
   
Na 
#1: Do you have the 
problem? 
       #2: Do you receive                 
    medications/treatment for it? 



























































































































































l)  Back pain 












m)  Rheumatoid arthritis 












n)  Hepatitis 






- - - 
o)  HIV 












Cronbach’s Alphaa 0.61b      




5.6.4 GENERAL HEALTH PERCEPTIONS 
Side-effects associated with CLE medications 
 Side-effects were measured using a single item from the LupusPRO.
292
 From 
Table 5.16, the average score was 0.98±1.55, which indicated that patients experienced 
serious side-effects associated with CLE medications most of the time in the past four 
weeks, with all of the time being the most common response (68.4%). 
 
Pill Burden 
 Similarly, pill burden was measured using a single item from the LupusPRO.
292
 
On average, the scale had a mean of 1.21±1.59 indicating that patients felt concerned 
most of the time about the number of CLE medications they currently take. Also, most 
patients commonly had concerns (58.4% indicated “all of the time”) about the number 
of medications they take for CLE [See Table 5.16]. 
 
Table 5.16: Mean and Frequency Distribution of Side-effects from CLE 




























































b.  Concerns about 
the number of 
medications you 
currently take 






















aTotals do not equal 57 due to missing responses  
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Skin Health Perception 
 
About 16 percent (15.8%) of patients most commonly reported having a neutral perception regarding their skin health. 
The average score on this measure was 5.14±3.02 [See Table 5.17]. 
 























related health on a 1-10 









































5.6.5 CHARACTERISTICS OF THE INDIVIDUAL 
Age 





The current sample of patients comprised mostly of females (84.2%) as 
summarized below in Table 5.18. 
Table 5.18: Frequency Distribution of Respondents’ Gender 
 
Education 
As depicted in Table 5.19, most (69.0%) of respondents reported their highest 
educational achievement as either high school or college. Due to several missing data, 
this variable was not included in the final analysis. 
 
Table 5.19: Frequency Distribution of Education  
    aTotals do not equal 57 due to missing responses  
 
Race/Ethnicity  
As shown in Table 5.20, African-American patients (N=31) represented the 
majority of survey respondents (54.4%). 
Gender N Percent (%) 
Female 48 84.2 
Male 9 15.8 
Total 57 100.0 
Education N Percent (%) 
Lower than High School  5 17.2 
High School 10 34.5 
College 10 34.5 






Table 5.20: Frequency Distribution of Race/Ethnicity  
Recoded Race/Ethnicity Variable 
Smoking Status 
Table 5.21 details the smoking status of respondents. Slightly over half (53.4%) 
of respondents reported never smoking cigarettes. In addition, approximately 32 percent 
reported being current cigarette smokers (31.5%).  
 
Table 5.21: Frequency Distribution of Smoking Status  
 Recoded Smoking Status Variable 
Ethnicity  N Percent (%) 
African-American  31 54.4 
Caucasian  18 31.6 
Hispanic 5 8.8 
Other
a
 2 3.5 




aRepresents those of mixed race/ethnicities 
 
Ethnicity  N Percent (%) 
African-American/Black 31 54.4 
Others (Caucasian, Hispanic, Asian, and Other) 26 45.6 




Smoking Status  N Percent (%) 
Never Smoker  29 53.7 
Current Smoker 17 31.5 




aTotals do not equal 57 due to missing responses  
 
Smoking Status  N Percent (%) 
Never Smoker  29 53.7 









5.6.6 CHARACTERISTICS OF THE ENVIRONMENT 
Marital Status 
 Forty-nine percent (49.1%) of the respondents most commonly reported either 
being married or having a domestic partner. When recoded, those who were not married 
(single, divorced, widowed, and separated) comprised a little more than half of the 
patient sample (50.9%) [See Table 5.22].  
Table 5.22: Frequency Distribution of Respondents’ Marital Status 
   
 
Recoded Marital Status Variable 
   
 
Income 
Using ZIP code data, the average annual income of the respondents was 




Using a single measure from LupusPRO,
292
 social support was measured on a 5-
point Likert scale. From Table 5.23, the average score was 3.00±1.35, which indicated 










Widowed 2 3.5 
Total 57 100.0 







Total 57 100.0 
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that patients received support from their friends and or family most of the time. Also, 
most patients commonly responded to receiving social support all of the time (56.4%).  
 






























 Most of 
the time 
 (3) 
 All of 
the time 
 (4) 
Generally, I receive 
support from friends 
and/or family… 
 
















aTotals do not equal 57 due to missing responses  
 
5.6.7 OVERALL QUALITY OF LIFE 
CLEQoL 
 Overall QoL, operationalized as CLEQoL, was one of the primary dependent 
variables measured with 36 questions using a 5-point Likert scale ranging from 0 (no 
effect) to 100 (effect experienced all the time), with higher scores indicating poorer 
overall quality of life. The individual means for CLEQoL questions (a-kk) are presented 
in Table 5.24. The highest means±SD per individual items were noted for items 
referring to the effect CLE has on sun protection efforts (67.86±37.45), worrying about 
sun flares (63.16±36.01), and skin sensitivity (62.71±32.78). Internal consistency of the 
items on the CLEQoL scale was acceptable at a Cronbach’s α = 0.97. 
The photosensitivity subscale had the highest mean score 61.90±30.44. The total 
CLEQoL score was 39.68 and a median of 31.60; this indicates that respondents had 
moderately high QoL [See Table 5.25]. The CLEQoL scale alpha value was 0.97, which 
met the acceptable level of 0.6.  
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To make the CLEQoL domains comparable to SF-36 so as to make inferences 
from the results, the five subscales were condensed to CLEQoL-Mental (Emotions) and 
CLEQoL-Physical (Symptoms, functioning, body image/cosmetic issues, and 
photosensitivity). 
 


























a. Skin Hurts (Sx) 










b. Disrupted sleep (Em) 










c. Worry about 
progression (Fxn) 










d. Affects work and 
hobbies (Em) 










e. Affects social life (Em) 










f. Depressed (Fxn) 










g. Skin burns or stings 
(Sx) 










h. Stay at home (Em) 










i. Worry about scars 
(Fxn) 










j. Skin itches (Sx) 










k. Affects closeness (Em) 










l. Ashamed (Fxn) 










m. Worry skin worse 
(Fxn) 










n. Do things alone (Em) 










o. Angry (Fxn) 










p. Water bothers (Sx) 










q. Difficult showing 
affection (Em) 
























s. Skin irritated (Sx) 






































t. Interaction with others 
(Em) 










u. Embarrassed (Fxn) 










v. Problem for loved 
ones (Em) 










w. Frustration (Fxn) 










x. Skin sensitive (Sx) 










y. Affects desires for 
others (Em) 










z. Humiliated by skin 
(Fxn) 










aa. Skin bleeds (Sx) 










bb. Annoyed (Fxn) 










cc. Sex life interference 
(Em) 










dd. Tired (Em) 










ee. Worry about sun 
flares (Ph) 










ff. Worry about hair loss 
(Bod) 










gg. Prevents outdoor 
activities (Ph) 










hh. Worry about what 
others are thinking 
(Bod) 










ii. Influence clothes (Bod) 










jj. Affects grooming 
practices (Bod) 










kk. Affects sun protection 
efforts (Ph) 










Score Total 56 39.29
b
    25.68     
Cronbach’s Alpha
c
               0.97 
*Item 18 on side-effects of treatment is not scored nor included in the final CLEQoL scale  
aTotals do not equal 57 due to missing responses  
bThe composite score for the overall scale calculation based on 57 responses, possible scale range 0 to 100  
cCronbach’s alpha based on 36 items 





Table 5.25: Mean CLEQoL Scores, Standard Deviations, and Cronbach’s Alpha 
Recoded CLEQoL Domain Mean Scores, Standard Deviations, and Cronbach’s 
Alpha 
aTotals do not equal 57 due to missing responses  
bThe composite score for the overall scale calculation based on 57 responses, possible scale range 0 to 100  
cCronbach’s alpha based on 10 items 
dCronbach’s alpha based on 26 items 





was the measure for the second dependent variable in this study. 
The items therein measure responses to eight subscales that relate to general health 
including physical functioning, role-physical, bodily pain, general health, vitality, social 
functioning, role-emotional and mental health. Each item is transformed from a 0 -100 
scale and converted to a norm-based score that is reflective of the U.S. general 





 Median SD Min Max Cronbach’s α
c
 
Emotions 57 42.24 37.50 29.64 0 100.00 0.94 
Symptoms 57 42.11 39.29 25.07 0 89.29 0.89 
Functioning 57 27.96 14.58 28.52 0 100.00 0.97 
Body image/cosmetic 
effects 
56 42.41 37.50 28.99 0 100.00 0.71 
Photosensitivity 56 61.90 66.67 30.44 0 100.00 0.74 
Total Score 56 39.29 31.60 25.68 0 97.92 0.97 
aTotals do not equal 57 due to missing responses  
bThe composite score for the overall scale calculation based on 57 responses, possible scale range 0 to 100  








 Median SD Min Max Cronbach’s 
α 
Skewness Kurtosis 
Mental 57 42.24 37.50 29.64 0 100.00 0.94c 0.36 -1.11 
Physical 56 38.07 32.21 24.79 0.96 97.12 0.96d 0.58 -0.66 
Total 
Score 
56 39.29 31.60 25.68 0 97.92 0.97
e
 0.52 -0.82 
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summary scores also ranging from 0 to 100 were obtained –Physical Component 
Summary (PCS) and Mental Component Summary (MCS) scores. 
 Mean PCS and MCS scores were 39.93±12.68 and 45.68±11.56, respectively, 
indicating that both the physical health and mental health scores were below the U.S. 
general population norm (50±10). Patients scored higher on the MCS domain than 
under the PCS domain, with mental health (MH) (67.93±23.65), role-emotional (RE) 
(65.50±39.32), and social functioning (SF) (64.91±30.93) being the highest scores. 
These findings are summarized in Table 5.26. 
 
Table 5.26: Mean SF-36 Scores, Standard Deviations, and Cronbach’s Alpha  
 
5.7 BIVARIATE ANALYSES AMONG THE REVISED WILSON AND CLEARY 
MODEL CONSTRUCTS 
To build the parsimonious model, appropriate bivariate analyses were conducted 











PCS 56 39.93 39.92 12.68 14.56 60.05 0.87 
   Physical Functioning (PF) 57 58.33 55.00 31.47 0 100.00 0.95 
   Role-Physical (RP) 56 43.42 25.00 44.70 0 100.00 0.92 
   Bodily Pain (BP) 56 60.14 52.00 30.00 0 100.00 0.75
*
 
   General Health (GH) 56 47.00 42.00 24.55 0 97.00 0.78 
MCS 55 45.68 47.73 11.56 17.24 65.25 0.81 
   Vitality (VT) 56 40.09 35.00 25.83 0 100.00 0.69 
   Social Functioning (SF) 55 64.91 62.50 30.93 0 100.00 -0.74
*
 
   Role-Emotional (RE) 57 65.50 66.67 39.32 0 100.00 0.76 
   Mental Health (MH) 55 67.93 72.00 23.65 0 100.00 0.81 
aTotals do not equal 57 due to missing responses; bThe composite score for the overall scale calculation based on 57 responses, 
possible scale range 0 to 100; cCronbach’s alpha based on 36 items; *Estimated by Spearman correlation; PCS: Physical Component 





5.7.1 Pearson’s Correlations 
Table 5.27 shows the Pearson’s correlations among the measures (subscale 
scores) of the CLEQoL scale. All five subscales were significantly and positively 
correlated with each other at a significance level of p<0.01.  
Table 5.27: Inter-Scale Correlations Matrix of the CLEQoL (N=57) 
 
EM SX FXN BOD PH Mental Physical  
EM 1.00       
SX 0.81
** 1.00      
FXN 0.88
** 0.78** 1.00     
BOD 0.76
** 0.58** 0.72** 1.00    
PH 0.58
** 0.49** 0.58** 0.70** 1.00   
Mental 1.00
** 0.81** 0.88** 0.76** 0.58** 1.00  
Physical 0.91
** 0.87** 0.96** 0.82** 0.71** 0.91** 1.00 
Emotions  (EM); Symptoms (SX); Functioning (FXN); Body image/Cosmetic effects (BOD); Photosensitivity (PH); Mental (CLEQoL-Mental); 
Physical (CLEQoL-Physical) 
Note: Pearson’s correlations are significant at * p < 0.05, ** p < 0.01 
 
Table 5.28 shows the Pearson’s correlations among the measures (subscale 
scores) of the SF-36 scale. All the domains and component scores were significantly 
and positively correlated with each other at a significance level of p<0.05.  
  Table 5.28: Inter-Scale Correlations Matrix of the SF-36 (N=57) 
 PF RP BP GH VT SF RE MH PCS MCS 
PF 1.00          
RP 0.73
** 1.00         
BP 0.78
** 0.69** 1.00        
GH 0.73
** 0.55** 0.60** 1.00       
VT 0.69
** 0.56** 0.69** 0.76** 1.00      
SF 0.71
** 0.57** 0.78** 0.63** 0.60** 1.00     
RE 0.57
** 0.61** 0.58** 0.44** 0.43** 0.56** 1.00    
MH 0.42
** 0.41** 0.41** 0.58** 0.58** 0.58** 0.53** 1.00   
PCS 0.92
** 0.82** 0.85** 0.73** 0.70** 0.67** 0.45** 0.27* 1.00  
MCS 0.44
** 0.43** 0.50** 0.57** 0.62** 0.69** 0.75** 0.92** 0.29* 1.00 
Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); 
Mental Health (MH); Physical Component Summary (PCS); Mental Component Summary (MCS) 




Table 5.29 shows the Pearson’s correlations among the subscale scores of 
CLEQoL and the predictor variables (interval-level) in the model. Summary of the 
findings are below. 
CLEQoL-Mental Domain 
Disease activity, pain, itch, fatigue, and body image were significantly and 
positively correlated with CLEQoL-Mental at a significance of p<0.01. Skin health 
perception, age, and social perception were significantly and negatively correlated with 
CLEQoL-Mental at a significance of p<0.05. 
 
CLEQoL-Physical Domain 
Disease activity, pain, itch, fatigue, and body image were significantly and 
positively correlated with CLEQoL-Physical at a significance of p<0.01, while skin 
health perception and social support were significantly and negatively correlated with 
CLEQoL-Physical at a significance of p<0.01. 
The Pearson’s correlations among the component scores of the SF-36 and the 
predictor variables (interval-level) in the model are depicted below in Table 5.30 as well 
as the summary of the findings. 
 
SF-36 Physical Component Summary (PCS)  
Pain, itch, fatigue, and body image were significantly and negatively correlated 
with PCS at a significance of p<0.01. Skin health perception was significantly and 
positively correlated with PCS at a significance of p<0.05. 
156 
 
SF-36 Mental Component Summary (MCS) 
Pain, itch, fatigue, and body image were significantly and negatively correlated 
with MCS at a significance of p<0.01. Social support was significantly and positively 
correlated with MCS at a significance of p<0.01. 
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Table 5.29: Correlations of Predictor Variables with CLEQoL (N=57) 
 MTL PHY CDA CDD DxD PAIN ITCH FAT BIM COM SIDE PB SKH AGE INC SOS 
MTL 1.00**                
PHY 0.91** 1.00               
CDA 0.33* 0.35** 1.00              
CDD 0.24 0.20 0.53** 1.00             
DxD -0.13 -0.16 0.04 0.21 1.00            
PAIN 0.59** 0.65** 0.31* 0.31* 0.07 1.00           
ITCH 0.57** 0.58** 0.35** 0.31* 0.05 0.72** 1.00          
FAT 0.58** 0.63** 0.14 0.06 -0.12 0.66** 0.49** 1.00         
BIM 0.79** 0.78** 0.36** 0.16 -0.21 0.62** 0.51** 0.51** 1.00        
COM -0.02 -0.03 0.02 0.16 0.16 -0.10 0.07 -0.22 -0.11 1.00       
SIDE -0.02 0.03 0.07 -0.06 0.07 0.03 0.05 0.08 0.02 -0.01 1.00      
PB 0.06 0.06 0.13 0.13 0.11 0.06 0.09 0.18 -0.01 0.02 0.00 1.00     
SKH -0.40** -0.39** -0.31* -0.15 0.12 -0.38** -0.31** -0.28** -0.47** -0.01 0.12 0.02 1.00    
AGE -0.28* -0.25 0.03 -0.09 0.12 -0.06 -0.21 0.05 -0.30* 0.03 -0.31* 0.20 -0.09 1.00   
INC -0.04 -0.01 -0.03 -0.27* -0.13 -0.08 0.18 0.07 0.04 -0.08 -0.07 -0.25 -0.11 0.17 1.00  
SOS -0.38** -0.36** 0.19 -0.38** 0.17 -0.17 0.21 -0.01 -0.46** -0.21 0.01 -0.09 0.22 0.18 -0.03 1.00 
Mental (MTL); Physical (PHY); CLASI Disease Activity (CDA); CLASI Disease Damage (CDD); Disease Duration (DxD); Pain (PAIN); Pruritus/Itch (ITCH); Fatigue (FAT); Body Image (BIM); Comorbidity 
(COM); Side-effects from CLE Medications (SIDE); Pill Burden (PB); Skin Health Perception (SKP); Age (AGE); Income (INC); Social Support (SOS)  
Note: Pearson’s correlations are significant at *p < 0.05, **p < 0.01 
 
Table 5.30: Correlations of Predictor Variables with SF-36 (N=57) 
 
Physical Component Summary (PCS); Mental Component Summary (MCS); CLASI Disease Activity (CDA); CLASI Disease Damage (CDD); Disease Duration (DxD); Pain (PAIN); Pruritus/Itch (ITCH);   
Fatigue (FAT); Body Image (BIM); Comorbidity (COM); Side-effects from CLE Medications (SIDE); Pill Burden (PB); Skin Health Perception (SKH); Age (AGE); Income (INC); Social Support (SOS) 
Note: Pearson’s correlations are significant at * p < 0.05, ** p < 0.01 
 PCS MCS CDA CDD DxD PAIN ITCH FAT BIM COM SIDE PB SKH AGE INC SOS 
PCS 1.00                
MCS 0.29* 1.00               
CDA -0.21 -0.20 1.00              
CDD -0.16 -0.16 0.53** 1.00             
DxD 0.06 -0.05 0.04 0.21 1.00            
PAIN -0.70** -0.55* 0.31* 0.31* 0.07 1.00           
ITCH -0.42** -0.59** 0.35** 0.31* 0.05 0.72** 1.00          
FAT -0.71** -0.44** 0.14 0.06 -0.12 0.66** 0.49** 1.00         
BIM -0.50** -0.38** 0.36** 0.16 -0.21 0.62** 0.51* 0.51** 1.00        
COM 0.12 0.03 0.02 0.16 0.16 -0.10 0.07 -0.22 -0.11 1.00       
SIDE -0.19 -0.05 0.07 -0.06 0.07 0.03 0.05 0.08 0.02 -0.01 1.00      
PB -0.12 -0.08 0.13 0.13 0.11 0.06 0.09 0.18 -0.01 0.02 0.00 1.00     
SKH 0.33* 0.24 -0.31* -0.15 0.12 -0.38** -0.31* -0.28* -0.47** -0.01 0.12 0.02 1.00    
AGE 0.04 0.12 -0.03 -0.09 0.12 -0.06 -0.21 -0.05 -0.30** 0.03 -0.31 0.20 -0.09 1.00   
INC 0.04 -0.01 -0.03 -0.27* -0.13 -0.08 0.18 0.07 0.04 -0.08 -0.07 -0.25 -0.11 0.17 1.00  





The predictor variables (binary level) used in the model were assessed to 
determine their relationships with each of the dependent variables. These predictor 
variables include: CLE subtype, depression, gender, race/ethnicity, smoking status, and 
marital status. None of the independent variables were significant with the CLEQoL 
mental and physical outcome variables [See Tables 5.31]. The findings from only the 
SF-36 analyses are thus presented below. 
 
SF-36 Mental Component Summary (MCS) 
The results from the analyses show that MCS scores (t=3.021, df=55, p=0.004; 
mean difference=9.30) in patients without depression (mean=48.62) were significantly 
higher than those with depression (mean=39.32). Therefore, the positive mean 
difference indicated that patients without depression had better mental health than did 
patients with depression [See Table 5.31]. 
 
SF-36 Physical Component Summary (PCS) 
 Race/ethnicity and smoking status were the only significant predictors of PCS. 
The t-test analyses from Table 5.31 show that the difference in PCS scores between 
those who were African-American/Black (mean=36.03) and Others (mean=44.59) was 
significant (mean difference=-8.56, t=-2.673, df=55, p=0.010). This difference in means 
shows that patients who were not African-American/Black had a higher PCS score 
(better physical health) than African-American/Black patients. Finally, the PCS scores 
(t=-2.05, df=52, p=0.046, mean difference=-7.01) was significantly higher for those 
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who had never smoked (mean=42.97) than patients who currently smoke/smoked 
cigarettes in the past (mean=35.97).   
 
Table 5.31: T-tests of Predictor Variables with Dependent Variables (N=57) 
 CLEQoL-Mental CLEQoL-Physical MCS PCS 
 t p-value t p-value t p-value t p-value 
CLE subtype 1.11 0.272 0.18 0.859 -0.06 0.954 0.42 0.674 
Depression -1.61 0.114 -1.81 0.077 3.02 0.004
** 0.63 0.534 
Gender -0.61 0.544 -0.24 0.810 -0.21 0.835 0.34 0.737 
Race/Ethnicity -0.22 0.829 0.03 0.978 0.05 0.962 -2.67 0.010
** 
Smoking 1.75 0.085 0.41 0.096 -1.45 0.152 -2.05 0.046
* 
Marital Status 0.55 0.582 0.16 0.409 0.62 0.540 -0.24 0.814 
  
 
5.8       DESCRIPTIVES OF STUDY SCALES TOTAL 
Table 5.32 provides a summary of the scale total scores calculated for each of 
the variables in the model.  
Table 5.32: Summary of the Mean Scores, Standard Deviations, and Ranges of 
Study Scales 
Scale N Mean SD Possible 
Range 
Actual Range 
CLEQoL      
Mental Domain 57 42.24 29.64 0 to 100 0 to 100.00 
          Emotions 57 42.24 29.64 0 to 100 0 to 100.00 
Physical Domain 56 38.07 24.79 0 to 100 0.96 to 97.12 
          Symptoms 57 42.11 25.07 0 to 100 0 to 89.29 
          Functioning 57 27.96 28.52 0 to 100 0 to 100.00 
          Body image/cosmetic effects 56 42.41 28.99 0 to 100 0 to 100.00 
          Photosensitivity 56 61.90 30.44 0 to 100 0 to 100.00 
SF-36      
Mental Component Summary (MCS) 55 45.68 11.56 0 to 100 17.24 to 65.25 
         Vitality (VT) 56 40.09 25.83 0 to 100 0 to 100.00 
 Social Functioning (SF)
*
 55 64.91 30.93 0 to 100 0 to 100.00 
 Role-Emotional (RE) 57 65.50 39.32 0 to 100 0 to 100.00 
 Mental Health (MH) 55 67.93 23.65 0 to 100 0 to 100.00 
  Physical Component Summary (PCS) 56 39.93 12.68 0 to 100 14.56 to 60.05 
 Physical Functioning (PF) 57 58.33 31.47 0 to 100 0 to 100.00 
 Role-Physical (RP) 56 43.42 44.70 0 to 100 0 to 100.00 
 Bodily Pain (BP)
*
 56 60.14 30.00 0 to 100 0 to 100.00 
 General Health (GH) 56 47.00 24.55 0 to 100 0 to 97.00 
Disease activity 57 5.51 5.41 0 to 70.00 0 to 29.00 
Disease damage 57 8.05 7.11 0 to 70.00 0 to 26.00 
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Table 5.32: Summary of the Mean Scores, Standard Deviations, and Ranges of Study 
Scales (Cont’d) 
Scale N Mean SD Possible Range Actual Range 
Disease duration 57 7.12 8.45 - 0.10 to 39.96 
Pain 57 3.16 3.46 0 to 10.00 0 to 10.00 
Pruritus/Itch 55 3.78 3.39 0 to 10.00 0 to 10.00 
Fatigue 55 5.18 3.57 0 to 10.00 0 to 10.00 
Body image 57 8.78 8.92 0 to 30.00 0 to 30.00 
Comorbidity 57 3.32 3.23 0 to 42.00 0 to 10.00 
Side-effects from 
CLE medications 
57 0.98 1.55 0 to 4.00 0 to 4.00 
Pill burden 53 1.21 1.59 0 to 4.00 0 to 4.00 
Skin health 
perception 
57 5.14 3.02 0 to 10.00 0 to 10.00 
Age 57 49.20 12.90 - 23.00 to 78.00 
Social support 55 3.00 1.35 0 to 4.00 0 to 4.00 
 
5.9       DATA SCREENING PRIOR TO ANALYSIS 
Multicollinearity 
To build the parsimonious model, multicollinearity was assessed between the 
seven interval-level variables (disease activity, pain, pruritus/itch, fatigue, body image, 
skin health perception, and social support), to determine if they were correlated with 
each other. Collinearity diagnostics were performed by examining the tolerance values 
(cut-off of <0.1) and variance inflation factor (cut-off of >10) between each pair of 
independent variables. None of the tolerance values were < 0.1 nor were any of the 
variance inflation factors > 10. Given that multicollinearity was not a problem, all 







The assumptions of multiple regression analysis (normality of residuals, 
homoscedasticity, linearity, and independence) were checked before statistical analyses. 
Each of the dependent variables and their subscale/component scores were checked 
prior to statistical analyses. The distributions of the residuals based on the histograms of 
the residuals and normality probability plots were found to be normal.  
Homoscedasticity was also assessed for each dependent variable and this 
assumption was met. The assumption of linearity was met based on the non-curved 
shape of the residual scatter plots of the dependent variables. Finally, the assumption of 
independence of residuals was met since participants received individual surveys 




5.10 SUMMARY OF BIVARIATE ANALYSES 
Table 5.33 details a summary of the bivariate analyses between each 
domain/subscale of the dependent variables and predictor variables. Only the significant 




Table 5.33: Summary of Significance of Results from Bivariate Analyses (All Predictor 
and Dependent Variables) 
 
                 means significant at p < 0.05                  means not significant              
+Indicates a positive significant relationship  









Biological and Physiological Factors 
1. CLE subtype     
2. Disease activity + +   
3. Disease damage      
4. Disease duration     
 
Symptom Status 
5. Pain + + - - 
6. Pruritus/Itch + + - - 
7. Fatigue + + - - 
 
Functioning 
8. Body image + + - - 
9. Depression   +  
10. Comorbidity      
 
General Health Perceptions 
11. Side-effects from 
CLE medications 
    
12. Pill burden     






Characteristics of the Individual 
14. Age -    
15. Gender     
16. Race/ethnicity    - 
17. Smoking status    - 
 
Characteristics of the Environment 
18. Marital status      
19. Income     
20. Social support - - -  
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5.11 TESTS OF HYPOTHESES 
Since none of the dependent variables violated the assumptions of multiple 
regression, there was no need for data transformation and rescoring. All of the 
dependent variables were normally distributed and there were no violations of skewness 
and kurtosis. To test the study hypotheses [See Chapter 4, Table 4.2], data analyses 
were conducted using t-tests, correlations, and multiple regression using parsimonious 
models built from bivariate analyses. 
 
Objective 2: To determine the predictive ability of biological and physiological 
factors (disease activity), symptom status (pain, pruritus, or fatigue), functioning 
(body image), general health perception (skin health perception) in explaining 
overall quality of life (QoL) in patients with CLE while controlling for 
characteristics of the individual (race/ethnicity, smoking status) and 
characteristics of the environment (social support). 
 
H2A: Biological and physiological factors (disease activity), symptom status (pain, 
pruritus, or fatigue), functioning (body image), general health perception (skin 
health perception) will explain a significant amount of variance in overall QoL 
(CLEQoL and SF-36) while controlling for characteristics of the individual 





CLE-QoL-Mental as Dependent Variable 
The CLEQoL-Mental regression model was significantly different from zero, 
F=11.10, df=9,50; p<0.001. Approximately 71 percent of the variation in overall QoL 
(mental) (R
2
=0.71) was accounted for by nine predictor variables, where the adjusted 
R
2
 was 65 percent (R
2
=0.65). Therefore, H2A was supported [See Table 5.34]. 
 
CLE-QoL-Physical as Dependent Variable 
The CLEQoL-Physical regression model was significantly different from zero, 
F=13.52, df=9,49; p<0.001. Seventy-three percent of the variation in overall QoL 
(physical) (R
2
=0.73) was accounted for by nine predictor variables, where the adjusted 
R
2
 was 69 percent (R
2
=0.69). Therefore, H2A was supported [See Table 5.35]. 
 
SF-36 MCS as Dependent Variable 
The SF-36 MCS regression model was significantly different from zero, F=5.31, 
df=9, 50; p<0.001. Nine predictor variables accounted for 54 percent of the variation in 
overall QoL (MCS) (R
2
=0.54). The adjusted R
2
 was 44 percent (R
2
=0.44). Therefore, 
H2A was supported [See Table 5.36]. 
 
SF-36 PCS as Dependent Variable 
The SF-36 PCS regression model was significantly different from zero, 
F=10.00, df=9, 50; p<0.001. Nine predictor variables accounted for 69 percent of the 
variation in overall QoL (PCS) (R
2
=0.69). The adjusted R
2
 was 62 percent (R
2
=0.62). 
Therefore, H2A was supported [See Table 5.37] 
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H2B1: Biological and physiological factor (disease activity) will be a positive and 
significant predictor of overall QoL (CLEQoL) while controlling for symptom 
status (pain, pruritus, or fatigue), functioning (body image), general health 
perception (skin health perception), characteristics of the individual 




CLE-QoL-Mental as Dependent Variable 
Disease activity was not a significant or positive predictor of overall QoL 
(CLEQoL-Mental) while controlling for other predictor variables (β=-0.02, p=0.853). 
Therefore, H2B1 was rejected [See Table 5.34]. 
 
 
CLE-QoL-Physical as Dependent Variable 
Disease activity was not a significant or positive predictor of overall QoL 
(CLEQoL-Physical) while controlling for other predictor variables (β=0.02, p=0.865). 
Therefore, H2B1 was rejected [See Table 5.35]. 
 
H2B2: Biological and physiological factor (disease activity) will be a negative and 
significant predictor of overall QoL (SF-36) while controlling for symptom status 
(pain, pruritus, or fatigue), functioning (body image), general health perception 
(skin health perception), characteristics of the individual (race/ethnicity, smoking 
status) and characteristics of the environment (social support). 
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SF-36 MCS as Dependent Variable 
Disease activity was not a positive and significant predictor of overall QoL (SF-
36 MCS) (β=0.04, p=0.760) while controlling for other predictor variables. Therefore, 
H2B2 was rejected [See Table 5.36]. 
 
SF-36 PCS as Dependent Variables 
Disease activity was not a positive and significant predictor of overall QoL (SF-
36 PCS) (β=0.03, p=0.742) while controlling for other predictor variables. Therefore, 
H2B2 was rejected [See Table 5.37]. 
 
H2C1: Symptom status (pain, pruritus, or fatigue), will be positive and significant 
predictor of overall QoL (CLEQoL) while controlling for biological and 
physiological factors (disease damage), functioning (body image) general health 
perception (skin health perception), characteristics of the individual 
(race/ethnicity, smoking status) and characteristics of the environment (social 
support). 
 
CLE-QoL-Mental as Dependent Variable 
Fatigue was a positive and significant predictor of overall QoL (CLEQoL-
Mental) while controlling for other predictor variables (β=0.23, p=0.037). Pain (β=-
0.10, p=0.522) and pruritus/itch (β=0.17, p=0.205) were not significant predictors. 




CLE-QoL-Physical as Dependent Variable 
Fatigue was a positive and significant predictor of overall QoL (CLEQoL-
Physical) while controlling for predictor variables (β=0.31, p=0.013). Pain (β=-0.04, 
p=0.820) and pruritus/itch (β=0.18, p=0.185) were not significant predictors. Therefore, 
H2C1 was supported for fatigue and rejected for pain and pruritus/itch [See Table 5.35]. 
 
H2C2: Symptom status (pain, pruritus, or fatigue), will be a negative and significant 
predictor of overall QoL (SF-36) while controlling for biological and physiological 
factors (disease activity), functioning (body image), general health perception (skin 
health perception), characteristics of the individual (race/ethnicity, smoking 
status) and characteristics of the environment (social support). 
 
 
SF-36 MCS as Dependent Variable 
Pruritus/itch (β=-0.41, p=0.017) and fatigue (β=-0.29, p=0.042) were negative 
and significant predictors of overall QoL (SF-36 MCS) while controlling for other 
predictor variables. Pain (β=-0.14, p=0.491) was not a significant predictor. Therefore, 
H2C2 was supported for pruritus/itch and fatigue, and rejected for pain [See Table 5.36]. 
 
SF-36 PCS as Dependent Variable 
Pain (β=-0.35, p=0.041) and fatigue (β=-0.47, p=0.000) were negative and 
significant predictors of overall QoL (SF-36 PCS) while controlling for other predictor 
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variables. Pruritus/itch (β=0.11, p=0.416) was not a significant predictor. Therefore, 
H2C2 was supported for pain and fatigue, and rejected for pruritus/itch [See Table 5.37]. 
 
H2D1: Functioning (body image) will be a positive and significant predictor of 
overall QoL (CLEQoL) while controlling for biological and physiological factors 
(disease activity), symptom status (pain, pruritus, or fatigue), general health 
perception (skin health perception), characteristics of the individual 
(race/ethnicity, smoking status) and characteristics of the environment (social 
support). 
CLE-QoL-Mental as Dependent Variable 
Body image (β=0.64, p=0.001) was a positive and significant predictor of 
overall QoL (CLEQoL-Mental) while controlling for other predictor variables. 
Therefore, H2D1 was supported [See Table 5.34].  
 
CLE-QoL-Physical as Dependent Variable 
Body image (β=0.49, p=0.002) was a positive and significant predictor of 
overall QoL (CLEQoL-Physical) while controlling for other predictor variables. 
Therefore, H2D1 was supported [See Table 5.35].  
 
H2D2: Functioning (body image) will be a negative and significant predictor of 
overall QoL (SF-36) while controlling for biological and physiological factors 
(disease activity), symptom status (pain, pruritus, or fatigue), general health 
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perception (skin health perception), characteristics of the individual 
(race/ethnicity, smoking status) and characteristics of the environment (social 
support). 
 
SF-36 MCS as Dependent Variable 
Body image (β=0.22, p=0.224) was not a negative and significant predictor of 
overall QoL (SF-3 MCS) while controlling for other predictor variables. Therefore, 
H2D2 was rejected [See Table 5.36]. 
 
 
SF-36 PCS as Dependent Variable 
Body image (β=-0.04, p=0.771) was not a negative and significant predictor of 
overall QoL (SF-36 PCS) while controlling for other predictor variables. Therefore, 
H2D2 was rejected [See Table 5.37]. 
 
H2E1: General health perception (skin health perception) will be a negative and 
significant predictor of overall QoL (CLEQoL) while controlling for biological and 
physiological factors (disease activity), symptom status (pain, pruritus, or fatigue), 
functioning (body image), characteristics of the individual (race/ethnicity, smoking 







CLE-QoL-Mental as Dependent Variable 
Skin health perception was not a negative and significant predictor of overall 
QoL (CLEQoL-Mental) while controlling for other predictor variables (β=0.02, 
p=0.808). Therefore, H2E1 was rejected [See Table 5.34]. 
 
CLE-QoL-Physical as Dependent Variable 
Skin health perception was not a negative and significant predictor of overall 
QoL (CLEQoL-Physical) while controlling for other predictor variables (β=0.02, 
p=0.839). Therefore, H2E1 was rejected [See Table 5.35]. 
 
H2E2: General health perception (skin health perception) will be a negative and 
significant predictor of overall QoL (SF-36) while controlling for biological and 
physiological factors (disease damage), symptom status (pain, pruritus, or fatigue), 
functioning (body image), characteristics of the individual (race/ethnicity, smoking 
status) and characteristics of the environment (social support). 
 
SF-36 MCS as Dependent Variable 
Skin health perception (β=0.05, p=0.710) was not a negative and significant 
predictor of overall QoL (SF-36 MCS) while controlling for other predictor variables. 






SF-36 PCS as Dependent Variable 
Skin health perception (β=0.11, p=0.289) was not a negative and significant 
predictor of overall QoL (SF-36 PCS) while controlling for other predictor variables. 
Therefore, H2C2 was rejected [See Table 5.37]. 
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Intercept 8.76 11.65  -14.75 32.30 0.45 
       
Independent Variables       
Biological and Physiological Factors       
Disease Activity  -0.10 0.53 -0.02 -1.17 0.98 0.853 
Symptom Status        
Pain -0.89 1.38 -0.10 -3.68 1.90 0.522 
Pruritus/Itch 1.48 1.15 0.17 -0.84 3.80 0.205 
Fatigue 1.92 1.00 0.23 0.87 3.94 0.037
*
 
Functioning       
Body Image 2.09 0.47 0.64 1.15 3.04 0.001
**
 
General Health Perception       
Skin Health Perception 0.24 0.99 0.02 -1.76 2.24 0.808 
       
Covariates       
Characteristics of the Individual       
Race/Ethnicity
b
 3.18 5.45 0.05 -7.85 14.21 0.564 
Smoking status
c
 8.79 5.69 0.15 -2.70 20.27 0.130 
Characteristics of the Environment       
Social Support  -1.36 2.35 -0.06 -6.11 3.38 0.565 




=0.65                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
      aCI = confidence interval of unstandardized coefficients; *Indicates significance at p < 0.05; **Indicates significance at p < 0.01 
    bRace/Ethnicity was dummy coded as “0” for” “African-American/Black” and “1” for “Others,” with “African-American/Black” as the comparator. 










  Table 5.35: Multiple Regression Analysis of Overall Quality of Life – CLE-QoL-Physical (N=49) 
 aCI = confidence interval of unstandardized coefficients; *Indicates significance at p < 0.05; **Indicates significance at p < 0.01  
bRace/Ethnicity was dummy coded as “0” for” “African-American/Black” and “1” for “Others,” with “African-American/Black” as the comparator. 


























Intercept 11.24 9.84  -8.64 31.12 0.260 
       
Independent Variables       
Biological and Physiological Factors       
Disease Activity  0.08 0.45 0.02 -0.83 0.99 0.865 
Symptom Status        
Pain -0.27 1.18 -0.04 -2.65 2.11 0.820 
Pruritus/Itch 1.31 0.97 0.18 -0.65 3.26 0.185 
Fatigue 2.21 0.85 0.31 0.49 3.92 0.013
*
 
Functioning       
Body Image 1.35 0.40 0.49 0.55 2.15 0.002
**
 
General Health Perception       
Skin Health Perception 0.17 0.84 0.02 -1.52 1.86 0.839 
       
Covariates       
Characteristics of the Individual       
Race/Ethnicity
b
 5.22 4.68 0.10 -4.23 14.67 0.271 
Smoking Status
c
 6.83 4.83 0.13 -2.93 16.59 0.165 
Characteristics of the Environment       
Social Support  -2.31 2.01 -0.12 -6.36 1.75 0.257 
































Intercept 46.36 5.45  35.49 57.62 0.000 
       
Independent Variables       
Biological and Physiological Factors       
Disease Activity  0.08 0.25 0.04 -0.43 0.58 0.760 
Symptom Status        
Pain -0.45 0.65 -0.14 -1.76 0.86 0.491 
Pruritus/Itch -1.35 0.54 -0.41 -2.44 -0.26 0.017
*
 
Fatigue -0.90 0.47 -0.29 -1.85 -0.15 0.042
*
 
Functioning       
Body Image 0.27 0.22 0.22 -0.17 0.72 0.224 
General Health Perception       
Skin Health Perception 0.17 0.47 0.05 -0.77 1.11 0.710 
Covariates       
Characteristics of the Individual       
Race/Ethnicity
b





 -1.53 2.67 -0.07 -6.92 3.87 0.569 
Characteristics of the Environment        
Social Support 3.31 1.10 0.41 1.08 5.54 0.005
**
 





aCI = confidence interval of unstandardized coefficients; *Indicates significance at p < 0.05; **Indicates significance at p < 0.01  
bRace/Ethnicity was dummy coded as “0” for” “African-American/Black” and “1” for “Others,” with “African-American/Black” as the comparator. 































Intercept 47.44 5.18  36.98 57.90 0.000 
       
Independent Variables       
Biological and Physiological Factors       
Disease Activity  0.08 0.235 0.03 -0.40 0.56 0.742 
Symptom Status        
Pain -1.30 0.61 -0.35 -2.54 -0.06 0.041
*
 
Pruritus/Itch 0.42 0.51 0.11 -0.61 1.45 0.416 
Fatigue -1.70 0.45 -0.47 -2.60 -0.80 0.000
**
 
Functioning       
Body Image -0.06 0.21 -0.04 -0.48 0.36 0.771 
General Health Perception       
Skin Health Perception 0.47 0.44 0.11 -0.42 1.36 0.289 
       
Covariates       
Characteristics of the Individual       
Race/Ethnicity
b





 -3.46 2.53 -0.14 -8.57 1.64 0.178 
Characteristics of the Environment       
Social Support 0.17 1.04 0.02 -1.94 2.28 0.870 





aCI = confidence interval of unstandardized coefficients; *Indicates significance at p < 0.05; **Indicates significance at p < 0.01  
bRace/Ethnicity was dummy coded as “0” for” “African-American/Black” and “1” for “Others,” with “African-American/Black” as the comparator. 






Objective 3: To determine if symptom status (pain, pruritus, or fatigue) is related 
to biological and physiological factors (disease activity), characteristics of the 
individual (race/ethnicity, smoking status) and characteristics of the environment 
(social support). 
Bivariate analyses (t-test and correlations) were used to assess the hypotheses 
related to this objective. The results are described in Tables 5.38 – 5.41 below.  
 
H3A1: There is no association between biological and physiological factors (disease 
activity) and symptom status – pain. 
 
Pain as the Outcome Variable  
  From Table 5.38, disease activity was positively and significantly associated 
with pain (r=0.31, p<0.05); as disease activity increased, so did pain. The hypothesis 
tested for objective 3 (H3A1) was rejected. 
 
H3A2: There is no association between biological and physiological factors (disease 
activity) and symptom status - pruritus. 
 
Pruritus/Itch as the Outcome Variable  
  Disease activity was positively and significantly associated with pruritus/itch 
(r=0.35, p<0.01). This means that as disease activity increased, pruritus increased. The 




H3A3: There is no association between biological and physiological factors (disease 
activity) and symptom status - fatigue. 
 
Fatigue as the Outcome Variable  
  There was no association between disease activity and fatigue (r=0.14, p=0.331). 
Thus, the hypothesis tested for objective 3 (H3A3) was supported [See Table 5.38]. 
 
  Table 5.38: Correlations of Disease Activity with Symptom Status (N=57) 
 Disease Activity Pain  Pruritus/Itch Fatigue 
Disease Activity 1.00    
Pain 0.31
*











 Note: Pearson’s correlations are significant at * p < 0.05, ** p < 0.01 
 
 
H3B1 – H3B3: There is no association between characteristics of the individual 
(race/ethnicity, smoking status) and symptom status (pain, pruritus, fatigue). 
Race/ethnicity as the Predictor Variable 
A t-test was used to assess the relationship between race/ethnicity and symptom 
status (pain). The differences in mean symptom scores (pain, pruritus, and fatigue) 
between the two groups (“African-American/Black” and “others”) were not statistically 










Table 5.39: T-tests of Race/Ethnicity
a
 with Symptom Status Variables (N=57) 



































       aRace/Ethncity was collapsed into two categories: African-American/Black (AA/B) and Others (Caucasian, Hispanic, Asian, and Other)   
         bFor t-test equality of means, equal variance assumed (The Levene test for equality of variance: p>0.05) 
          
 
 Smoking Status as the Predictor Variable 
The differences in mean symptom scores between the two groups 
(“Current/former smoker” and “never smoker”) were statistically significant for pain 
(t=2.13, df=52, p<0.05) and pruritus/itch (t=2.09, df=52, p<0.05) [See Table 5.40]. This 
means that patients who were current/former smokers experienced higher symptom 
levels (pain and pruritus/itch) than those who had never smoked. The hypotheses for 
objectives H3B1-H3B2 were not rejected. However, the hypothesis for H3B3 was accepted 












Table 5.40: T-tests of Smoking Status with Symptom Status Variables (N=57) 







































       aSmoking status was collapsed into two categories: Current/former smoker and never smoker 
         bFor t-test equality of means, equal variance assumed (The Levene test for equality of variance: p>0.05) 
          *Asterisk indicates statistical significance at p<0.05 
 
 
H3C1 – H3C3: There is no association between characteristics of the environment 
(social support) and symptom status (pain, pruritus, fatigue). 
Social Support as the Predictor Variable  
  There was no significant relationship among pain (r=-0.17, p=0.213), 
pruritus/itch (r =-0.22, p = 0.115), fatigue (r =0.01, p=0.952) and social support. The 
hypotheses tested for objective 3 (H3C1 – H3C3) were supported [See Table 5.41]. 
     Table 5.41: Correlations of Social Support with Symptom Status (N=57) 
 Social 
Support 
Pain  Pruritus/Itch Fatigue 
Support 1.00    
Pain -0.17 1.00   
Pruritus/Itch -0.22 0.72
**










Objective 4: To determine if functioning (body image) is related to symptom status 
(pain, pruritus, or fatigue), characteristics of the individual (race/ethnicity, 
smoking status) and characteristics of the environment (social support). 
Multiple regression was used to assess the related hypotheses of this objective. 
The results are described in Table 5.42 below. The functioning regression model was 
significantly different from zero, F=10.96; df=6,50; p<0.001. Sixty percent of the 
variation in functioning (body image) (R
2
=0.60) was accounted for by the six 
independent variables, where the adjusted R
2




H4A1 – H4A3: There is no association between symptom status (pain, pruritus, or 
fatigue) and functioning (body image). 
The hypotheses, H4A1 and H4A3, were rejected for pain (β=0.42, p=0.018) and 
fatigue (β=0.27, p=0.043), respectively [See Table 5.42]. However, the H4A2 was 
accepted as pruritus/itch had no association with functioning (β=0.00, p=0.985). 
Therefore, the hypotheses were rejected for pain and fatigue, and accepted for 
pruritus/itch [See Table 5.42]. 
 
H4B1 – H4B2: There is no association between characteristics of the individual 
(race/ethnicity, smoking status) and functioning (body image).  
This hypothesis was rejected for race/ethnicity (β=0.20, p=0.047) [See Table 
5.42]. This statistical result suggests that there is a significant relationship between 
race/ethnicity and functioning. However, the hypothesis for smoking status was 
accepted as there was no relationship between smoking status and body image (β=-0.05, 
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p=0.658). Therefore, H4B1 was rejected for race/ethnicity and H4B2 was accepted for 
smoking status [See Table 5.42]. 
 
H4C: There is no association between characteristics of the environment (social 
support) and functioning (body image). 
From Table 5.42, social support was negatively and significantly associated with 
body image (β=-0.45, p=0.000). Therefore, H4C was rejected. 
 





















Intercept 9.76 2.76  4.02 15.13 0.001 
       
Independent Variables       
Symptom Status        
Pain 1.10 0.45 0.42 0.20 2.00 0.018
*
 
Pruritus/Itch 0.07 0.39 0.00 -0.77 0.79 0.985 
Fatigue 0.69 0.33 0.27 0.02 1.35 0.043
*
 
       
Covariates       
Characteristics of the 
Individual 
      
Race/Ethnicity
b





 -0.81 1.82 -0.05 -4.49 2.86 0.658 
Characteristics of the 
Environment 
      
Social Support -2.98 0.68 -0.45 -4.34 -1.62 0.000
**
 





 aCI = confidence interval of unstandardized coefficients; *Indicates significance at p < 0.05; **Indicates significance at p < 0.01  
bRace/Ethnicity was dummy coded as “0” for” “African-American/Black” and “1” for “Others,” with “African-American/Black” as the   
comparator. 







Objective 5: To determine if general health perception (skin health perception) is 
related to functioning (body image), characteristics of the individual 
(race/ethnicity, smoking status) and characteristics of the environment (social 
support). 
The results from the multiple regression are described in Table 5.43 below. The 
regression model was significantly different from zero, F=3.25; df=4,51; p<0.05. 
Twenty-two percent of the variation in general health perception (skin health 
perception) (R
2
=0.22) was accounted for by the six independent variables, where the 
adjusted R
2




H5A: There is no association between functioning (body image) and general health 
perception (skin health perception). 
This hypothesis (H5A) was rejected as the statistical result suggests that there is a 
significant and negative relationship between functioning and skin health perception 
(β=-0.43, p=0.005) [See Table 5.43].  
 
H5B1 – H5B2: There is no association between characteristics of the individual 
(race/ethnicity, smoking status) and general health perception (skin health 
perception). 
There was no relationship between race/ethnicity and skin health perception (β=-
0.05, p=0.700). Also, there was no significant difference between smoking and skin 
health perception (β=-0.13, p = 0.324). The hypotheses tested for objective 5 (H5B1 – 
H5B2) were accepted [See Table 5.43]. 
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H5C: There is no association between characteristics of the environment (social 
support) and general health perception (skin health perception). 
This hypothesis was accepted as there was no relationship between social 
support and skin health perception (β=0.01, p=0.963) [See Table 5.43]. 
 
Table 5.43: Multiple Regression Analysis of General Health Perception (Skin 





















Intercept 5.41 1.94  1.51 9.31 0.008 
       
Independent Variables       
Functioning        
Body Image -0.14 0.05 -0.43 -0.24 -0.05 0.005
**
 
       
Covariates       
Characteristics of the Individual       
Race/Ethnicity
b
 -0.31 0.81 -0.05 -1.94 1.31 0.700 
Smoking Status
c
 0.79 0.79 0.13 -0.81 2.39 0.324 
Characteristics of the 
Environment 
      
Social Support 0.02 0.33 0.01 -0.65 0.68 0.963 





aCI = confidence interval of unstandardized coefficients; *Indicates significance at p < 0.05; **Indicates significance at p < 0.01  
bRace/Ethnicity was dummy coded as “0” for” “African-American/Black” and “1” for “Others,” with “African-American/Black” as the comparator. 








Objective 6: To compare the predictive ability of each of the two models (Model 1 
– CLEQoL and Model 2 – SF-36), in patients with CLE according to the proposed 
theoretical framework of the Revised Wilson and Cleary Model.  
 
H6A: The model with CLEQoL (Model 1) as the dependent variable will have a 
higher predictive ability than the model with SF-36 (Model 2), using the Williams’s 
t-tests: 
𝑡𝑛−3 = (𝑟12 − 𝑟13)√






4 (1 − 𝑟23)
3
 
where |𝑅| = 1 − 𝑟12
2 − 𝑟13
2 − 𝑟23
2 + 2𝑟12𝑟13𝑟23 
To compare the regression models, correlations from the regression outputs [See 
Table 5.44] were input into the equation above. Plugging the appropriate correlation 
values into the equation yielded the results displayed in Table 5.45. These results 
indicate that the difference between the two correlated correlations is statistically 
significant between the two models. Because the statistical t-test was higher than the 
critical t-test, the H0 was accepted; the predictor set has a better fit for higher R
2
 groups, 
i.e., CLEQoL mental has a better fit than the MCS model and CLEQoL physical has a 
better fit than the PCS model. Summarily, the CLEQoL models – mental and physical 





































































         

















































































          Physical Component Summary (PCS); Mental Component Summary (MCS) 
         *Correlation is significant at the 0.05 level (2-tailed). 





     Table 5.45: Williams’ t-Test For Comparing Two Nonindependent Correlations With Common Variables 
 r12 r13 r23 N Statistical t df 1-tailed α Critical t 
CLEQoL Mental and MCS models 0.83 0.25 0.31 57 5.969 54 0.05 1.67 





5.12 SUMMARY OF TESTS OF HYPOTHESES 
Table 5.46 shows the summary of the hypotheses test results. Twenty-four of the 43 hypotheses (56%) were supported 
via the study objectives [See Table 5.46]. 
 Table 5.46: Summary of Hypotheses Test Results 
Hypotheses CLEQoL 







Objective 2: To determine the predictive ability of biological and physiological factors (disease activity), symptom status (pain, pruritus, or 
fatigue), functioning (body image), general health perception (skin health perception) in explaining overall quality of life (QoL) in patients with 
CLE while controlling for characteristics of the individual (race/ethnicity, smoking status) and characteristics of the environment (social support). 
H2A: Biological and physiological factors (disease activity), symptom status (pain, 
pruritus, or fatigue), functioning (body image), general health perception (skin 
health perception) will explain a significant amount of variance in overall QoL 
(CLEQoL and SF-36) while controlling for characteristics of the individual 
(race/ethnicity, smoking status) and characteristics of the environment (social 
support). 
Supported Supported Supported Supported 
H2B1: Biological and physiological factor (disease activity) will be a positive and 
significant predictor of overall QoL (CLEQoL) while controlling for symptom 
status (pain, pruritus, or fatigue), functioning (body image), general health 
perception (skin health perception), characteristics of the individual (race/ethnicity, 











H2B2: Biological and physiological factors (disease activity) will be a negative and 
significant predictors of overall QoL (SF-36) while controlling for symptom status 
(pain, pruritus, or fatigue), functioning (body image), general health perception 
(skin health perception), characteristics of the individual (race/ethnicity, smoking 













H2C1: Symptom status (pain, pruritus, or fatigue), will be a positive and significant 
predictor of overall QoL (CLEQoL) while controlling for biological and 
physiological factors (disease activity), functioning (body image) general health 
perception (skin health perception), characteristics of the individual (race/ethnicity, 













Table 5.46: Summary of Hypotheses Test Results (Cont’d) 








H2C2: Symptom status (pain, pruritus, or fatigue), will be a negative and 
significant predictors of overall QoL (SF-36) while controlling for biological 
and physiological factors (disease activity), functioning (body image), general 
health perception (skin health perception), characteristics of the individual 









H2D1: Functioning (body image) will be a positive and significant predictor of 
overall QoL (CLEQoL) while controlling for biological and physiological 
factors (disease activity), symptom status (pain, pruritus, or fatigue), general 
health perception (skin health perception), characteristics of the individual 












H2D2: Functioning (body image) will be a negative and significant predictor of 
overall QoL (SF-36) while controlling for biological and physiological factors 
(disease activity), symptom status (pain, pruritus, or fatigue), general health 
perception (skin health perception), characteristics of the individual 










H2E1: General health perception (skin health perception) will be negative and 
significant predictors of overall QoL (CLEQoL) while controlling for biological 
and physiological factors (disease damage), symptom status (pain, pruritus, or 
fatigue), functioning (body image), characteristics of the individual 










H2E2: General health perception (skin health perception) will be negative and 
significant predictors of overall QoL (SF-36) while controlling for biological 
and physiological factors (disease damage), symptom status (pain, pruritus, or 
fatigue), functioning (body image), characteristics of the individual 













Table 5.46: Summary of Hypotheses Test Results (Cont’d) 
Objective 3: To determine if symptom status (pain, pruritus, or fatigue) is related to biological and physiological factors (disease activity), 
characteristics of the individual (race/ethnicity, smoking status) and characteristics of the environment (social support). 
H3A1: There is no association between biological and physiological factors (disease activity) and symptom 
status (pain). 
Not supported 
H3A2: There is no association between biological and physiological factors (disease activity) and symptom 
status (pruritus). 
Not supported 
H3A3: There is no association between biological and physiological factors (disease activity) and symptom 
status (fatigue). 
Supported 
 Race/Ethnicity Smoking  
H3B1: There is no association between characteristics of the individual (race/ethnicity, smoking status) and 




H3B2: There is no association between characteristics of the individual (race/ethnicity, smoking status) and 




H3B3: There is no association between characteristics of the individual (race/ethnicity, smoking status) and 
symptom status - fatigue. 
Supported Supported 
 
H3C1: There is no association between characteristics of the environment (social support) and symptom status 
(pain). 
Supported 
H3C2: There is no association between characteristics of the environment (social support) and symptom status 
(pruritus). 
Supported 
H3C3: There is no association between characteristics of the environment (social support) and symptom status 
(fatigue). 
Supported 
Objective 4: To determine if functioning (body image) is related to symptom status (pain, pruritus, or fatigue), characteristics of the individual 
(race/ethnicity, smoking status) and characteristics of the environment (social support). 
H4A1: There is no association between symptom status – pain and functioning (body image). Not supported 
H4A2: There is no association between symptom status – pruritus and functioning (body image). Supported 
H4A3: There is no association between symptom status – fatigue and functioning (body image). Not supported 
H4B1: There is no association between characteristics of the individual (race/ethnicity) and functioning (body 
image). 
Not supported 
H4B2: There is no association between characteristics of the individual (smoking status) and functioning (body 
image). 
Supported 






Table 5.46: Summary of Hypotheses Test Results (Cont’d) 
Objective 5: To determine if general health perception (skin health perception) is related to functioning (body image), characteristics of the 
individual (race/ethnicity, smoking status) and characteristics of the environment (social support). 
H5A: There is no association between functioning (body image) and general health perception (skin health 
perception). 
Not supported 
H5B1: There is no association between characteristics of the individual (race/ethnicity) and general health 
perception (skin health perception). 
Supported 
H5B2: There is no association between characteristics of the individual (smoking status) and general health 
perception (skin health perception). 
Supported 
H5C: There is no association between characteristics of the environment (social support) and general health 
perception (skin health perception). 
Supported 
Objective 6: To compare the predictive ability of each of the two models (Model 1 – CLEQoL and Model 2 – SF-36), in patients with CLE 
according to the proposed theoretical framework of the Revised Wilson and Cleary Model.  
H6A: The model with CLEQoL (Model 1) as the dependent variable will have a higher predictive ability than 
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CHAPTER SIX: DISCUSSION AND CONCLUSIONS 
This chapter provides a discussion of the study results. This study examined the 
predictive ability of constructs from the Revised Wilson and Cleary model in 
understanding the overall QoL of life in patients with CLE. This chapter begins with a 
review of the research question and study objectives/hypotheses followed by a 
discussion of the focus group findings. After which, the study sample, as well as the 
study findings were discussed and compared with previous research. The last part of 
this chapter evaluates the study model and presents discussions on the study 
implications, future research, study limitations, and conclusions. 
 
6.1 REVIEW OF RESEARCH QUESTIONS 
CLE, like most dermatological disease, is recognized for its detrimental impact 
on the quality of life (QoL) in patients by exerting significant burden on patients 
themselves and disrupting the lives of loved ones and individuals closest to them.
21,73,74
 
Unlike other dermatologic diseases, CLE is considered to be one of the most 
debilitating, causing both industrial disability and vocational handicap in patients.
30,36
 
Further, some of the symptoms experienced by CLE patients are subjective,
21,55,76
 and 
may not be captured accurately by clinical assessment tools. As a result, subjective 
measures, such as patient-reported outcomes (PROs) are needed to accurately measure 
QoL in these patients. Studies that have assessed QoL in CLE patients make use of PRO 
measures that were not specifically developed for these patients and that do not have 
reported psychometric properties.
20,21,26,55,73,74,160,262
 As a result, it is possible that all the 
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important issues relevant to CLE patients may not be captured. By using specific PRO 
measures, we can identify what factors make up the QoL in CLE patients. 
Consequently, these factors, especially the modifiable ones, can be targeted to improve 
the QoL of patients. Further, the development and validation of CLE-specific PRO 
measures can be used to create CLE-specific attributes that could be used in 
determining therapeutic efficacy in future clinical trials. Hence, this current study fills 
these gaps as there are no known studies that have specifically examined the factors 
contributing to the QoL in patients by using a disease-specific PRO and a theoretical 
framework. 
 
6.2 FOCUS GROUP (FG) FINDINGS 
FGs were conducted to explore, describe and clarify the patients’ perspective of 
how CLE has impacted their lives, and to examine patients’ perceptions of unmet needs 
regarding CLE treatment and care. While confirming CLE’s negative impact on 
QoL,
21,26,314
 findings from the FGs delineate physical, mental, and medication effects 
from CLE, CLE’s impact on social interactions, coping strategies, and unmet needs 
regarding their treatment and management.  
The physical limitations imposed upon patients by CLE can be disruptive and 
problematic.
20,21,236
 Itching and other skin symptoms such as burning and 
photosensitivity can affect one’s ability to engage in daily activities, and affect their 
social interactions. Providers can help alleviate these symptoms with appropriate 
medications and counseling on photoprotective methods to help offset these issues. 
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Moreover, our FGs elicited strong sentiment about the negative QoL impact of 
permanent alterations in physical appearance including scarring and dyspigmentation 
that cause significant body image issues – which were the most unique contributions to 
the literature.
10,315
 Patients employed grooming practices to cover their skin blemishes 
with long-sleeved clothing, heavy makeup, and wigs. The importance of these practices 
was further underscored by multiple patients wishing they received education on 
masking their skin blemishes earlier. Despite these concerns, current QoL instruments 
used for CLE clinical trials such as the Skindex and Dermatology Life Quality Index,
316-
318
 do not sufficiently evaluate the impact of these unique features of CLE. Adding 
questions to probe the extent to which patients cover their CLE lesions and alter their 
outdoor practices would help address this deficiency.  





confers social difficulties on patients. Due to the unpredictability of the disease, patients 
find it hard to sometimes foster interactions with those around them. Providers can seek 
out behaviors suggestive of social isolation by asking patients about preference to stay 
home or do things alone because of their CLE. By retreating and isolating themselves, 
patients may be at a greater risk of worsening their mental health. Several patients 
expressed frustrations about how CLE is often perceived by others as less severe 
because it is skin-related with mostly subjective signs and symptoms. Educating the 
public about CLE is key to creating the awareness needed to understand the disease 
better and to provide the needed support and empathy to patients with CLE.  
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Positive and negative coping strategies were cited by several patients with CLE. 
Having strong support systems through friends and family was fortunately shared by 
many patients. Patients (especially newly-diagnosed ones) who receive psychosocial 
supports have fared better with their disease management and participate more in their 
healthcare.
321,322
 Furthermore, anecdotal comments made by FG participants showed 
that patients valued being with other patients with CLE and the safe environment to 
share information related to their concerns, needs, and experiences. Many patients 
reported that the FGs helped normalize their QoL issues related to CLE. These FGs 
validated the importance of patient support systems, which can reduce feelings of 
isolation, anxiety, and depression and promote better overall mental health in patients 
with CLE. The ability to self-manage the symptoms experienced in chronic, disabling 
diseases (such as CLE) is important to reduce the impact of the disease on QoL.
323
 In 
addition, coping has been reported to be an important mediator in the ability of adults to 
achieve a reasonable well-being.
324,325
  
CLE patients also strongly expressed a desire for medications to improve not 
only acute symptoms such as itching and burning but also chronic skin sequelae 
including scarring, dyspigmentation, and alopecia. Clinical trials in lupus patients often 
use improvement in CLASI activity scores, which results in reduction of acute 
symptoms (e.g. itching, burning), as a primary outcome measure. However, they often 
do not report changes in CLASI damage scores that measure amount of scarring and 
dyspigmentation.
316,326,327
 This limitation underscores the need to develop therapeutic 
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agents in CLE that alleviate both acute and chronic skin sequelae in CLE, which would 
be more likely viewed as therapeutic success by patients.  
 
6.3 REVISED WILSON & CLEARY STUDY FINDINGS 
Overall QoL was the main outcome variable of the study. In the Revised Wilson 
and Clearly Model, QoL is determined by biological and physiological factors, 
symptoms status, functioning, general health perception, and characteristics of the 
individual and environmental characteristics.  
 
 
6.3.1 Overall Quality of Life 
In this study, overall QoL was operationalized using two measures – a disease-
specific instrument, CLEQoL and a generic instrument – Short Form (SF)-36. 
 
6.3.1.1 CLEQoL 
 Overall, patients experienced all of the domains in the CLEQoL rarely or some 
of the time. Of all the initial five domains of the CLEQoL, CLE patients were most 
affected in the lupus-specific domains – photosensitivity and body image/cosmetic 
effects and were least affected in the functioning domain; these all fall under the 
CLEQoL-physical domain. While the body/image cosmetic effects domain is a unique 
contribution to the literature, other studies have reported similar findings with the 





Within the photosensitivity domain, patients were most concerned with the 
effect of the sun on their protection efforts and the effect of sun flares. These physical 
limitations imposed upon patients by CLE can be disruptive and problematic, which is 
consistent with findings from other studies.
20,21,236
 Specifically, photosensitivity can 
affect patient’s ability to engage in daily activities, and affect their social interactions. 
Providers can help alleviate these symptoms with appropriate medications and 
counseling on photoprotective methods to help offset these issues. Moreover, CLE 
results in permanent alterations in physical appearance including scarring and 
dyspigmentation that cause significant body image issues.
10,315
 
Within the body image/cosmetic issue domains, patients were most concerned 
with losing their hair, which is consistent with findings from another study.
236
 For 
patients with chronic diseases, such as CLE, alterations in physical appearance as a 
result of the disease course may cause significant body image issues.
10,315
 For female 
patients especially the younger ones, these cosmetic issues can be a major problem and 
can impact their ability to cope with the disease. Rather than expose the physical 
manifestations of their disease, many patients (especially females) resort to the use of 
extra clothing, heavy makeup, and wigs to cover up. Some of these cover-up measures 
are used all year round and may not be convenient during hot and sunny times of the 
year. For patients with CLE, possessing a positive self-concept (such as positive attitude 
and presence of family support) may assist with body image issues experienced. 
Patients can also be equipped with adequate social skills, as part of psychosocial 





 When combined into two domains, patients in this current study were most 




 In this CLEQoL model (both physical and mental), after controlling for all the 
predictor variables, symptoms status (fatigue) and functioning (body image) showed 
positive and significant relationships with overall QoL. 
 
6.3.1.2  SF-36 
As expected, CLE patients reported significantly lower quality of life than the 
U.S. general population, both on the physical (PCS) and mental component summary 
scores (MCS). CLE patients scored lowest on questions related to role-physical from 
the PCS domain and vitality from the MCS domain. These low scores on the PCS 
domain are similar to findings in patients with clinical depression and recent myocardial 
infarction, and worse than patients with hypertension.
236
 Similarly, the low scores 
reported on the MCS domain were similar to those with congestive heart failure and 
clinical depression, and worse in patients with type 2 diabetes mellitus and in those with 
a recent myocardial infarction.
236
  
The physical functioning and bodily pain scores were moderate, which indicates 
some limitation in physical functioning and some disability and reduction in physical 
well-being due to body pain, respectively. This finding from the bodily pain scores are 
supported by the mild levels of pain reported by patients on the pain NRS. The poor 
scores on role-physical suggest that patients experienced considerable role-disability 
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due largely with their physical health. Of particular note were the very low vitality and 
general health scores, relative to those seen in the U.S. population. The low scores on 
vitality could be related to the low ratings on fatigue scores among patients in this 
current study.   
In this SF-36 MCS model, after controlling for all the predictor variables, 
symptom status (pruritus/itch and fatigue), characteristics of the individual 
(race/ethnicity), and characteristics of the environment (social support) showed 
significant relationships with overall QoL. For the SF-36 PCS model, pain and fatigue 
(measures of symptom status) and race/ethnicity were predictors of overall QoL.  
 
6.3.2 Evaluation of the Study Model of Overall QoL 
The hypotheses that the study models would predict significant amounts of 
variance in overall QoL were supported by the data. In the two CLEQoL models – 
mental and physical, the combination of fatigue and body image explained 71.0 and 
73.0 percent of the variance in overall QoL, respectively.   
Both the MCS and PCS models from SF-36 accounted for significant amount of 
variances too, 54.0 and 69.0 percent, respectively. In the MCS model, the large variance 
in overall QoL was largely due to the contribution of pruritus/itch, fatigue, 
race/ethnicity, and social support. While pain, fatigue, and race/ethnicity contributed to 
the variance in overall QoL from the PCS model.  
To put these explained variances (R
2
) in perspective, a review of articles 
utilizing the Revised Wilson & Cleary model depicted a wide range of explained 
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variance in overall QoL, from a low of 10 percent to a high of 61 percent.
214,220,235,329,330
 
In this study, the explained variances, ranging from 54 – 73 percent, were slightly 
higher than the averages described in the Revised Wilson and Cleary Model. 
Nonetheless, in terms of examining overall QoL in patients with CLE, the Revised 
Wilson and Cleary Model appears to be theoretically sound and has some practical 
utility. 
 
6.3.3 Factors Associated with Overall QoL 
Of all nine predictor variables, corresponding to six constructs included in the 
four regression models, a total of six predictor variables (from four constructs) were 
significant with overall QoL. The findings from each of the constructs are described 
below. 
 
6.3.3.1 Symptom Status 
Pain, pruritus/itch, and fatigue served as the proxies for symptom status in this 
study. These three variables were significantly related to overall QoL, and related 
hypotheses were supported across the four regression models, collectively. 
 
6.3.3.1.1 Pain 
       From the SF-36 PCS model, pain was negatively associated with overall 
QoL, meaning that patients that reported high levels of pain had poor physical health 
scores. This inverse relationship between increasing pain and lower QoL in CLE 
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patients have been reported in other studies.
55,331
 In other disease conditions, such as 
fibromyalgia, back pain, and arthritis, pain has been reported to have varying 
relationships with QoL.
332-334
 Plausible explanations for these contrary findings could 
be due to the lack of specificity in the QoL measure or also because of the way ‘pain’ 
was operationalized in these studies. Rather than measuring the intensity of pain on a 
spectrum, most of these studies measured the absence or presence of pain. Thus, it is 
important to measure pain experiences across a spectrum so as to understand the effect 
of pain on QoL.  
     The physical limitations imposed upon patients by CLE can be very 
disruptive and problematic. These limitations can impair functionality, especially when 
pain is present.
55,331
 As a modifiable factor, pain can be targeted by interventions aimed 
at improving the QoL in patients with CLE, especially given its impact on physical 
health. Further, pain or inadequate pain management has been consistently cited as a 




6.3.3.1.1.1 Factors Associated with Pain   
       Disease activity and smoking status were positively associated with pain. In 
a recent study conducted by Mendez-Flores, Orozco-Topete, Bermudez-Bermejo, & 
Hernandez-Molina,
55
 pain was also found to be positively correlated with CLASI 
activity scores; thus, corroborating the findings from our current study. In conclusion, 
pain is a self-reported outcome associated with disease activity; therefore, treatment 
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targeted at improving disease activity in CLE patients could consider focusing on pain 
management as well.  
 This study also demonstrated an association between current/former smokers 
and symptoms – pain, a relationship that has not been well established in previous 
studies in CLE patients.
21,67
 However, an unpublished article conducted in DLE patients 
reported that in addition to having poorer QoL, current smokers experienced increased 
CLE symptoms, such as pain.
37
 Exposure to cigarette smoke has been reported to 
activate tissue-damaging and inflammatory factors, such as matrix metalloproteinase 
activity, leading to pain.
340,341
 This current study’s findings on the relationship between 
positive smoking status and increasing pain levels highlights the importance of 
understanding self-reported pain in CLE patients who had either smoked in the past or 
currently smoke. When pain is present and elevated, patients might turn to cigarettes as 
a means of reducing pain, which in turn could increase pain levels and reinforce 
smoking habits. Thus, health care providers could provide smoking cessation programs 
to help patients manage their symptoms better, and such interventions could incorporate 
pain management as a component of therapy. 
 
6.3.3.1.2 Pruritus/Itch 
  Pruritus was a significant predictor of overall QoL in the SF-36 MCS model. 
This relationship was negative, as increasing scores on pruritus led to a decrease in 
mental health. This is contrary to findings from a study conducted in CLE patients.
55
 
However, findings from studies in other skin diseases, such as psoriasis and 
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 Experiencing pruritus may be a sign of increased disease activity and loss of 
control over the disease and could possibly be responsible for the decline in mental 
health. Potential management of pruritus might enhance patients’ sense of control over 
CLE and its symptoms, which could invariably improve mental health. 
 
6.3.3.1.2.1 Factors Associated with Pruritus/Itch 
           Similar to pain, disease activity and smoking status were positive 
predictors of pruritus/itch. Regarding disease activity, there is limited information on its 
association with pruritus. Unlike pain, disease activity has not been reported to have an 
association with pruritus.
55
   
           Positive current and past smoking histories have been reported to increase 
systemic vascular inflammatory processes such as IL6,
340,343
 which can worsen some 
symptoms such as pruritus. As a result, patients could be counseled on the importance 
of smoking cessation to help ensure that symptoms such as pruritus are reduced. 
 
6.3.3.1.3 Fatigue 
   Of all the predictor variables used in the four regression models, fatigue was 
the only significant variable across all models. Thus, it can be asserted that fatigue is a 
strong factor that affects both the physical and mental domains of QoL, which is 
consistent with research on fatigue and QoL.
344-346
 In addition, regardless of the 
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measure of QoL, fatigue still appears to have an impact on QoL. Determining how these 
patients are affected by fatigue and assessing their current experience with fatigue could 
lend understanding to the relevant domains (both physical and mental) underpinning 
QoL. Fatigue appears to be a distinct symptom which plays a large role in determining 
both the mental and physical handicaps that CLE patients experience. Fatigue could 
begin with a decline in physical activity, but can escalate to a wider range of negative 
effects that can leave patients feeling out of control and isolated, thereby impacting 
mental health.
347
 This vicious cycle can leave patient helpless and in a distressing 
position.
347
 As such, interventions that reverse the effect or onset of fatigue could have a 
positive effect of QoL. Therefore, clinical trials should consider incorporating fatigue 
measures as an assessment of QoL.  
 
6.3.3.2 Functioning 
 Body image, a measure of functioning, was operationalized using the Body 
Image Scale (BIS). Body image was positively and significantly associated with overall 
QoL in both the CLEQoL models (mental and physical). 
 
6.3.3.2.1 Body Image 
 The mean BIS score obtained in the current study was 8.78 (SD: 8.92; range: 
0-30); which is within the range reported in other studies of diverse diagnoses (range of 
4.27-14.22).
289,348-351
 Currently, there is no clinical cutoff for body image 
dissatisfaction, however, Hopwood et al.
352
 suggested that values > 10 on the BIS can 
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be used as a threshold indicating body image dissatisfaction. Thus, our findings show 
that the participants in this current study experienced a lesser degree of body image 
dissatisfaction. 
  Body image was a positive significant predictor of both mental and physical 
health on the CLE-specific QoL measure. This means that patients with higher degrees 
of dissatisfaction with their body experienced poorer mental and physical health. These 
findings of the impact of body image on the two domains of QoL have been confirmed 
in other studies.
350,353
 The significant contribution of body image towards both mental 
and physical QoL could be because a majority of participants in this current study were 
female; this is consistent with previous study findings.
350
 Further, findings from a 
growing literature demonstrates that women experience more body dissatisfaction than 
men,
354




  Body image issues experienced by CLE patients may be also due to the 
cosmetic changes from irreversible skin damage. Currently, none of the QoL measures 
used in CLE patients examine body image. Our study findings underscore the 
importance of incorporating body image into QoL assessments. Visible changes such as 
dyspigmentation, hair loss, or scarring, can directly affect body image by altering a 
person’s physical appearance, which could also cause self-esteem issues.
348
 Perhaps, 
these cosmetic changes experienced by CLE patients in addition to affecting mental 
health can also reduce physical functioning, leading to declines in physical health. 
Further, studies have shown that patients with skin diseases experience distress not only 
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from the disease but also from how others perceive them as a result of their 
appearance.
31,32
 Thus, dermatologic patients often have higher rates of mental health 
issues, like anxiety and depression than the general population.
33-35,356-360
 Therefore, 
QoL instruments in CLE studies should also incorporate other attributes such as body 
image to capture the disease effect and treatment impact on patients. The overarching 
goal of including body image measures should be to promote body acceptance, which 
may in turn positively impact QoL. 
 
6.3.3.2.1.1 Primary Drivers of Body Image 
 The overall mean of body image was slightly lower than the cutoff 
recommended as the threshold for body image dissatisafaction.
352
 Nonetheless, our 
findings suggest that patients with CLE experience some degree of body image 
dissatisfaction. The highest means achieved were on items referent to scarring (item j), 
physical attractiveness (item b), and self-consciousness (item c). For each of these 
items, more than 50 percent of the participants indicated being bothered by the cosmetic 
effects of CLE by some degree. These findings are supported by extant literature 
conducted in patients with skin diseases who are often bothered by their appearance.
31,32
 
Scarring had the highest mean, which is contrary to findings in other studies using the 
BIS scale where most of these studies either omit this item or report low scores on it.
348-
350,353
 A plausible explanation for this could be that most of these studies were 
conducted in patients with cancer, and as such scarring may have not been a very 
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relevant issue. However, in CLE patients, scarring has been documented in visible sites 
such as the face, and has been reported to be associated with impairment in QoL.
361,362
 
       Since CLE can cause skin damage ranging from dyspigmentation and 
scarring to hair loss which leads to major changes in the physical appearance of 
patients, body image is therefore an important component of quality of life.
289
 These 




6.3.3.2.1.2 Factors Associated with Body Image 
  Pain, fatigue, and race/ethnicity were significant and positive predictors of 
body image, while social support was negatively related to body image. While no such 
findings have been reported in CLE patients, body image has been shown to be affected 
in other patients experiencing chronic pain.
365-367
 This association reported in the 
current study is therefore not surprising as some of the manifestations of CLE can cause 
painful lesions,
55
 which often cause scarring and could lead to body image issues. These 
findings directly support the growing evidence that body image can be distorted in 
people with pain.
365,366
 The clinical implication of this finding is that given the 
relationship between body image and pain, the successful treatment of pain could 
improve body image in CLE patients. 
    Data from the current study also suggests that fatigue is related to body 
image dissatisfaction. Patients with higher levels of fatigue experienced more body 
image dissatisfaction. These findings may indicate that body image is a component of 
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patient well-being that depends on vitality and physical functioning.
368
 It is also 
plausible that body image dissatisfaction may signal increase in disease severity.  
 Regarding race/ethnicity, there were racial differences in body image 
dissatisfaction between African-American/Black vs other groups, with non-African-
American/Black group reporting a higher degree of body image dissatisfaction. This 
finding is in congruence with a considerable body of research that reports that African-
American/Blacks are more satisfied with their body appearance than people from other 
racial/ethnic groups.
369-372
 There are no clear theories within the literature to explain 
these between-group racial differences in perception of body image.
373,374
 Nonetheless, 
it is imperative that the needs of non-African-American/Black CLE patients be met, to 
decrease disparities in body image satisfaction currently experienced by their African-
American/Black counterparts. Specifically, these patients could be equipped with 
adequate social skills, as part of psychosocial interventions, which may be helpful when 
addressing comments or looks from others.
328
 
  Finally, social support was a negative and significant predictor of body 
image. Patients who received more support from their friends/family experienced lower 
levels of body image dissatisfaction. Studies have not generally investigated the 
relationships between body image and social support. It is logical to assume that 
patients with support from loved ones, perhaps in the form of encouragement and 
positive feedback, may help patients develop and maintain a positive body image. 
Future research is needed to more fully elucidate these relationships and their potential 
impact on overall QoL 
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6.3.3.3 Characteristics of the Individual 
 The two SF-36 models showed that race/ethnicity was the only significant 
predictor associated with overall QoL. 
 
 
6.3.3.3.1 Description of Demographic Variables 
 Participants in this current study were predominantly female and middle-
aged, which are consistent with the literature which shows that CLE affects females 
more disproportionately than males.
21,49,73
 Most of the patients in our study had chronic 
CLE, with DLE being the most common type; this could be because majority of our 







 Race/ethnicity had a significant, bi-directional relationship with overall 
QoL; while it was negative in the SF-36 MCS model, it was positive in the SF-36 PCS 
model. Regarding the MCS model, compared to African-American/Black patients with 
CLE, non-African-American/Black patients experienced lower mental health. 
Conversely, compared to African-American/black patients with CLE, non-African-
American/Black patients had better physical health. This dynamic observed warrants 
further study as they are still unexplored in the literature. A better understanding of 
these specific demographic factors that affect mental and physical health can be areas of 
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opportunity for developing culturally-appropriate interventions that can improve the 
overall QoL of diverse CLE patients. 
 
6.3.3.4 Characteristics of the Environment 
 Study results indicated that social support was a significant and positive 
predictor of mental health. 
 
6.3.3.4.1 Social Support  
 Patients who received support from their family/friends had higher mental 
health scores than patients who did not. These findings show that social bonds and 
supportive relationships with friends and loved ones are essential to fostering better 
mental health. Bonds such as these can also be a protective factor from the effects of 
stress.
376
 Indeed, there is compelling evidence from the literature that receiving social 
support is significantly associated with mental well-being.
377
 Encouraging family 
members and friends to become more involved in the form of providing much-needed 
support may help to improve the QoL of patients. The concept of social support in 
chronic illness is not new and has been used in other settings.
378-380
 Such support 
systems may be useful in reducing the feelings of isolation, anxiety, depression and 






6.4 IMPLICATIONS FOR HEALTHCARE RESEARCH 
Based on the results obtained from this current study, the SF-36 and the 
CLEQoL were concluded to be adequate measures of overall QoL in patients with CLE. 
However, the disease-specific measure, CLEQoL, was the better instrument as it had a 
higher predictive ability than the generic QoL measure, SF-36. The CLEQoL models 
exhibiting higher predictive ability than the SF-36 models could also mean that the 
former has better responsiveness and thus, recorded both clinical and subjective changes 
in CLE patients. To this end, clinicians and healthcare researchers might consider using 
disease-specific measures in QoL assessments in CLE patients. Physicians could also 
use the CLEQoL measure for routine monitoring of their patients’ well-being; this can 
be attained by administering the survey at baseline and follow-ups. 
Understanding the experiences of CLE patients, through the exploration of QoL 
constructs within a theoretical framework, provides healthcare providers with an 
understanding of the disease’s impact on patients. In turn, healthcare providers can aid 
patients in their journey in the diagnosis to recovery continuum through empirically-
guided expertise.  
Focusing on only objective indicators (such as disease activity and damage, as 
typically measured within the CLASI), as it is mostly done in CLE QoL assessments, 
will not provide a complete and accurate estimate of QoL in CLE patients. Hence, 
physicians/clinicians caring for CLE patients should consider including subjective 
measures (such as body image) during their QoL assessments. Further, the CLEQoL 
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measure demonstrated adequate reliability in this current population and with continued 
use of this scale in future studies, construct validity can be ascertained.  
Finally, this study has empirically tested associations that influenced QoL in 
CLE patients and lends support for further investigation of this patient outcome model. 
Focusing on QoL allows health outcomes researchers and clinicians to target concerns 
and issues that are relevant to the patient, especially as healthcare becomes more 
patient-centered. The model used in this study has provided a springboard for 
interventions that can be focused on health promotion, symptom management, and the 
alleviation of disease effects. 
 
 
6.5 SUGGESTIONS FOR FUTURE RESEARCH 
Due to the limitation of sample size in this current study, it is possible that some 
findings could have been significant in studies with larger and more diverse samples. 
Hence, future research could replicate this study in a larger and more heterogeneous 
sample of CLE patients to further assess QoL in CLE patients, specifically to better 
compare CLE subtypes. Perhaps, such replications will allow for exploration of other 
possible pathways within the Revised Wilson and Cleary Model and to fully test 
potential indirect relationships among the variables in the Revised Wilson and Cleary 
Model. 
 In chronic and disabling diseases, such as CLE, utilizing self-managing 





 In this study, coping strategies adopted by CLE patients were not 
assessed. In order to elucidate the effect on QoL, future studies should consider 
including coping strategies as a potential correlate or mediating factor in QoL studies in 
CLE patients. 
 Due to sample size considerations, the present study included nine out of the 
initial 21 variables in the final regression model to represent antecedents of QoL in CLE 
patients. Future studies could explore the full model and assess its contribution in 
explaining overall QoL. Disease activity was initially correlated with QoL, which was 
consistent with past studies in CLE patients
21,26,37,55,160
 but this relationship ceased being 
significant in the final regression model. Further studies examining the plausible 
explanation of this finding may provide additional understanding.  
 None of the variables from the general health perceptions selected for this study 
were significant. Perhaps, additional factors relevant to CLE representing this construct 
need to be identified to yield greater insight into general health perceptions affecting 
QoL.  
 While the CLEQoL exhibited a higher predictive ability than the SF-36 in the 
current study, findings provided a cross-sectional view of examined relationships. Also, 
given that measures such as disease activity in CLE patients have been reported to 
fluctuate over time,
313
 longitudinal studies are needed to examine the responsiveness of 
the CLEQoL to changes in skin disease activity in patients with CLE. 
 Finally, future studies could use a more robust methodology such as Structural 
Equation Modeling (SEM)
384
 to simultaneously test all of the casual relationships (total, 
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direct, and indirect) among the factors that comprise overall QoL. In addition to testing 
the validity of the model, SEM can be used to test the measurement model to determine 
how well the data collected fits the theoretical model. Given that CLE severity increases 
from its acute to its chronic form,
50
 SEM could allow for testing with different CLE 
populations to determine if the model performs equally among the various CLE 
subgroups. SEM can also be used to build parsimonious models to identify weak 
relationships for deletion.  
 
6.6 STUDY LIMITATIONS 
Limitations are inevitable in studies designed to address research questions, and 
these limitations could have an impact on the overall study findings. This current study 
is not without its limitations and the hope is that by highlighting them, future 
researchers can use these to modify their studies accordingly.  
A primary limitation of this study pertains to the generalizability of the findings. 
This study involved a convenience sample of patients with CLE, obtained from two 
outpatient clinics – University of Texas (UT) Southwestern Medical Center and 
Parkland Health and Hospital System – to increase the patient pool. It is, therefore, 
possible that our study population may not be representative of the CLE population as a 
whole. Second, it is also likely that participation in the survey may have been 
influenced by the nature of the relationship between a patient and their 
physicians/providers. Finally, some patients with CLE may have had other chronic 
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conditions (such as SLE) that may mimic some CLE symptoms and thus may have 
influenced their responses to survey items. 
The relatively small sample size also posed an additional challenge. Limited 
sample size could have led to reduced statistical power to detect additional relationships 
among variables. The current study was based on a cross-sectional design, at a single 
point in the disease process. As a result, conclusions regarding changes in quality of life 
over time cannot be made. Therefore, longitudinal studies are needed for the 
examination of patients’ overall QoL beginning from the stage of diagnosis through the 
CLE continuum of care. In addition, longitudinal analyses can be combined with latent 
curve and autoregressive models
385
 to support the causal relationships implied in the 
Revised Wilson and Cleary Model.  
Since this was a study of the QoL in CLE patients at one period in time, 
responses provided by patients on the survey questions may have been reflective of 
their view at that particular time point. For example, patients with higher disease 
activity as at the time of the data collection could have provided responded based on 
their current experiences with CLE. 
The study incorporates medical history variables and health status indicators 
which were obtained from medical chart reviews and registries. Hence, the errors in 
coding these secondary sources of information may have affected this current study. 
Some variables, for example fatigue, had longer recall periods than others. Thus, it is 





 Finally, social desirability is also a possible limitation, as patients may 
have provided biased responses on the QoL survey.  
Despite these limitations, this project has some strength. One strength of the 
current study included the addition of some variables (such as body image) that have 
not been formally investigated before in patients with CLE. Another study strength is 
that it serves as a useful pilot study that explored the relationship between the constructs 
within the Revised Wilson and Cleary Model and investigated its utility in examining 
overall QoL in CLE patients. Results obtained from this study will be beneficial in 
designing future studies in this area. 
 
6.7 CONCLUSIONS 
This current study supports the utility of the Revised Wilson and Cleary Model 
in better understanding QoL in CLE patients. Several modifiable (e.g., pain, pruritus, 
fatigue, body image, and social support) and non-modifiable (e.g., race/ethnicity) 
factors were predictive of overall QoL in CLE patients and could be used to help health 
care providers interpret and assess QoL outcomes in CLE patients. Beginning with 
these modifiable factors, specific interventions can be customized to be responsive to 
CLE patients in improving the quality of their lives. 
Of all the factors that predicted quality of life, variables associated with 
symptom status (pain, pruritus/itch, and fatigue) were the most important, contributing 
far more than other predictors especially the objective clinical indicators. Examining 
these measures in CLE patients could significantly aid patients in improving their QoL. 
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Furthermore, the findings of the study indicate that certain patients may be more 
affected, especially regarding their physical QoL (African-Americans/Blacks) and their 
mental QoL (non-African-Americans/Blacks). Therefore, attention is warranted in these 
areas for the development of culturally-relevant interventions. 
Finally, this study integrated patient-centered and clinical measures which 
facilitated a fuller theoretically-based understanding of QoL issues in CLE patients. The 
Revised Wilson and Cleary Model has been widely used in other disease states but not 
in CLE patients. This study presents a first step in testing the utility and validity of this 













Appendix A – Focus Group Recruitment 
Dear ________________________________ (Participant Name),  
Researchers at The University of Texas at Austin and The University of Texas Southwestern 
Medical Center are conducting a study to understand how cutaneous lupus erythematosus (CLE) 
affects the quality of life in patients. We are inviting you to participate because you had previously 
agreed to be contacted for future research in other study.  
What is involved in this study? We are inviting patients who have a diagnosis of CLE based on 
diagnosis; are aged 18 years and above; and able to understand written and spoken English. You will 
be asked to participate in a 1 to 1.5 hour-long focus group session with 6 – 10 other patients with 
CLE. You will be asked open-ended questions to find out how CLE affects your overall QoL. You 
will receive monetary compensation for your participation. 
How do I participate in this study? If you are interested in participating in this research project, 
please provide the following information to Motolani Ogunsanya at tmadedipe@utexas.edu or call 
512-775-8720. To submit responses via email, please see below:   
Name: _________________________________________ 
Best Contact Phone Number: _______________________________ 
What is the best time to participate in a focus group (Please place an X by your responses)? 
Time of week 
Weekend ______ 
Weekday ______ 
Both weekend and weekday______ 
 
Time of day 
Evening______ 
Day______ 
Both, evening and day______ 
 
Thank you and we look forward to hearing from you soon! 
Sincerely, 
 Benjamin Chong, MD 
Assistant Professor 
Department of Dermatology 
University of Texas 
Southwestern Medical Center 
 
Motolani Ogunsanya, B.Pharm, MS 
Doctoral Candidate 
College of Pharmacy 
Health Outcomes and Pharmacy Practice 
Division 




Appendix B – Brief Pre-Focus Group Survey 
 
Quality of Life in Patients with Cutaneous Lupus Erythematosus (CLE) 
Thank you for agreeing to be a part of this focus group study!  Please read and answer the 
questions below carefully. Your answers are very important to us. 
 
1. What is your gender? 
 Male    Female 
 
2. In what year were you born? 19 ____ 
3. What was your age at diagnosis: ______ 
 
4. Which of the following best describes your racial background? 
 
Caucasian       
  Northern European (Swedish, Irish, German, Ukrainian)  
  Southern European (Italian, Portuguese, Greek)  
  Other European   
  Unknown Ancestry   
 
Asian 
 Far East   
 Southeast Asia 
 Indian subcontinent 
 Uncertain ancestry 
 
Other 
 African American  
 American Indian/Alaska Native 
  Middle Eastern 
 Mixed Race 
  Native Hawaiian/Pacific Islander  




5. Which of the following best describes your ethnic background? 
 Cuban        
 Mexican American        
 Puerto Rican             
 Not Hispanic/Latino  
 Other______________ 
   
6. Which of the following best describes the geographic residence where you grew up? 




7. Which of the following best describes your marital status? 
 Single, in a relationship                 
 Single, not in a relationship  
 Married        




8. What is your highest level of education (current classification)? 
 Less than High School                    
 High School Graduate or GED                       
 Freshman (College) 
 Sophomore (College) 
 Junior (College) 
 Senior (College)        
 Graduate Student                            
 Postgraduate (e.g., MD, PhD)   
 Other (Please Specify) ____________________ 
 
9. How would you rate your overall health? 
 Poor         
 Fair    
 Good        
 Excellent 
 
10. What type of health insurance do you have? (Check all that apply) 
 Private insurance (e.g. BlueCross/Blue Shield, Humana)  
 CHIP (Children’s Health Insurance Plan)  
 Medicare          
 Medicaid                                                               
 No insurance/Self-pay      
 Not sure 
 Other (Please Specify) ____________________ 
 
 
11. Have you ever smoked cigarettes on a regular basis?  
 Yes          
 No 
 
a. Do you smoke now?   
 Yes       
 No 
 
b. If you currently smoke, how many packs per day? __________ 
 
 
THANK YOU FOR YOUR PARTICIPATION 




Appendix C – Focus Group Moderator Guide 
 
Introduction  
Hi, my name is [Name] and I’ll be your moderator today. Welcome to our focus group 
discussion.  
The purpose of this focus group session is to talk with you about your how cutaneous lupus 
erythematosus (CLE) affects your overall quality of life. The information obtained from this 
focus group will be used to develop a survey that will be administered to a larger group of 
patients with CLE. 
This session will be audio recorded. However, no names will be used for any portion of the 
larger study.  Fake names will be used instead of your real names once I begin recording. Here 
are the name cards to place in front of you; these will be used to identify each of you from this 
point forward. Information obtained from this focus group session will not be associated with 
any specific focus group participant. The purpose of the audio recording during the focus group 
session ensures that all the important information is captured and is available for inclusion in 
the final questionnaire. The audio tapes will be stored in a locked file cabinet and will be used 
only by research personnel. This session is expected to last between 1 – 1.5 hours and you have 
the right to stop participating at any time. 
Confidentiality is important and in any publications or presentations, I will make sure that you 
will not be identified in any way, by department, etc. Also, whatever is said in this room will 
not be shared with anyone other than the researchers for whom this conversation is being 
recorded. Remember that we will also assign you pseudonyms, so that your responses can 
remain anonymous. That’s very important, so that everyone may speak freely.  
Here’s a copy of the information sheet that you may read.  
To also get to understand your responses better, we will be collecting some information about 
you. Kindly take a few minutes to fill out this survey [hands demographic survey questions 
to participants] and put it back into the folder in the middle of the table. 
Group Rules 
As the session moderator, I will ask the questions and keep everyone on track. I will keep track 
of time, and therefore, I may need to interrupt the discussion to move forward in the interest of 
time. It is important that everyone feels comfortable and at ease during the discussion. There is 
no right or wrong answer to any of the questions. You are encouraged to speak freely about the 
issues discussed as everyone’s input is valuable to the discussion.   
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The moderator will give participants a few minutes to write down answers to each 
question below and then discuss them as a group.  Participants will be a given a sheet of 




1. Briefly tell me/write down all the ways that CLE affects you. 
Probe: Kindly tell me how CLE affects your work life, daily activities, social 
life, personal relationships, leisure activities, or any other ways possible. Also 
tell me the impact of CLE on photosensitivity, alopecia, and your mental 
health. 
 
2. Which other areas can you think of that has been affected by CLE? 
 
3. Now, please take a moment to review the questionnaires in front of you. 
Beginning with the first questionnaire labeled Skindex 29+3, what do you 
think about the items on this questionnaire as they pertain to CLE?  
Probe: Are they relevant to CLE? What other items can be added to it to make 
it more relevant to CLE? 
 
4. Finally, please take a moment to review the other questionnaires in front of 
you. It is labeled as VitiQoL. What do you think about the items on this 
questionnaire as they pertain to CLE? 
Probe: Are they relevant to CLE? What other items can be added to it to make 
it more relevant to CLE? 
 
 
Conclusion - We have covered the desired topics today.  Do you have anything that you want 
to add with respect to what we talked about? Any final observations or comments? If not, then I 
would like to thank you for your time and participation. Please wait a few moments to receive 










Appendix D – Skindex-29+3 Questionnaire 
 
Instructions: These questions concern your feelings over the past 4 weeks about the 
skin condition that has bothered you the most. Please check the answer that comes 
closest to the way you have been feeling. 
 NEVER        RARELY    SOMETIMES     OFTEN              ALL THE   
                                                                        TIME                                  
1. My skin hurts        1              2              3             4              5 
2. My skin condition affects how well I sleep        1              2              3             4              5 
3. I worry that my skin condition may be serious        1              2              3             4              5 
4. My skin condition makes it hard to work or do 
hobbies     
   1              2              3             4              5 
5. My skin condition affects my social life       1              2              3             4              5 
6. My skin condition makes me feel depressed        1              2              3             4              5 
7. My skin condition burns or stings        1              2              3             4              5 
8. I tend to stay at home because of my skin condition      1              2              3             4              5 
9. I worry about getting scars from my skin condition      1              2              3             4              5 
10. My skin itches        1              2              3             4              5 
11. My skin condition affects how close I can be with 
those I love  
   1              2              3             4              5 
12. I am ashamed of my skin condition        1              2              3             4              5 
13. I worry that my skin condition may get worse        1              2              3             4              5 
14. I tend to do things by myself because of my skin 
condition    
   1              2              3             4              5 
15. I am angry about my skin condition        1              2              3             4              5 
16. Water bothers my skin condition (bathing, 
washing hands)     
   1              2              3             4              5 
17. My skin condition makes showing affection 
difficult    
   1              2              3             4              5 
18. I worry about side-effects from skin 
medications/treatments*  
   1              2              3             4              5 
19. My skin is irritated        1              2              3             4              5 
20. My skin condition affects my interactions with 
others     
   1              2              3             4              5 
21. I am embarrassed by my skin condition        1              2              3             4              5 
22. My skin condition is a problem for the people I 
love     
   1              2              3             4              5 
23. I am frustrated by my skin condition        1              2              3             4              5 
24. My skin is sensitive        1              2              3             4              5 
25. My skin condition affects my desire to be with 
people     
   1              2              3             4              5 
26. I am humiliated by my skin condition        1              2              3             4              5 
27. My skin condition bleeds        1              2              3             4              5 
28. I am annoyed by my skin condition        1              2              3             4              5 
29. My skin condition interferes with my sex life        1              2              3             4              5 
30. My skin condition makes me tired        1              2              3             4              5 
31. I worry about going outside because the sun might 
flare my disease 
   1              2              3             4              5 
32. I am worried about my hair loss    1              2              3             4              5 
33. My skin disease prevents me from doing outdoor 
activities. 
   1              2              3             4              5 
*Item will not be scored 
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Appendix E – VitiQoL Questionnaire 
 
Instructions: The purpose of these questions is to assess whether the aspect of your skin 
affected your life during the last month, from 0 (not at all/ not applicable) to 5 (all the time): 
                                                                                                     NOT AT ALL                                                                         ALL THE TIME         
1. Have you been bothered by the 
appearance of your skin 
condition? 
       0 1          2              3             4            5 
2. Have you felt frustrated about 
your skin condition? 
       0 1          2              3             4            5 
3. Have your skin conditions made 
it hard to show affection? 
       0 1          2              3             4            5 
4. Has your skin condition affected 
your daily activities? 
       0 1          2              3             4            5 
5. When you were talking to 
someone, have you worried 
about what they may be 
thinking of you? 
       0 1          2              3             4            5 
6. Have you been afraid that 
people will find fault with you?  
       0 1          2              3             4            5 
7. Have you felt embarrassed or 
self-conscious because your 
skin? 
       0 1          2              3             4            5 
8. Has your skin condition 
influenced the clothes you 
wear? 
       0 1          2              3             4            5 
9. Has your skin condition affected 
your social or leisure activities? 
       0 1          2              3             4            5 
10. Has your skin condition affected 
your emotional well-being? 
       0 1          2              3             4            5 
11. Has your skin condition affected 
your overall physical health? 
       0 1          2              3             4            5 
12. Has your skin condition affected 
your grooming practices (i.e., 
haircut, use of cosmetics)? 
       0 1          2              3             4            5 
13. Has your skin condition affected 
your sun protection efforts 
during recreation (i.e., limiting 
exposure time during sun peak 
hours, seeking shade, wearing a 
hat, long sleeves or pants)? 
       0 1          2              3             4            5 
14. Has your skin condition affected 
your chances of making new 
friends?  
       0 1          2              3             4            5 
15. Have you worried about 
progression or spread of 
diseases to new areas of the 
body? 




Instructions: These questions concern your feelings over the past 4 weeks about the skin condition that has 
bothered you the most. Please check the answer that comes closest to the way you have been feeling.   
 
Appendix F – CLEQoL Questionnaire 
  
 
          NEVER        RARELY    SOMETIMES       OFTEN      ALL THE 
                                                                                                         TIME 
1. My skin hurts     1              2              3             4              5 
2. My skin condition affects how well I sleep     1              2              3             4              5 
3. I worry that my skin condition may be serious     1              2              3             4              5 
4. My skin condition makes it hard to work or do 
hobbies     
1              2              3             4              5 
5. My skin condition affects my social life    1              2              3             4              5 
6. My skin condition makes me feel depressed     1              2              3             4              5 
7. My skin condition burns or stings     1              2              3             4              5 
8. I tend to stay at home because of my skin condition    1              2              3             4              5 
9. I worry about getting scars from my skin condition     1              2              3             4              5 
10. My skin itches     1              2              3             4              5 
11. My skin condition affects how close I can be with 
those I love  
1              2              3             4              5 
12. I am ashamed of my skin condition     1              2              3             4              5 
13. I worry that my skin condition may get worse     1              2              3             4              5 
14. I tend to do things by myself because of my skin 
condition    
1              2              3             4              5 
15. I am angry about my skin condition     1              2              3             4              5 
16. Water bothers my skin condition (bathing, washing 
hands)     
1              2              3             4              5 
17. My skin condition makes showing affection difficult    1              2              3             4              5 
18. I worry about side-effects from skin 
medications/treatments*  
1              2              3             4              5 
19. My skin is irritated     1              2              3             4              5 
20. My skin condition affects my interactions with others     1              2              3             4              5 
21. I am embarrassed by my skin condition     1              2              3             4              5 
22. My skin condition is a problem for the people I love     1              2              3             4              5 
23. I am frustrated by my skin condition     1              2              3             4              5 
24. My skin is sensitive     1              2              3             4              5 
25. My skin condition affects my desire to be with people     1              2              3             4              5 
26. I am humiliated by my skin condition     1              2              3             4              5 
27. My skin condition bleeds     1              2              3             4              5 
28. I am annoyed by my skin condition     1              2              3             4              5 
29. My skin condition interferes with my sex life     1              2              3             4              5 
30. My skin condition makes me tired     1              2              3             4              5 
31. I worry about going outside because the sun might 
flare my disease 
1              2              3             4              5 
32. I am worried about my hair loss.     1              2              3             4              5 
33. My skin condition prevents me from doing outdoor 
activities. 
1              2              3             4              5 
34. When talking to someone, I sometimes worry about 
they may be thinking of me. 
1              2              3             4              5 
35. My skin condition has influenced the clothes I wear. 1              2              3             4              5 
36. My skin condition has affected my grooming 
practices (i.e., haircut, use of cosmetics). 
1              2              3             4              5 
37. My skin condition has affected my sun protection 
efforts during recreation (i.e., limiting exposure time 
during sun peak hours, seeking shade, wearing a hat, 
long sleeves or pants). 
1              2              3             4              5 
*Item will not be scored 
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Appendix G – SF-36 Questionnaire 
 
Instructions: This survey asks for your views about your health. This information will help keep track of 
how well you are able to do your usual activities.  
 
Please check the box that corresponds to your choice using the scales listed below.  
1.  In general, how would you say your health is: 
Excellent Very Good Good Fair Poor 
     
 
 
2. Compared to one year ago, how would you rate your health in general now? 
Much better now 
than one year ago 
Somewhat 
better now than 
one year ago 
About the same Somewhat worse 
now than one 
year ago 
Much worse 
now than one 
year ago 
       
 
 
The following questions are about activities you might do during a typical day. Does your health now 










3. Vigorous activities, such as running, lifting heavy 





4. Moderate activities, such as moving a table, 






5. Lifting or carrying groceries    
6. Climbing several flights of stairs    
7. Climbing one flight of stairs    
8. Bending, kneeling, or stooping    
9. Walking more than a mile    
10. Walking several blocks    
11. Walking one block    










During the past 4 weeks, have you had any of the following problems 




13. Cut down the amount of time you spent on work or other 
activities 
  
14. Accomplished less than you would like   
15. Were limited in the kind of work or other activities   
16. Had difficulty performing the work or other activities (for 







During the past 4 weeks, have you had any of the following problems 
with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)? 
Yes No 
 
17. Cut down the amount of time you spent on work or other 
activities 
  
18. Accomplished less than you would like   





20. During the past 4 
weeks, to what extent 
has your physical 
health or emotional 
problems interfered 
with your normal 
social activities with 
family, friends, 
neighbors, or groups? 





















21. How much bodily 
pain have you had 

















22. During the past 4 
weeks, how much 
pain interferes with 
your normal work 
(including both work 
outside the home and 
housework)? 





















These questions are about how you feel and how things have been with you during the past 4 weeks. 
For each question, please give the one answer that comes closest to the way you have been feeling.  
How much of the time during 
the past 4 weeks… 






A good    










23. Did you feel full of pep?       
24. Have you been a very 
nervous person? 
      
25. Have you felt so down in 
the dumps that nothing 
could cheer you up? 
      
26. Have you felt calm & 
peaceful? 
      
27. Did you have a lot of 
energy? 
      
28. Have you felt down-
hearted and blue? 
      
29. Did you feel worn out?       
30. Have you been a happy 
person? 
      











32.  During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives, etc.)? 
All of the time    Most of the time  Some of the time  A little of the time                  None of the 
time 
     
 











33. I seem to get sick a little easier 
than other people 
     
34. I am as healthy as anybody I 
know 
     
35. I expect my health to get 
worse 
     
36. My health is excellent      
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Appendix H – Consent to Participate in Research  
(Cutaneous Lupus Erythematosus) 
Title of Research: Molecular Studies of Cutaneous Lupus 
 
Funding Agency/Sponsor: University of Texas Southwestern Medical Center, 
National Institutes of Health, Biogen Incorporated 
 
Study Doctors: Benjamin F. Chong, MD 
 
In case of questions, you may call these study doctors or research personnel during 




Please read this consent form carefully and take your time making a decision about 
whether to participate.  As the researchers discuss this consent form with you, please 
ask him/her to explain any words or information that you do not clearly understand.  
The purpose of the study, risks, inconveniences, discomforts, and other important 
information about the study are listed below.  If you decide to participate, you will be 
given a copy of this form to keep. 
 
Why is this study being done? 
This study is being done to help determine the cause of skin lesions in lupus. We 
believe that lupus has many different causes, including genetic, immunological, and 
environmental factors. We are trying to understand how all of these factors could cause 
or worsen disease. The information gathered from this study may lead to better 
diagnostic techniques and new medications that can treat your condition more 
effectively and safely. 
 
Why am I being asked to take part in this research study? 
You are being asked to take part in this study because you have signs and symptoms 
suggestive of lupus in the skin.  
 
What is involved in the study? 
If you agree to be in this study, you will be asked to sign this consent form and will 




 Questions: A study doctor or research personnel will ask you questions about 
your skin disease, health, the health of your family members, medications you 
take for any health problems, and quality of life. 
 Samples of Blood: At each visit, up to two to three tablespoons of blood will be 
drawn from a vein in your arm with a small sterile needle. This is the standard 
method used to obtain blood for routine hospital tests.  We will be using this 
blood for research purposes including DNA analysis. We may ask for a second 
blood sample if the research laboratory cannot process the first sample. During 
this five-year study, up to thirty-three tablespoons of blood will be drawn. 
 Skin biopsy:  A study doctor will perform one or two punch biopsies in the 
affected and/or unaffected lupus skin. The areas to be biopsied will be injected 
with a local anesthetic, and then a piece of skin about the size of a pencil’s 
eraser head will be removed. The area will be closed with sutures, and a bandage 
will be placed over the wound.   
 Medical Record:  You are also being asked for permission to obtain from your 
medical records information about your age, gender, race, age of diagnosis, 
disease location, personal and family history of autoimmune diseases, and past 
treatments that will make your tissue samples even more useful to the 
researchers.  
 Photography: The photographs taken will not identify you, as your face will 
not be photographed. If your face is photographed, your eyes will be blacked out 
to protect your identity. The photographs will be used to determine if there has 
been improvement in your cutaneous lupus.  If you do not wish to have the 
photographs taken, you can still participate in this research study.  By initialing 
below you agree to have photographs taken of your lesion, and for these 
photographs to be used in future scientific publication.  These photographs will 
not be used for promotional purposes. 
 
I wish to be photographed as a part of this study.              __________    _________ 
                                                                                                  Initial                Date 
I do NOT wish to be photographed as a part of this study.  _________    _________ 
                                                                                                   Initial               Date 
 
By agreeing to participate in this research, you agree to be included in this research 
database. Investigators may use your health information for future research on various 
autoimmune diseases including genetic research. However, your personally identifiable 
information will never be released to researchers, so they will not know who you are or 




How long can I expect to be in this study? 
You will have one main visit for this study. After this time, we will invite you to return 
up to ten more times on a semi-annual basis to evaluate any changes in your skin lupus. 
If the skin lupus is noted to have changed, or a new type is seen, the investigator will 
perform additional biopsies of the new sites. 
   
While your direct participation in this study will be over once you have completed the 
procedures/visits described above, the DNA isolated from your blood/tissue sample 
may continue to be studied for many years. In many genetic studies, testing of the DNA 
may go on for very long periods of time. This is true because we are continually finding 
new genes that may be involved in lupus in the skin.  
 
 
What are the risks of the study? 
Questions 
We will ask you questions about your health.  However, you can skip any question that 
makes you uncomfortable.  
 
Skin Biopsy 
Possible risks of the skin biopsy include pain with anesthesia injection, bleeding, and 
scarring. Uncommon risks include infection and skin rashes from bandage and/or anti-
bacterial ointment application. 
 
Risks of Blood Drawing  
Possible risks associated with drawing blood from your arm include minimal discomfort 
and/or bruising. Infection, excess bleeding, clotting, and/or fainting also are possible, 
although unlikely. You will have about two to three tablespoons of blood collected for 
this research study. 
 
Unforeseen Risks and New Information 
There may possibly be risks to your participation in this research, which the researchers 
do not know about now.  You will be told if any new information becomes available 
during the study that could cause you to change your mind about continuing to 
participate or that is important to your health or safety. 
 
Loss of Confidentiality 
In general, when information is collected, there is a potential risk for loss of 
confidentiality.  However, every effort will be made to keep your information 
confidential.  
 
What to do if I have problems?  
If you have unusual symptoms, pain, or any other problems while you are in the study, 
you should report them to the research staff right away.  Telephone numbers where they 
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can be reached are listed on the first page of this consent form. 
 
What are the possible benefits of this study? 
There is no direct benefit for you to participate in this study. However, we hope the 
information learned from this study will benefit others with skin lupus in the future. 
Information gained from this research could lead to better treatment options for skin 
lupus.  
 
Will I be contacted in the future? 
You have the option to elect to be contacted in the future in order to obtain follow-up 
information or to ask you to take part in more research.  
 
 Yes __________initials  No __________initials 
 
If you elect “yes”, please call Benjamin Chong, MD at 214-648-3427 and maintain a 
current address and telephone number on file. Please notify Benjamin Chong, MD if 
your legal name changes.  
 
 
What other options do I have? 
You may choose to not participate in this study.  If you decide not to take part in this 
research study, it will have no effect on your medical care. 
 
Will I be paid if I take part in this research study? 
Yes. A 10-dollar gift card will be awarded for your participation in this study. 
 
Depending on the number of skin samples obtained for the study, you will be paid 
$25.00 or $50.00 in return for your participation in the study. There are no funds 
available to pay for transportation to and from the research center, lost time away from 
work and other activities, lost wages, or child care expenses. 
 
How will I be paid? 
You will be given the gift card upon signing the required consent form documentation 
and completing study visit documents and procedures.  
 
If skin samples are obtained, you will be issued a UT Southwestern Greenphire 
ClinCard, which can be used as a credit or debit card. You will also receive instructions 
on how to use the card. In order to receive study payments, your name, address, date of 
birth and Social Security Number (SSN) will be collected from you by the research 
staff. All information will be stored in a secure fashion and will be deleted from the UT 





Important Information about Study Payments 
1. Your SSN is needed in order to process your payments. Should you decide 
not to provide your SSN, your study participation payment will decrease at 
the current IRS tax rate. Study payments are considered taxable income and 
are reportable to the IRS. 
2. An IRS Form 1099 will be sent to you if your total payments are $600 or 
more in  
a calendar year. 
3. Your information will not be shared with any third parties and will be kept  
completely confidential. 
 
This information will remain confidential unless you give your permission to share it 
with others, or if we are required by law to release it.  
 
If you are an employee of UT Southwestern, your payment will be added to your 
regular paycheck and income tax will be deducted. You will not receive a ClinCard. 
 
UT Southwestern, as a State agency, will not be able to make payments to you for your 
participation in this research if the State Comptroller has issued a “hold” on all State 
payments to you. Such a “hold” could result from your failure to make child support 
payments or pay student loans, etc. If this happens, UT Southwestern will be able to pay 
you for your taking part in this research 1) after you have made the outstanding 
payments and 2) the State Comptroller has issued a release of the “hold.” 
 
 
Will my insurance provider or I be charged for the costs of any part of this research 
study? 
No. Neither you, nor your insurance provider, will be charged for anything done only 
for this research study (i.e., the Screening Procedures, Experimental Procedures, or 
Monitoring/Follow-up Procedures described above).   
 
However, the expenses for routine health check-ups or standard medical care for your 
any medical problem (care you would have received whether or not you were in this 
study) is your responsibility (or the responsibility of your insurance provider or 
governmental program).  You will be charged, in the standard manner, for any 
procedures performed for your standard medical care. 
 
What will happen if I am harmed as a result of taking part in this study? 
It is important that you report any suspected study-related illness or injury to the 
research team listed at the top of this form immediately. 
 
Compensation for an injury resulting from your participation in this research is not 
available from The University of Texas Southwestern Medical Center at Dallas and 
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Parkland Health & Hospital System. 
 
You retain your legal rights during your participation in this research. 
 
Will my information be kept confidential? 
Information about you that is collected for this research study will remain confidential 
unless you give your permission to share it with others, or as described below.  You 
should know that certain organizations that may look at and/or copy your medical 
records for research, quality assurance, and data analysis include:   
 
• UT Southwestern Medical Center at Dallas 
• Parkland Health and Hospital System 
• Representatives of domestic and foreign government and regulatory agencies, 
like the Food and Drug Administration (FDA), involved in keeping research safe 
for people 
• UT Southwestern Institutional Review Board  
• National Institutes of Health 
• Biogen Incorporated 
• University of Pennsylvania 
 
In addition to this consent form, you will be asked to sign an "Authorization for Use and 
Disclosure of Protected Health Information."  This authorization will give more details 
about how your information will be used for this research study, and who may see 
and/or get copies of your information. 
 
To help us further protect the information the investigators have obtained a Certificate 
of Confidentiality from the U.S. Department of Health and Human Services (DHHS).  
This Certificate adds special protections for research information that identifies you and 
will help researchers protect your privacy.  This Certificate does not mean the 
government approves or disapproves of our project. 
For more information about the Certificate of Confidentiality, please read “More 
Information about This Research” at the end of this consent form. 
 
Whom do I call if I have questions or problems? 
For questions about the study, contact Benjamin Chong, MD, at 214-648-3427. In case 
of an emergency, please call 214-645-2400. 
 
For questions about your rights as a research participant, contact the UT Southwestern 








Your signature below certifies the following: 
 
•  You have read (or been read) the information provided above. 
•  You have received answers to all of your questions and have been told who to call 
if you have any more questions. 
•  You have freely decided to participate in this research. 









Date   Time: 
AM/PM 
________________________________________________ 
Name of person obtaining consent (printed) 
  
________________________________________________ 
Signature of person obtaining consent 
 ________________ 
Date   Time: 
AM/PM 
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Appendix I - Survey of Quality of Life (QoL) in Patients with 
Cutaneous Lupus Erythematosus (CLE) 
 
We are interested in understanding more about how CLE affects your quality of life.  The results of this 
survey will be compiled and reported in aggregate as part of an effort to identify the factors that affect 
your quality of life. We do not have any identifying information linking you to your responses. 
 
Section I. Quality of Life – Question 1-11 
 
This survey asks for your views about your health.  This information will help keep track 
of how you feel and how well you are able to do your usual activities.  Thank you for 
completing this survey! 
For each of the following questions, please mark an  in the one box that best describes 
your answer. 
1. In general, would you say your health is: 
 
Excellent Very good Good Fair Poor 
     
  1  2  3  4  5 
 
2. Compared to one year ago, how would you rate your health in general now? 
 
Much better 




than one year 
ago 
About the 




than one year 
ago 
Much worse 
now than one 
year ago 
     
 1  2  3  4  5 
 
3. The following items are about activities you might do during a typical day. Does your  
health now limit you in these activities?  If so, how much? 










   
a   Vigorous activities, such as running, lifting  
 heavy objects, participating in strenuous  
 sports …………………………………………….. 1 .... ………. 2………… 3 
 
b   Moderate activities, such as moving a  
 table, pushing a vacuum cleaner,  









d Climbing several flights of stairs…………………... 1 .. ………. 2………… 3 
 
e  Climbing one flight of stairs……………………….. 1 . ………. 2………… 3 
 
f  Bending, kneeling, or stooping…………………….. 1 .. ………. 2………… 3 
 
g Walking more than a mile………………………….. 1 . ………. 2………… 3 
 
h Walking several blocks…………………………….. 1 . ………. 2………… 3 
 
i Walking one block………………………………….. 1 . ………. 2………… 3 
 
j  Bathing or dressing yourself………………………... 1 . ………. 2………… 3 
 
4. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of your physical 
health? 
 
 Yes No 
 
  
a  Cut down on the amount of time you spent  
 on work or other activities……………………………………........ 1…….…... 2 
 
b  Accomplished less than you would like…...…………………........ 1…….…... 2 
 
c  Were limited in the kind of work or other  
   activities…...…………………………………………………........ 1…….…... 2 
 
d  Had difficulty performing the work or other  
 activities (for example, it took extra effort) …...………………........ 1…….….. 2 
 
 
5. During the past 4 weeks, have you had any of the following problems with your work 
or other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
 
 Yes No 
 
  
a  Cut down on the amount of time you spent  
on work or other activities.............................................................. 1…………… 2 
b  Accomplished less than you would like ........................................ 1………….... 2 
 
c  Did work or other activities less carefully  
   than usual ....................................................................................... 1………….... 2 
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6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbors, 
or groups? 
 
Not at all Slightly Moderately Quite a bit Extremely 
     
 1  2  3   4  5 
 
7. How much bodily pain have you had during the past 4 weeks? 
 
None Very mild Mild Moderate Severe Very 
Severe 
      
 1  2  3  4  5  6 
 
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
 
Not at all A little bit Moderately Quite a bit Extremely 
     
 1  2  3  4  5 
9. These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the 





















      
 
a   Did you feel full of pep?................. 1…….. 2……. 3……. 4……. 5…… 6 
b  Have you been a very nervous  
 person?............................................. 1…….. 2……. 3……. 4……. 5…… 6 
 
c  Have you felt so down in the  
 dumps that nothing could cheer 
  you up?............................................ 1…….. 2……. 3……. 4……. 5…… 6 
 
 











f  Have you felt downhearted  
 and blue?........................................... 1…….. 2……. 3……. 4……. 5…… 6 
g  Did you feel worn out?.................. 1…….. 2……. 3……. 4……. 5…… 6 
 
h  Have you been a happy person?.... 1…….. 2……. 3……. 4……. 5…… 6 
 
i  Did you feel tired? ........................ 1…….. 2……. 3……. 4……. 5…… 6 
 
 
10. During the past 4 weeks, how much of the time has your physical health  or  
emotional problems interfered with your social activities (like visiting friends, 
relatives, etc.)? 
 
All of the 
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
     
 1  2  3   4  5 
 
 













     
a  I seem to get sick a little easier 
 than other people............................... 1…….. 2……. 3……. 4………. 5 
b  I am as healthy as anybody I  
 know.................................................. 1…...... 2……. 3……. 4……….. 5 
c  I expect my health to get 















SECTION II. Skin condition and CLE– Question 12a-12kk  
 
These questions concern your feelings over the past 4 weeks about the skin condition that has 
bothered you the most.  
Please check the answer that comes closest to the way you have been feeling.        
12.  Never   Rarely   Sometimes   Often       All of the time                                                                                                                     
a. My skin hurts.                                                            
b. My skin condition affects how well I sleep.                                                            
c. I worry that my skin condition may be 
serious.     
                                                           
d. My skin condition makes it hard to work or 
do hobbies.     
                                                           
e. My skin condition affects my social life.                                                               
f. My skin condition makes me feel 
depressed.     
                                                           
g. My skin condition burns or stings.                                                                
h. I tend to stay at home because of my skin 
condition.    
                                                           
i. I worry about getting scars from my skin 
condition.     
                                                           
j. My skin itches.                                                                
k. My skin condition affects how close I can 
be with those I love.  
                                                           
l. I am ashamed of my skin condition.                                                                
m. I worry that my skin condition may get 
worse.     
                                                           
n. I tend to do things by myself because of my 
skin condition.    
                                                           
o. I am angry about my skin condition.                                                                
p. Water bothers my skin condition (bathing, 
washing hands).     
                                                           
q. My skin condition makes showing 
affection difficult.    
                                                           
r. I worry about side-effects from skin 
medications/treatments.  
                                                           
s. My skin is irritated.                                                            
t. My skin condition affects my interactions 
with others.     
                                                           
u. I am embarrassed by my skin condition.                                                              
v. My skin condition is a problem for the 
people I love.    
                                                           
w. I am frustrated by my skin condition.                                                            
x. My skin is sensitive.                                                             
y. My skin condition affects my desire to be 
with people.     
                                                           
z. I am humiliated by my skin condition.                                                            
aa. My skin condition bleeds.                                                            
bb. I am annoyed by my skin condition.                                                                
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cc. My skin condition interferes with my sex 
life. 
                                                           
dd. My skin condition makes me tired.                                                            
ee. I worry about going outside because the 
sun might flare my disease. 
                                                           
ff. I am worried about my hair loss.                                                                
gg. My skin disease prevents me from doing 
outdoor activities. 
                                                           
hh. When talking to someone, I sometimes 
worry about they may be thinking of me. 
                                                           
ii. My skin condition has influenced the 
clothes I wear. 
                                                           
jj. My skin condition has affected my 
grooming practices (i.e., haircut, use of 
cosmetics). 
                                                           
kk. My skin condition has affected my sun 
protection efforts during recreation (i.e., 
limiting exposure time during sun peak 
hours, wearing a hat, long sleeves or 
pants). 
                                                           
 
Section III. Symptoms Associated With CLE – Question 13-15  
Next, we would like to understand how some symptoms relevant to your CLE impact you.   
Please circle the one number on the scale that best answers the question. 
 
13. On average, how much PAIN have you experienced in the last 24 hrs? 
 
0 1 2 3 4 5 6 7 8 9 10 
No pain          Pain as bad as 
             you can imagine    
 
   
14. On average, how much ITCH have you experienced in the last 24 hrs? 
 
0 1 2 3 4 5 6 7 8 9 10 
No itch          Itch as bad as 
             you can imagine    
 
 
15. On average, how much FATIGUE have you experienced in the past week? 
 
0 1 2 3 4 5 6 7 8 9 10 
No fatigue                  Fatigue as bad  
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Section IV. Functioning with CLE – Question 16-19 
 
In this section, we would like to know how you feel about your appearance, and about any 
changes that may have resulted from your CLE or treatment.  
 
Please check the answer that comes closest to the way you have been feeling about 
yourself, during the past week. 
16.  Not at all            A little         Quite a bit        Very    
                                                                          much    
a. Have you been feeling self-conscious about your 
appearance?  
 
b. Have you felt less physically attractive as a result of 
your disease or treatment? 
                                              
c. Have you been dissatisfied with your appearance when 
dressed? 
                                              
d. Have you been feeling less feminine/masculine as a 
result of your disease or treatment? 
                                              
e. Did you find it difficult to look at yourself naked?                                               
f. Have you been feeling less sexually attractive as a 
result of your disease or treatment?  
                                              
g. Did you avoid people because of the way you felt about 
your appearance? 
                                              
h. Have you been feeling the treatment has left your body 
less whole? 
                                              
i. Have you felt dissatisfied with your body?                                               
                                                                                                                          Not          A little         Quite      Very                Not                  
                                                                                                                                                at all                             a bit          Much          applicable 
j. Have you been dissatisfied with the appearance of your 
scar? 
                                                
 
17. Have you been diagnosed (by a professional) with depression  
 
 Yes       
 No  
 
18. Are you currently being treated for depression?  
 
 Yes       









If “No,” skip to Question 19. 
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19. History of other Medical Conditions  
 
Instructions: Answer No or Yes in the first column for ALL problems listed.  





#2: Do you receive 
medications or 
other treatment for 
it? 
#3: Does it limit 
your activities? 
a) Heart disease  No      Yes if “Yes”  No      Yes  No      Yes 
b) High blood pressure  No      Yes   No      Yes  No      Yes 
c) Lung disease  No      Yes   No      Yes  No      Yes 
d) Diabetes  No      Yes   No      Yes  No      Yes 
e) Ulcer or stomach 
disease 
 No      Yes   No      Yes  No      Yes 
f) Kidney disease  No      Yes   No      Yes  No      Yes 
g) Liver disease  No      Yes   No      Yes  No      Yes 
h) Anemia or other blood 
disease 
 No      Yes   No      Yes  No      Yes 
i) Cancer  No      Yes   No      Yes  No      Yes 
j) Depression  No      Yes   No      Yes  No      Yes 
k) Osteoarthritis, 
Degenerative arthritis 
 No      Yes   No      Yes  No      Yes 
l) Back pain  No      Yes   No      Yes  No      Yes 
m) Rheumatoid arthritis  No      Yes   No      Yes  No      Yes 
n) Hepatitis  No      Yes   No      Yes  No      Yes 
o) HIV   No       
Yes 
  No      Yes  No      Yes 
 
Section V. General Health Perceptions of CLE – Question 20-21 
Next, we would like to understand your views about the effect of CLE and its treatment on your 
health. There are no right or wrong answers.  
Please check the answer that corresponds to your choice using the scales listed below. 
20. In the past four weeks, how often did you experience the following due to your 
CLE? 
 None of 
the time 
A little of 









a. Serious side effects 
associated with CLE 
medications. 
      
b. Concerns about the 
number of medications 
you currently take for 
your CLE. 




21. Estimate your SKIN-RELATED HEALTH on a 1-10 scale as you see it today? 
 
Please circle the one number on the scale that best answers the question. 
 
0 1 2 3 4 5 6 7 8 9 10 
Worst                               Perfect health         
skin                          (i.e., total body burn) 
   
 
Section VI. Patient Demographic and Personal Characteristics – Questions 22-29 
Now, we would like to know a little about you so we can better understand your responses. 
Please check the answer that corresponds to your choice or by writing in your response 
where appropriate.  
 
22. In what year were born?   19_____   (please use a two digit number) 
23. What is your gender? 
 Male         Female             
24. What is your highest level of education? 
 Lower than High School  High School      College   Graduate Degree               
  
25. Which of the following best describes your racial/ethnic background? 
 African American                       Asian      Caucasian   
 Hispanic                                      Other_________________ 
 
26. Have you ever smoked cigarettes on a regular basis?  
 Yes          
 No 
 
a. Do you smoke now?   
 Yes     No 
27. Which of the following best describes your marital status? 
 Single    Widowed    Divorced  
  Separated     Married/Domestic Partner 
 
28. Which is your current zip code? _________________ 
 
29. Finally, please rate the level of support that you receive from your loved ones using the item 
below: 
Generally, I receive support from friends and/or family… 
None of the 
time 
 
A little of the time 
 
  
Some of the 
time 
 
Most of the 
time 
 







THANK YOU FOR YOUR PARTICIPATION! 
If “No,” skip to Question 27. 
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Figure J.1: Histogram of Standardized Residuals from Regression of CLEQoL-




Figure J.2: Histogram of Standardized Residuals from Regression of 
















Figure J.4: Histogram of Standardized Residuals from Regression of SF-36 




Figure J.3: Histogram of Standardized Residuals from Regression of SF-36 













Figure K.1: Normal P-Plot of Regression of Standardized Residuals from 




Figure K.2: Normal P-Plot of Regression of Standardized Residuals from 















Figure K.3: Normal P-Plot of Regression of Standardized Residuals from 





Figure K.4: Normal P-Plot of Regression of Standardized Residuals from 

















Figure L.2: Scatterplot of Residuals from Regression of Standardized Residuals from 




Figure L.1: Scatterplot of Residuals from Regression of Standardized Residuals 
















Figure L.4: Scatterplot of Residuals from Regression of Standardized Residuals 





Figure L.3: Scatterplot of Residuals from Regression of Standardized Residuals 
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